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Abstract
Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the 
central nervous system (CNS) characterised by focal lesions of inflammation and 
demyelination, with subsequent axonal damage. Although the cause is not yet known, 
it is thought to be autoimmune in origin. Antibodies are implicated in the disease 
process, as these are detectable in the cerebrospinal fluid (CSF) seen as oligoclonal 
bands (OCBs) following isoelectric focussing. However, the target antigen of these 
antibodies has not yet been fully characterised. Post-translational modification of 
myelin basic protein (MBP) and other CNS-specific proteins, including citrullination of 
arginine residues, results in conformational changes in the protein. This leads to 
increased degradation by proteases and exposure of new epitopes, which may then 
cause the production of autoantibodies targeting the myelin sheath. The process of 
citrullination is carried out by a family of enzymes known as peptidylarginine 
deiminases (PADs) with PAD2 and PAD4 expressed in the brain. Excess citrullination 
occurs in MS, with MBP isolated from MS white matter being more highly citrullinated 
than in healthy control white matter. This thesis aimed to investigate the in vitro 
expression of PAD2 and PAD4 by cells of the CNS to gain a better understanding of 
how these enzymes might be regulated and their possible role in the pathogenesis of 
MS. Cells were treated with pro-inflammatory cytokines in vitro, to mimic in vivo 
inflammatory conditions, and following this, PAD2 and PAD4 mRNA expression was 
determined using real-time PCR. PAD2 mRNA was significantly decreased in the 
presence of pro-inflammatory cytokines IL-1 (3, TNF-a and IFN-y in three preparations of 
primary human astrocytes, a human foetal microglial cell line (CHME3) and a brain 
endothelial cell line (hCMEC/D3). Furthermore, treatment of CHME3 cells with anti­
inflammatory cytokines IL-4, IL-10 and TGF-(3 also resulted in the down-regulation of 
PAD2 mRNA. PAD4 was undetectable. Thus pro- and anti-inflammatory cytokines 
down-regulate expression of PAD2 mRNA in vitro, which indicates that increased 
citrullination of CNS proteins in MS is not due to the inflammatory milieu in the CNS, 
suggesting additional mechanisms must be involved in the up-regulation of PAD2 and 
PAD4 enzymes reported in MS tissue.
Subsequently, in vivo studies were carried out investigating the distribution and 
expression of PAD2 and PAD4 enzymes, and citrullinated proteins, in post-mortem 
control, MS normal appearing white matter (NAWM) and MS lesional brain tissue by 
immunohistochemistry. Higher levels of citrullinated proteins were observed in MS 
lesions compared to control and NAWM brain tissue, and were associated with areas 
of myelin thinning with on-going demyelination, and was co-localised to GFAP-positive 
astrocytes. PAD2 expression was difficult to detect. Western blotting of proteins 
extracted from these MS brains showed citrullination of multiple proteins, two of which 
were identified as glial fibrillary acidic protein (GFAP) and MBP, the latter also 
confirmed by mass spectrometry. This agrees with previous studies implicating 
citrullination in the pathogenesis of MS. Lastly, an enzyme-linked immunosorbant 
assay (ELISA) method was developed to detect anti-citrullinated protein antibodies 
(ACPAs) against citrullinated MBP peptides in the CSF and serum of patients newly 
diagnosed with MS, other neurological diseases (ONDs) and controls, to determine 
whether higher levels of antibodies were observed in individuals with MS. No significant 
increases in the levels of ACPAs were found in the CSF and serum of individuals with 
MS compared to ONDs and controls. Although not significant, increased reactivity of 
MS patient CSF immunoglobulins towards citrullinated MBP peptides was observed. 
Furthermore, an association was found between reactivity towards citrullinated MBP 
peptides and patients testing positive for OCBs. Evidence presented in this thesis 
demonstrates an important role of citrullination in the pathogenesis of MS. The results 
of this thesis indicate that further investigations into the role of citrullination in MS, 
particularly with regards to assessment of further citrullinated peptides as antigenic 
targets in ELISA assays, are warranted.
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Chapter 1
General Introduction
1.1 Innate and adaptive immunity
The body is constantly exposed to pathogenic organisms and in order to combat this, 
the immune system has evolved to protect against infection of the host cells. The first 
line of defence against pathogens is the anatomical and physiological barriers, which 
include the skin, the cilia of the lungs and lysozyme in tears, and these prevent the 
entry of some pathogenic organisms into the body. However, many of these pathogens 
are able to evade these anatomical and physiological barriers, and this is where the 
adaptive immune system becomes paramount. The immune system is composed of 
two types: (1) innate immunity and (2) adaptive immunity (Table 1.1; Figure 1.1).
1.1.1 Innate immunity
Innate immunity was originally thought to offer non-specific immunity; however, recent 
advances in this field have led to considerable changes in this concept. The innate 
immune system relies on a limited number of receptors referred to as pathogen 
recognition receptors (PRRs) to detect invading pathogens but compensates for this 
limited number by targeting conserved microbial components that are shared by large 
numbers of pathogens (Turvey and Broide 2010). Speed is the most prominent 
characteristic of the innate immune system, as within minutes of pathogen exposure, 
the innate immune system starts generating a protective inflammatory response. The 
innate immune system also plays a vital part in activating the adaptive immune 
response.
The innate immune system is composed of both cellular and humoral elements (Figure
1.2). A number of haematopoietic cells are involved, including macrophages, dendritic 
cells, mast cells, neutrophils, natural killer (NK) cell and NK T cells. In addition to 
haematopoietic cells, non-haematopoietic cells also play a role in innate immunity, 
including the skin and epithelial cells lining the respiratory, gastrointestinal, and 
genitourinary tracts. To enhance the effect of these cellular defences, innate immunity 
also has a humoral component that consists of well-characterised components, such 
as complement proteins, lipopolysaccharide (LPS) binding protein, C-reactive proteins 
and antimicrobial peptides (Turvey and Broide 2010).
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Figure 1.1: The three levels of the human immune system. (Adapted from Turvey and Broide 2010).
Key: AMP; antimicrobial peptide, CRP; C-reactive protein, LPS; Lipopolysaccharide, MBL; Mannose binding lectin, NK; natural killer.
In addition to the detection of pathogens, the innate immune system is also able to 
detect immunologic danger through the detection of damage-associated molecular 
patterns (DAMPS), such as high mobility group box 1 protein (HMGB1) released from 
dying cells (Bianchi 2007). Finally, receptors of NK cells are also able to detect healthy 
cells expressing ‘self molecules and deliver an inhibitory signal to prevent activation of 
the immune response against host tissue (Joncker and Raulet 2008).
Neutrophils, macrophages, and monocytes are the major phagocytic cells of the innate 
immune system. Neutrophils engulf pathogens and localise them to intracellular 
vacuoles where they are exposed to toxic effector molecules, such as nitric oxide and 
degradative enzymes to destroy the pathogen, and play a major role in the clearance of 
microbial pathogens (Kennedy and DeLeo 2009). Macrophages and monocytes are 
also highly phagocytic for microbes and particles that have been marked for clearance 
either through opsonisation by antibodies and/or complement (Chaplin 2010). In 
addition to this important role in the innate immune response, monocytes and 
macrophages also play vital roles in the adaptive immune response by ingesting 
microbial antigens, processing them into peptide fragments, and presenting them to T 
cells (Chaplin 2010). The most potent antigen presenting cells (APCs) are the broad 
class of dendritic cells (DCs) that are present in most tissues of the body and 
concentrated in the secondary lymphoid organs (Lambrecht and Hammad 2009).
All APCs express both class I and II major histocompatibility complex (MHC) molecules 
that are required for recognition of processed antigen by the T cell receptor (TCR) on T 
cells; the key cellular components of the adaptive response (see section 1.2). All cells 
bearing MHC molecules have the ability to act as APCs if appropriately stimulated 
(Chaplin 2010).
DCs are important in initiating the adaptive immune response by migrating from the site 
of infection to regional lymph nodes where they present pathogen-derived antigen to 
naive CD4+ T cells. Activated DCs express co-stimulatory molecules essential to T cell 
activation and can instruct the differentiation of naive CD4+ T cells into T helper cells. In 
addition, this cross-talk between DCs and T cells can lead to clonal expansion and 
migration of T cells to B cell areas to assist with antibody production (Gallucci et a!., 
1999).
1.1.2 Adaptive immunity
The adaptive immune system consists of T and B cells, and unlike the innate immune 
system, requires antigen exposure in order to mount an effective immune response 
hence ‘adaptive’ (Turvey and Broide 2010). In contrast to the limited number of PRRs
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used by the innate immune system, the adaptive immune system has an extremely 
diverse, randomly generated repertoire of receptors that are encoded by gene 
elements that somatically rearrange to assemble antigen-binding molecules with great 
specificity for individual, unique foreign structures (Chaplin 2010). This great diversity in 
receptors enables these cells to recognise virtually any foreign antigen, however, due 
to this arm of the immune system requiring antigen exposure before mounting a 
response there is a delay of approximately 5 days, due to clonal expansion of antigen- 
specific T and B cells. In addition to the time delay of the adaptive immune response, 
there is also a risk of autoimmune disease, as receptors for self-proteins are created by 
means of the random process of gene rearrangement that generates receptors 
expressed by T and B cells (Turvey and Broide 2010). However, substantial tolerance 
mechanisms are in place to eliminate or regulate self-reactive cells (see section 1.1.3).
A key feature of the adaptive response is that it produces long-lived cells that persist as 
memory cells until a second exposure with their specific antigen, where they rapidly re­
express effector functions (Chaplin 2010). The adaptive immune response therefore 
manifests immune memory, enabling it to contribute prominently to a more effective 
host response against specific pathogens following a second encounter.
The major role of the T-cell arm of the adaptive immune response is to identify and 
destroy infected cells and is responsible for cell-mediated immunity. T cells can also 
recognise peptide fragments of antigen that have been taken up by APCs through 
phagocytosis or pinocytosis. The immune system has evolved to enable T cells to 
recognise foreign antigens through recognising two molecules on the surface of these 
APCs: (1) a self-component i.e. MHC and (2) a foreign peptide. MHC molecules are 
cell surface glycoproteins that bind peptide fragments of proteins that have either been 
synthesised within the cell i.e. endogenous antigens (class I MHC molecule) or 
ingested by the cell and proteolytically processed i.e. exogenous antigens (class II 
MHC molecules) (Chaplin 2010).
1.1.2.1 Major histocompatibility complex class I and II
There are three HLA class I molecules; HLA-A, -B and -C. Class I MHC molecules are 
cell-surface heterodimers consisting of a polymorphic transmembrane a-chain and a 
nonpolymorphic p2-microglobulin protein, with the a chain determining whether the 
class I molecule is an HLA-A, B or C molecule (Bjorkman 1997). The genes for the a- 
chain and the p2-microglobulin protein are encoded on chromosome 6 and 15, 
respectively (Bjorkman 1997). The ch and a2 domains of the a-chain forms a groove in 
which the antigenic peptides can bind producing a complex of both class I MHC 
molecule and antigenic peptide which is recognised by TCR present on the surface of
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the T cell (Bjorkman 1997). This complex is vital for recognition by T cells, as the TCR 
shows no measurable affinity for the antigenic peptide alone and very low affinity for 
MHC molecules containing other peptides. This concept is now known as “MHC 
restriction” in which T cells can only recognise their specific antigen when it is 
presented by a specific self-MHC molecule (Zinkernagel and Doherty 1997). The a3 
domain of the MHC molecule interacts only with the CD8 molecule on cytotoxic T cells, 
which restricts the recognition of antigenic peptides that are presented in class I HLA 
molecules to CD8+ cytotoxic cells (Joshi and Kaech 2008).
So far, more than 650 alleles have been identified at the HLA-A locus, more than 1,000 
alleles at the HLA-B locus and more than 350 alleles at the HLA-C locus 
(Immunogene). The highly polymorphic nature of the a-chain is predominantly in the 
amino acids in the peptide-binding groove, resulting in different peptide-binding 
specificities of different class I alleles. There are three distinct HLA class I genes, each 
is highly polymorphic, and heterozygous individuals have six distinct peptide-binding 
grooves. Each class I protein can bind many different peptides, having six peptide- 
binding molecules results in the ability to bind a very diverse collection of antigenic 
peptides (Chaplin 2010). Generally, the antigenic peptides that are found bound in the 
peptide-binding groove of the HLA class I molecules are derived from proteins 
synthesised within the cell bearing the class I molecules. MHC class I molecules are 
most effective in delivering viral peptides in a virus-infected cell to the cell surface for 
recognition and elimination by cytotoxic CD8+ T cells. Exogenous antigens can also be 
internalised by endocytosis and presented in class I molecules by APCs in a process 
called “cross-presentation” (Melief 2003). This is of great importance in the fight against 
virally infected cells in which the host is prevented from being able to present antigen 
(Sigal et a!., 1999).
There are three class II molecules: HLA-DR, -DQ and -DP (Bjorkman 1997). Similar to 
the class I molecules, class II HLA molecules also consist of an a and a (3-chain 
(Bjorkman 1997). When the common a-chain is paired with the DRB1 chain it produces 
the HLA-DRB1 protein, so far more than 500 HLA-DRB1 alleles have been identified. 
This a-chain can also pair with DRB2-DRB9, where there are a total of 60 alleles. The 
HLA-DQ encodes one polymorphic a-chain which has 25 alleles and one polymorphic 
(3-chain which has 72 alleles. Lastly, the HLA-DP encodes one polymorphic a-chain 
which has 16 alleles and one polymorphic (3-chain which has 118 alleles (Chaplin 
2010). An individual can express two different HLA-DQ and two different HLA-DP 
proteins, and HLA-DR a-chain can pair with both an HLA-DRB1 and an HLA-DRB3 
chain, each person can express distinct HLA-DR proteins. Each of these HLA 
molecules can bind a large repertoire of antigenic peptides. The a-i and (3-i domains
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combine to form the peptide-binding groove and the (32 domain interacts with the CD4 
molecule present on the surface of the CD4+ T helper cell. The CD4 molecule 
enhances the interaction between the T cells and the class II expressing APCs (Konig 
et al., 1996). Class II proteins are expressed on a number of immune cells, including B 
cells, DCs, monocytes and macrophages. Class II proteins are most effective in 
presenting antigenic proteins of extracellular pathogens, such as most bacteria, 
parasites, and virus particles that have been released from infected cells to CD4+ T 
helper cells.
Different HLA types have been associated with susceptibility to certain diseases. A 
recent epidemiological study has shown that more than 40 diseases are associated 
with certain HLA class I or HLA class II alleles, most of which are autoimmune in nature 
(see section 2.1) (Ghodke et al., 2005). HLA presentation is limited to protein antigens, 
and in order to detect lipids a further molecule is used for presentation to T cells. CD1 
molecules consist of a and (3 chains and are structurally similar to class I HLA 
molecules, but are important in the presentation of lipids to T cells (Balato et al., 2009).
1.1.2.2 T cell receptor
The largest class of T cells express a(3 TCRs on their surface and recognise peptide 
antigens presented by either class I or II MHC proteins. These a(3 T cells differentiate 
into: (1) CD8+ T cells which act to kill cells infected with intracellular microbes or (2) 
CD4+ T cells which regulate both the cellular and humoral immune responses. A much 
smaller group of a(3 T cells express CD161 NK cell antigens rather than CD4 or CD8, 
and are called NK-T cells, and recognise glycolipid antigens presented by CD1 
molecules rather than through HLA molecules. NK-T cells appear to play an 
immunoregulatory role and release numerous cytokines following activation, including 
interleukin-4 (IL-4) and interferon-y (IFN-y) (Godfrey et al., 2004). These a(3 TCR T 
cells account for approximately 90-95% of T cells, with the remaining 5-10% 
expressing y5 TCRs on their cell surface.
TCRs are somatically assembled from variable, diversity, and joining gene elements, 
with recombinase enzymes assembling these elements in a seemingly random 
process. This produces a wide range of receptor sequences, some of which are 
functional. In the thymus these T cells expressing functional TCR genes are selected 
(Miller 2002). The thymus consists of three compartments that are all important for the 
development of T cells: (1) subcapsular zone, (2) thymic cortex, and (3) thymic 
medulla. The subcapsular zone is where bone marrow-derived prothymocytes 
differentiate, proliferate and rearrange their TCR (3-chains. Following this, the cells then 
move to the cortex where the a-chain gene segments rearrange to form functional,
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mature a(3 receptors. Following positive selection these T cells become either CD4+ or 
CD8+ T cells.
CD4+ T cells are helper cells and are important in activating both the humoral and 
cellular responses; a proportion of these CD4+ T cells play an important role in down- 
regulating the immune response and are regulatory T (Treg) cells (LaRosa and Orange
2008). CD8+ T cells are important in directly killing cells infected with intracellular 
microbes and also contain a population of cells that suppress the immune response 
(Trapani et al., 2000).
1.1.2.3 T cell activation
For T cell activation, in addition to the TCR, a cell surface molecule called CD3 is also 
required. The interaction of the CD3/TCR complex with MHC molecules presenting 
antigenic peptides only results in partial signal for cell activation. Full activation requires 
additional co-stimulatory molecules, including CD28 expression on the surface of T 
cells and the expression of CD80 or CD86 on the surface of the APC (Nurieva et al.,
2009).
Resting naive CD4+ T cells release very low levels of cytokines but following 
stimulation through the presentation of antigens by APCs, CD4+ T cells begin to 
produce IL-12 and are called ThO. Depending on cytokines present at the site of 
activation these T cells differentiate into Th1, Th2 or Th17 helper cells (Sallusto and 
Lanzavecchia 2009). Th1 cells support cell-mediated immune responses and Th2 cells 
support humoral and allergic responses. Th17 cells are induced early in the adaptive 
immune response to extracellular bacteria and help in the recruitment of neutrophils to 
eliminate these pathogens. Th17 cells are also involved in many autoimmune diseases.
The second branch of the adaptive immune response is the B-cell arm which is 
responsible for humoral immunity. B cells constitute approximately 15% of peripheral 
blood leukocytes and are defined by their capacity to produce immunoglobulins. Each 
B cell possesses specified immunoglobulin on its surface made up of two identical 
heavy (H) chains and two identical k or A light (L) chains. Each chain is encoded by 
variable (V), diversity (D), joining (J) and constant region genes. Each part of the VL 
and VH chains are made up of three hypervariable regions, and it is these regions 
which vary in sequence from one antibody molecule to another, and create the antigen- 
binding region of the molecule (Burnet 1976). The heavy chain constant regions of the 
antibody molecule pair to form the Fc domain which carries out the effector function, 
including binding to Fc receptors and activating the complement system (see section
1.3). The genes encoding the k light chain, A light chain and the heavy chain are
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encoded on chromosomes 2, 22 and 14, respectively. The heavy chain gene contains 
exons which encode nine different constant regions that are used to produce the 
different classes and subclasses of immunoglobulins (Chaplin 2010).
1.1.2.4 B cell development
B cells differentiate from haematopoietic stem cells in the bone marrow and undergo 
antigen receptor assembly through somatic joining of genes (Nagasawa 2006). In the 
bone marrow CD19- CD20- stem cells go through many stages of maturation taking 
them from stem cells, pro-B-cells, then pre-B-cells and eventually naive CD20+ CD19+ 
lgD+ and lgM+ B (Nikbin et al., 2007). Immunoglobulins are encoded by multiple 
genes, which rearrange during the pro-B-cell stage to create a unique cell surface 
receptor that defines its specificity for antigen. During this stage of B cell development, 
many B cells are generated with different specificities. This process of random somatic 
joining of genes occurs in the bone marrow in the absence of a pathogenic antigen. 
Whilst in the bone marrow these B cells are subjected to negative selection similar to T 
cell development in the thymus, where the majority die in the bone marrow by 
apoptosis during development due to their antigen receptors (antibodies, IgM) being 
assembled incorrectly or are directed against self-antigens.
Once these cells have survived negative selection in the bone marrow, these naive B 
cells expressing IgM and IgD on their cell surface, migrate via the bloodstream to the 
spleen and other lymphoid tissues, where they mature within the secondary lymphoid 
organs and germinal centres (GC). In an immune response to a pathogen, antigen- 
dependent development begins in the GC of secondary lymphoid organs under the 
influence of T cells (Liu et al., 1992; MacLennan 1994; Schmidlin et al., 2009). T cells 
provide “help” for B cells to mature, which includes both the induction of isotype 
switching by T cell cytokines and the activation of somatic mutation (Chaplin 2010). 
When naive B cells encounter their respective antigen they capture it through 
membrane bound IgM, internalise and process it intracellularly. These antigenic 
peptides are then presented on the B cell surface bound to the class II HLA molecule. 
Antigen uptake increases expression of MHC class II molecules and the expression of 
co-stimulatory molecules CD80 and CD86. CD4+ T cells then become activated 
through the binding of costimulators and peptide class II complex, which in turn then 
leads to the CD4+ T cell to signal to the B cell through the interaction of CD40 ligand 
on CD4+ T cells with CD40 on B cells. This signalling through CD40 is essential for the 
induction of isotype switching (Korthauer et al., 1993; Gray, Siepmann and Wohlleben
1994).
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1.1.2.5 B cell isotype switching
T cells produce a number of cytokines which can influence isotype switching: (1) IL-10 
results in switching to IgGi and lgG3, (2) IL-4 and IL-13 results in switching to IgE, (3) 
transforming growth factor-p (TGF-p) results in switching to IgA, and (4) IFN-y induces 
switching to lgG2. During this period of isotype switching random somatic mutations in 
the antigen-binding portions of the heavy and light chains also occurs (MacLennan 
1994; Klein and Dalla-Favera 2008). Inside the GC, these mature B cells undergo 
positive selection, whereby if these mutations result in a lowered affinity for the antigen 
then the cell undergoes apoptosis and if these mutations result in an increased affinity 
for the antigen, then this leads to extensive proliferation of this cell producing the 
antibody, also called clonal expansion.
Those B cells that survive the process of positive selection either become: (1) antibody- 
producing plasma cells or (2) memory B cells. The first subset undergoes clonal 
expansion, lose their surface immunoglobulin (Ig) molecules, and secrete antibodies of 
one class (Goldsby et al., 2003; Avery et al., 2005). The second subset do not release 
their surface antibodies and remain surface antibody-expressing cells; memory B cells. 
These memory B cells circulate in the peripheral blood and lymph nodes until 
subsequent encounter with the same antigen, when an extremely efficient secondary 
antibody response is mounted.
In addition to their ability to act as antigen presenting cells to T cells and their ability to 
produce antibodies, B cells are vital in driving the differentiation of T cells through 
producing an array of cytokines. Production of tumour necrosis factor-a (TNF-a) by B 
cells amplifies Th1 differentiation whereas IL-6 and TGF-p production promote Th17 
production (Bettelli et al., 2007; Menard et al., 2007). Secretion of IL-4 and IL-10 by B 
cells results in the development of Th2 cells (Harris et al., 2000).
The immune system has evolved to coordinate a variety of responses against 
numerous pathogens whilst remaining silent towards self-antigens and also those 
derived from commensal organisms that exist in the body (see section 1.1.3). However, 
if these processes are not strictly maintained, chronic inflammation and/or 
autoimmunity can develop (see section 1.2).
1.1.3 Immunological tolerance
In order to ensure that both the innate and adaptive immune system only responds to 
foreign pathogens and not self-proteins, a number of mechanisms are in place to 
ensure tolerance of self-proteins; these are divided into two types: (1) central tolerance
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and (2) peripheral tolerance. Central tolerance is established in the thymus for T cells 
and in the bone marrow for B cells.
1.1.3.1 Central tolerance
Central tolerance is established within the thymus by purging self-reactive thymocytes, 
and thus reducing the propensity for autoreactivity among mature T cells in the 
periphery (Metzger and Anderson 2011). T cells are derived from hematopoietic stem 
cells but migrate to the thymus to undergo maturation. Upon entry into the thymus, the 
majority of T cell precursors commit to the a(3 T-cell lineage and at this stage are 
double negative i.e. do not express CD4 or CD8 coreceptors (Washburn et al., 1997; 
Rothenberg and Dionne 2002; Wolfer et al., 2002). However, once in the thymic cortex 
these thymocytes undergo TCR p chain rearrangement in a ligand-independent 
process, followed by rearrangement of the a chain, and upregulation of both CD4 and 
CD8 molecules; also called double-positive (DP) T cells (Fehling et al., 1995; Irving et 
al., 1998). These DP thymocytes are programmed to undergo apoptosis unless a 
‘rescue signal’ is delivered via TCR and self-peptide-MHC ligation. DP thymocytes with 
a minimal threshold of reactivity to the particular self-MHC haplotypes survive, whereas 
those that fail to recognise self-MHC molecules undergo apoptosis. During this time 
prior to apoptosis there is a three day window in which rearrangement of the a-chain 
occurs, referred to as receptor editing, which aims to increase the likelihood of 
successful self-MHC restriction (Petrie et al., 1993; McGargill et al., 2000; Huang et al., 
2005). Around 95% of these DP thymocytes fail to demonstrate any specificity for an 
MHC ligand and undergo “death by neglect” or apoptosis (Egerton et al., 1990; Surh 
and Sprent 1994). Those DP thymocytes that express TCR that are able to bind an 
MHC ligand with mild avidity are positively selected and mature into single-positive 
(SP) thymocytes expressing either CD4 or CD8 (Starr et al., 2003). During this time 
chemokines are also produced which directs these T cells to undergo further 
maturation in the thymic medulla (Kwan and Killeen 2004; Misslitz et al., 2004; Ueno et 
al., 2004).
It is in the thymic cortex that positive selection occurs, whereby cells are tested to see if 
their receptors have sufficient affinity for self-MHC molecules, if not these cells undergo 
apoptosis and are cleared by macrophages. During this time cells express both CD4 
and CD8, however, those that are selected based on their interaction with class I MHC 
become CD4' CD8+ whereas those selected based on the interaction with class II MHC 
become CD4+ CD8' (Boehmer et al., 1989).
Once in the thymic medulla, these positively selected thymocytes must survive 
negative selection. During this process thymocytes are screened for any reactivity
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against self, autoreactivity, by subjecting these cells to an array of tissue-specific 
proteins that are under the control of autoimmune regulator (AIRE) gene (Chaplin 
2010). Medullary thymic epithelial cells express AIRE and it is these cells that are 
responsible for the negative selection of tissue-specific autoreactive T cells (Anderson 
et al., 2002). Thymocytes that express high-avidity TCR for self-peptide-MHC 
complexes undergo apoptosis. This process of clonal deletion serves to reduce the 
frequency of strongly self-reactive T cells in the periphery. Less than 5% of these 
developing T cells survive both positive and negative selection, those that do are 
released into the circulation. In the blood and secondary lymphoid organs 60-70% of T 
cells are CD4+ CD8' and the remaining are CD4' CD8+. However, despite this 
mechanism of negative selection of thymocytes reacting to self proteins, this process is 
not complete and a number of autoreactive T cells have been shown to escape into the 
periphery (Walker and Abbas 2002).
1.1.3.2 Peripheral tolerance
The incompleteness of central tolerance in removing the mature T cells with self­
antigen specificity necessitates additional mechanisms to maintain peripheral 
tolerance, where Tregs and tolerogenic DCs participate actively. These mechanisms 
include further clonal deletion of mature autoreactive T cells in the periphery, rendering 
these cells anergic, or actively suppressed (Arnold et al., 1993; Parijs and Abbas 1998; 
Walker and Abbas 2002) Tregs are specialised for immune suppression and disruption 
in the development of Tregs is a primary cause of autoimmune and inflammatory 
diseases in humans (see section 2.2). In particular CD4+ CD25+ Tregs have emerged 
as important players in the maintenance of peripheral self-tolerance and down- 
regulation of various immune responses (Maloy and Powrie 2001; Sakaguchi 2004).
Although the exact nature of Treg-mediated immune suppression is unknown, a 
number of mechanisms have been proposed, which include release of 
immunosuppressive cytokines, IL-10 and TGF-(3, cell-contact-dependent suppression 
and killing of APCs (Shevach, Thornton and Suri-Payer 1998; Takahashi et al., 1998; 
Asseman et al., 1999; Levings et al., 2002; Sakaguchi et al., 2008). Activated Tregs 
may also downregulate expression of CD80/86 on APCs or stimulate DCs to produce 
indoleamine 2, 3-dioxygenase (IDO), which is toxic to cells; both of which are 
dependent on CTLA-4 expressed on Foxp3+ CD25+ CD4+ Tregs (Cederbom et al., 
2000; Takahashi et al., 2000; Mahnke et al., 2007).
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1.1.3.3 Dendritic cells and tolerance
In addition to Tregs, DCs, the professional APCs of the immune system (see section 
1.1), also have the potential to induce imunity or tolerance, depending on the state of 
activation, activation signals, and cytokine milieu (Banchereau and Steinman 1998; 
Belz et al., 2002) DCs exist in three functional stages: (1) immature, (2) semi-mature 
and (3) mature. Immature DCs scan self and foreign antigens but in the absence of 
inflammatory stimuli express low levels of MHC class II and costimulatory molecules, 
and are therefore unable to activate T cells (Mahnke et al., 2002). Semi-mature DCs 
are loaded with antigen but in the absence of inflammatory stimuli are once again 
unable to stimulate T cells due to low expression of MHC class II and costimulatory 
molecules (Mahnke et al., 2002). Therefore, self-antigen presented by either immature 
or semi-mature DCs are unable to activate T cells inducing a state a functional 
inactivation in naive T cells called anergy (Randolph et al., 2008). In addition to this, 
when autoreactive T cells are repeatedly stimulated by immature DCs these cells may 
undergo apoptosis through activation-induced cell death (AICD) involving ligation of 
CD95 (Suss and Shortman 1996). Immature DCs may become activated in the 
presence of an antigen and inflammatory stimuli leading to maturation of DCs and 
activation of T cells (Gallucci et al., 1999). As mentioned previously, DCs produce I DO 
which suppresses T-cell proliferation and promotes T-cell apoptosis, and therefore 
directly contributes to T-cell tolerance (Munn et al., 2002; Terness et al., 2002; 
Swanson et al., 2004).
1.2 Autoimmunity
1.2.1 Breakdown of tolerance in autoimmunity
Breakdown of self tolerance leads to autoimmunity. Although the causes of 
autoimmunity remain to be elucidated, there are many studies documenting the link 
between breakdown of tolerance and development of autoimmune diseases.
1.2.2 Autoimmunity
The production and activation of autoreactive T and B cells leads to the development of 
autoimmunity. Autoimmune diseases are characterised by an inappropriate, excessive, 
inflammatory response against self, which results in destruction of tissue (Zenewicz et 
al., 2010). Although there is usually one primary end-organ target in individuals afflicted 
by an autoimmune disease, such as destruction of the pancreatic islet cells in the 
autoimmune disease type I diabetes mellitus (T1DM), numerous other organs are often
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also affected. Although the aetiology of autoimmune diseases remains to be 
elucidated, the causes are likely to be a combination of both genetic and environmental 
factors (Costenbader et al., 2012).
1.2.3 Multifactorial nature of autoimmunity
1.2.3.1 Genetics
Within families, clustering of distinct autoimmune diseases has been reported, 
suggesting the presence of shared pathogenic factors across autoimmune conditions. 
Families with autoimmune diseases, rheumatoid arthritis (RA) or multiple sclerosis 
(MS) are more likely to also manifest other autoimmune diseases (Lin et al., 1998; 
Broadley et al., 2000). Families with multiple members with MS have a much higher 
frequency of other autoimmune diseases compared to families with only a single 
member affected by the disease (Broadley et al., 2000). This suggests a cumulative 
enrichment of autoimmune susceptibility loci in these select cohorts.
Interestingly, monozygotic (MZ) twins show significantly higher concordance for 
autoimmunity than dizyogotic twins, implicating genetics as an important factor in the 
development of autoimmune conditions. Flowever, this concordance rate varies, with 
up to 70% in T1DM and only up to 30% concordance in MS (Ballestar 2010; Breton et 
al., 2011), which demonstrates that there is a genetic predisposition to developing 
autoimmune diseases but also shows that environmental factors must also influence 
the precipitation of disease in these genetically predisposed individuals (Thorsby and 
Lie 2005). A number of genes have emerged as important in predisposing individuals 
to the development of autoimmune diseases, the most studied and greatest association 
has been found in genes within the MFIC complex.
The MHC consists of 252 genes, many of which are highly polymorphic, in particular 
the human leukocyte antigens (HLA) class I and II genes encoding the peptide- 
presenting class I and II molecules (see section 1.1.2.1) (Thorsby and Lie 2005). A 
number of population studies have demonstrated strong associations between 
autoimmune diseases and HLA class I and II molecules. In some cases certain HLA 
molecules are associated with a specific autoimmune disease, such as HLA-DQ2 and 
coeliac disease, whereas some HLA molecules may be associated with a number of 
diseases, such as the HLA-DQ6 haplotype, which is associated with both MS and 
T1DM (Thorsby and Lie 2005). Although the reasons for this genetic predisposition to 
autoimmune disease in individuals expressing these particular HLA alleles is not yet 
fully elucidated, it is proposed that self-peptides are preferentially recognised and 
presented by these disease-predisposing HLA molecules.
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The application of genome-wide association studies (GWAS) to the study of 
autoimmune diseases has identified an increasing number of disease-associated loci in 
addition to HLA genes. The association signals for many of these associated loci do 
not directly implicate a single protein-encoding gene, and the causative role for 
candidate genes can only be speculated. However, a large number of major loci have 
been observed to demonstrate genome-wide evidence for association in distinct 
autoimmune diseases (for review see Thorsby and Lie 2005; Zenewicz et al., 2010). 
Associated loci include a broad array of immune-associated genes involved in 
lymphocyte activation, microbial recognition, and cytokine and cytokine receptors 
(Gregersen and Olsson 2009).
In individuals with an autoimmune disease, many tolerogenic mechanisms are altered 
by genetic loci implicated in autoimmunity. Some of these mechanisms are involved in 
central tolerance in the thymus and bone marrow that delete self-reactive B and T cells, 
whereas others involve peripheral mechanisms including Tregs (Wing and Sakaguchi
2009).
AIRE is essential in ensuring central tolerance (see section 1.1.3.1), mutations 
affecting AIRE lead to a relaxing of selection against self-reactive T cells in the thymus, 
resulting in a rare and aggressive autoimmune disease called autoimmune 
polyendocrine syndrome 1 (Shikama et al., 2009). Tregs play a critical role in 
maintaining peripheral tolerance (see section 1.1.3.2) and mutations of the FOXP3 
gene, which is essential for the development and function of Tregs, causes the 
autoimmune disease immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome (IPEX) which is fatal in the first two years of life (Bennett et al., 2001; 
Torgerson and Ochs 2007)
Pre-B cells in the bone marrow are highly autoreactive but become less so on 
differentiation, which is activated by the gene encoding tyrosine phosphatase non­
receptor type 22 expressed by lymphocytes (PTPN22) (Menard et al., 2011). A 
substitution of the amino acid arginine by tryptophan within this PTPN22 gene affects 
intracellular signalling inhibiting the activation of T and B cells, leading to failure to 
delete autoreactive T cells during thymic selection and impaired activation of Tregs 
(Vang et al., 2005). This PTPN22 tryptophan risk allele renders individuals more 
susceptible to developing a number of humoral autoimmune diseases, including T1DM, 
RA, and systemic lupus erythematosus (SLE) (Criswell et at., 2005; Bottini, et al. 2006; 
Barrett et al., 2009). In addition to PTPN22, there are a number of other associated loci 
containing candidate genes encoding molecules expressed by lymphocytes that 
modulate co-stimulatory functions, including CTLA-4, that contribute to genetic 
susceptibility to a number of common autoimmune diseases, including T1DM and RA
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(Wellcome Trust Case Control Consortium, 2007). This highlights the central role of 
lymphocyte activation in humans in the adaptive immune response.
Cytokines and cytokine receptor genes have been associated with autoimmunity. IL-2 
is a central mediator of T cell growth, and its signalling is regulated by its affinity to its 
receptors. Polymorphisms in the IL-2 receptor alpha (IL2RA or CD25) gene is 
associated with a number of autoimmune diseases, including T1DM, MS, RA and 
Crohn’s disease (Hafler et al., 2007; Lowe et al., 2007; Franke et al., 2010; Stahl et al.,
2010). This can affect the growth and survival of regulatory and pro-inflammatory T 
cells. MS has also been associated with IL-7 receptor alpha (IL7R) polymorphisms 
(Hafler et al., 2007; Barrett et al., 2009).
In addition to genetic variants altering lymphocyte activation and cytokine signalling, 
variants in genes related to innate immunity have also been identified with a number of 
autoimmune diseases. An example of this are variants of the NOD2 gene and its 
association with Crohn’s disease; explaining the heritability of this disease (Abraham 
and Cho 2009). NOD2 is a pattern recognition receptor that is usually involved in the 
recognition of bacterial peptidoglycan and subsequently activation of NF-k(3. In addition 
to NOD2, variants in the autophagy gene ATG16L1 have also been associated with 
Crohn’s disease (Abraham and Cho 2009).
1.2.3.2 Environment
A number of environmental agents have been found to play a role in the pathogenesis 
of autoimmune diseases including infection, ultraviolet light, chemicals or other factors 
capable of modulating immune responses such as occupational/environmental 
pollutants or drugs, and behavioural factors, such as smoking and diet (Borchers et al., 
2010; Ranque and Mouthon 2010; Selmi et al., 2010; Tobon et al., 2010; Selmi et al.,
2011).
Infection has long been associated with the development of autoimmune diseases. 
During infection, DCs take up and process self-antigens as well as foreign antigens, 
and in genetically susceptible individuals this may lead to activation of low affinity 
autoreactive T cells. This is called the “adjuvant effect” of infection in the pathogenesis 
of autoimmunity (Israeli et al., 2009). Another hypothesis involves molecular mimicry, 
whereby particular structures of certain pathogens imitate self-antigens resulting in the 
activation of autoreactive T cells, and attack of both foreign and self proteins (Blank et 
al., 2007). A well-documented organism where molecular mimicry is known to take 
place is infection with Streptococcus pyogenes which leads to rheumatic fever and 
glomerulonephritis.
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A number of occupational exposures have been linked to the development of a range 
of autoimmune diseases, in particular silica, solvents, and ionising radiation (Gourley 
and Miller 2007; Cooper et al., 2010). A strong association has been found between 
silica exposure and risk of developing several rheumatic autoimmune diseases, 
including scleroderma, RA and SLE (Khuder et al., 2002; Finckh et al., 2006; Cooper et 
al., 2010; McCormic et al., 2010).
Various solvents have also been linked to an increased risk of developing autoimmune 
diseases, including RA and MS (for review see (Gourley and Miller 2007). Ionising 
radiation has been linked with an increased risk of developing autoimmune thyroid 
disease (AITD) (Volzke et al., 2005). Ultraviolet radiation (UVR) resulting in more than 
one incidence of severe sunburn has been linked with an increased risk of developing 
lupus, whereas exposure to ultraviolet radiation has been found to significantly reduce 
the risk of developing MS (Freedman et al., 2000; Bengtsson et al., 2002).
In terms of behavioural factors, diet has also be linked to the development of 
autoimmune diseases, in particular gluten has been found to induce coeliac disease in 
genetically susceptible individuals and dietary meat and protein have been found to be 
associated with an increased risk of developing RA (Pattison et al., 2004; Alaedini and 
Green 2005). Cigarette smoking has been shown to significantly increase the chances 
of developing RA, although the exact mechanisms for this are unclear. A number of 
epidemiological studies have shown strong gene-environment interactions between 
smoking and the presence of HLA-DRB1 shared epitope (HLA SE) and PTPN22. 
Individuals who carry these susceptibility genes and smoke greatly increase their risk 
of developing RA (Costenbader et al., 2010; Karlson et al., 2010).
Environmental factors may also directly affect Tregs contributing to autoimmunity. 
Under normal physiological conditions Tregs display greater proliferation and higher 
metabolic activity than effector T cells and are therefore more sensitive to 
environmental agents such as ionising radiation, drugs and vitamins (Yamaguchi et al., 
2007; Costenbader et al., 2010; Karlson et al., 2010).
1.2.3.3 Epigenetics
Epigenetics is a new area of research in autoimmune diseases, and refers to changes 
in gene expression that do not involve changes in the actual DNA sequence (Lu et al.,
2010). These epigenetic mechanisms are sensitive to external stimuli and therefore 
environmental effects can be mediated by changes in epigenetic regulation. The major 
mechanisms of epigenetic gene regulation are through DNA methylation and histone 
modifications, which interact with one another in modulating chromatin architecture,
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leading to either silencing or transcription of the gene. More recently micro RNAs 
(miRNA) have also been identified that are involved in epigenetics. miRNAs are non­
coding RNA that can suppress translation by binding to complementary target mRNA 
species resulting in degradation of the target (Ruan et al., 2009).
DNA methylation consists of the addition of a methyl group to the fifth carbon of 
cytosine residues, resulting in their conversion to 5-methylcytosines. DNA methylation 
occurs predominantly at CpG islands, which are regions in the genome exceeding 500 
base pairs with a CG content higher than 55% (Gardiner-Garden and Frommer 1987; 
Illingworth and Bird 2009). These CpG islands have key regulatory functions, and are 
found at the promoter regions of approximately 50% of all genes (Bird 2002).
Histones are highly conserved proteins that reside within the nuclei of cells and provide 
DNA condensation and organisation in the nucleus, as well as modulating DNA 
accessibility to the transcription machinery. Modulation of transcription can be altered 
by chemical modifications of histones, including acetylation and methylation. In 
acetylation, histone acetyltransferase (HAT) promotes gene expression by transferring 
acetyl groups to lysine, whereas histone deacetylase (HDAC) remove acetyl groups 
resulting in gene repression (Gregory et al., 2001; Roth et al., 2001; Thiagalingam et 
al., 2003). Histone methylation can result in both gene activation and repression 
depending on where in histones the methyl group is added to lysine residues (Bauer et 
al., 2002; Schotta et al., 2004).
The potential role of epigenetics in environmental/genetic interactions, where 
environmental changes produce modifications in gene expression has received much 
interest. Studies have shown an association between DNA methylation and exposure 
to prenatal tobacco smoke, alcohol consumption and environmental pollutants 
(Baccarelli et al., 2009; Tarantini et al., 2009; Breton et al., 2011; Zhang et al., 2011). 
Epigenetics may explain the disconcordance of autoimmune diseases in MZ twins, as 
differences in phenotype become greater as twins age, a termed referred to as 
‘epigenetic drift’ (Fraga et al., 2005; Ballestar 2010). This epigenetic drift occurs during 
life according with the different exposures to environmental stressors. Concordance 
rates among MZ twins vary widely depending on the autoimmune disease, but with the 
exception of primary biliary cirrhosis (PBC), T1DM and coeliac disease, are well below 
50% indicating major environmental contributions (Meda et al., 2011).
A number of autoimmune diseases have been shown to be associated with epigenetic 
changes, including SLE, RA, T1DM and MS (for review see (Meda et al., 2011). An 
example of this is in RA, where it has been proposed that RA synovial fibroblasts have 
a major role in the initiation and perpetuation of the disease, either through decreased
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global DNA methylation or hypomethylation of CpG islands (Neidhart et al., 2000; 
Meinecke et al., 2005; Karouzakis et al., 2009). RA monocytes show increased 
resistance to apoptosis through changes in the methylation state of CpG islands within 
the promoter of death receptor 3 (Takami et al., 2006), with unmethylated CpG islands 
within the IL-6 promoter gene in monocytes found to be associated with hyperactivation 
of the inflammatory response (Nile et al., 2008).
1.2.3.4 Gender
Gender seems to play a crucial role in predisposition to developing an autoimmune 
disease, as more than 78% of individuals afflicted with an autoimmune disease are 
women (Fairweather et al., 2008). Generally, women are almost three times more likely 
to acquire an autoimmune disease compared to men, with the ratio between women 
and men varying between different autoimmune diseases (Oliver and Silman 2009). In 
SLE, AITD and Sjogren’s syndrome (SS) the ratio is 9:1, females to males, whereas in 
RA and MS this rate is lower at 2:1 (Whitacre 2001; Borchers et al., 2010; Kivity and 
Ehrenfeld 2010; Sellner et al., 2011). In addition to this, female gender is a risk factor 
for the development of multiple autoimmune diseases, also called polyautoimmunity 
(Rojas-Villarraga et al., 2010). Although the exact reason for this gender association 
remains to be fully elucidated, there are a number of possible mechanisms that have 
been suggested.
The strongest evidence appears to be the influence of hormones and the association 
with autoimmune diseases. Women are known to elicit a stronger humoral and cellular 
response compared to men, with women displaying a higher CD4:CD8 ratio, and 
increased number of both circulating CD4+ T cells and antibodies (Amadori et al.,
1995). A number of different hormones have been investigated for their association 
with the development of autoimmunity in women. Oestrogens have been shown to 
direct the immune system to a Th2 response rather than a Th1 response, resulting in 
increased B cell activation and the production of autoantibodies whereas prolactin 
stimulates both cell and humoral based immunity (McCarthy 2000; McMurray 2001). A 
number of autoimmune diseases have been shown to be negatively affected by the 
hormones oestrogen and progesterone, including SLE, RA and MS (for review see 
(Quintero et al., 2011)). An example of this is in RA, where synovial fluid levels of 
oestrogens are significantly elevated in both male and female patients with RA 
resulting in the activation of macrophages and the proliferation of fibroblasts 
(Castagnetta et al., 2003; Cutolo et al., 2004).
Pregnancy and hormones are another important association with gender. The signs 
and symptoms of MS and RA are reduced during pregnancy but are exacerbated
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following delivery of the baby, with this improvement during pregnancy thought to be 
linked to a shift from a Th1 to a Th2 response and worsening on return to this Th1 
response (Wegmann et al., 1993; Marzi et al., 1996). Other hormonal influences have 
also been studied including mensus, menopause and hormonal contraceptives, in 
addition to possible genetic factors, such as X-chromosome inactivation and X 
chromosome monosomy (for review see (Quintero et al., 2011)).
1.2.3.5 Geoepidemiology
There is an overall North-South gradient for immune disorders in North America, 
Europe and also in China (Yang et al., 1998; Bach 2002; Wallin et al., 2003). In Europe 
there is also a West-East gradient; an example of this is T1DM which has a lower 
incidence in Bulgaria and Romania compared to Western Europe, however incidence 
in these countries is increasing (Green and Patterson 2001). This gradient cannot be 
explained by genetic differences; an example of this is the incidence of T1DM is six­
fold higher in Finland compared to Russia, even though the genetic background of the 
population is the same (Kondrashova et al., 2005). Migration studies have shown that 
offspring of immigrants coming from a country with a low incidence acquire the same 
incidence as the host country for both T1DM and MS (Leibowitz et al., 1973; Bodansky 
et al., 1992; Hammond et al., 2000). This is well demonstrated in the case of T1DM 
where there is increasing frequency of T1DM in immigrants from Pakistan to the United 
Kingdom and also in the case of MS where there is increasing frequency of this 
disease in immigrants from Asia to the United States (Detels et al., 1972; Staines et al., 
1997). In addition to these examples, the prevelance of SLE is much higher in African 
Americans compared to West Africans (Symmons 1995).
1.3 Multiple sclerosis
MS is a chronic inflammatory neurodegenerative disease, which predominantly affects 
the white matter of the central nervous system (CNS) and is the most common 
neurological disease in young adults, with a mean age of onset of 30 years (Trapp et 
al., 1998). The disease is characterised by destruction of the myelin sheath, which 
insulates the axons of nerves, resulting in lesions of demyelinated axon fibres 
(Lassmann 2004). Within these lesions there is infiltration of macrophages, activated 
astrocytes and microglia, in addition to T and B lymphocytes (Musse and Harauz 
2007). It is this demyelination and subsequent axonal damage that leads to irreversible 
disability in people with MS (Musse and Harauz 2007). Symptoms of the disease vary 
depending on the area in the CNS where these lesions are formed, but include loss of 
sensation and motor control in addition to visual, speech, swallowing and sphincter
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disturbances, cognitive impairment, pain and fatigue. Despite considerable research, 
the cause of MS it still not known, although genetic and environmental factors influence 
disease incidence and it is thought to be autoimmune in origin (Musse and Harauz
2007).
1.3.1 Clinical presentation and disease course of MS
There are four different clinical subtypes of MS, which are divided based on the clinical 
course of the disease (Figure 1.2) (Lublin and Reingold 1996). Relapsing-remitting MS 
(RRMS) is the most common form of the disease, accounting for approximately 90% of 
cases initially (Schwarz et al., 2006; Zuvich, et al. 2009). RRMS is characterised by 
acute attacks where there are periods of a worsening in neurological function 
(relapses) followed by either a partial or full recovery (remission), with recurrent attacks 
over a period of time (Podojil and Miller 2006; Zuvich, et al. 2009). However, 
approximately 60% of these patients find that as the disease progresses complete 
recovery from these attacks does not occur, leading to secondary progressive MS 
(SPMS). SPMS is similar to RRMS as there are periods of acute attacks where there is 
an increase in disability, however, during remission of this attack there is only partial 
recovery of symptoms leading to progressive disability over time (Lublin and Reingold
1996). This progression from RRMS and SPMS takes an average of 19 years from the 
initial onset of the disease (Rovaris et al., 2006). Primary progressive MS (PPMS) is 
much less common, accounting for approximately 10% of cases, and is characterised 
by progressive disability from onset of disease, with no significant periods of relapse 
and/or remission (Podojil and Miller 2006; Miller and Leary 2007). Lastly, progressive 
relapsing MS (PRMS) is the least common subtype, occurring in less than 5% of cases, 
and is similar to PPMS as it is characterised by progressive onset of disability from 
disease onset, however, with clear periods of relapses without remission (Lublin and 
Reingold 1996; Podojil and Miller 2006).
1.3.2 Diagnosis
A diagnosis of MS is based on showing lesion dissemination in space and time, i.e. that 
clinical episodes affecting separate sites within the CNS have occurred at least 30 days 
apart, and involves excluding other neurological disorders that can clinically and 
radiologically mimic MS (Charil et al., 2006). The principle of diagnosis is to establish 
from clinical evidence, supplemented by laboratory investigations, that disease activity, 
which is consistent with focal demyelination, has affected more than one part of the 
CNS on more than one occasion (McDonald et al., 2001; Polman et al., 2005; 
Compston and Coles 2008). Diagnosis can be made based on clinical assessment
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only, but usually involves the use of magnetic resonance imaging (MRI) to visualise 
enhancing and non-enhancing lesions in the brain and/or spinal cord and the presence 
of oligoclonal bands (OCBs) on isoelectric focusing (IEF) of cerebrospinal fluid (CSF) 
(McDonald et al., 2001). MRI shows white matter lesions in more than 95% of MS 
patients. However, their presence alone cannot be used in the diagnosis of MS, as 
characteristic radiological lesions can appear in people with other neurological 
conditions, such as acute disseminated encephalomyelitis (ADEM), and older 
individuals have non-specific white matter cerebral lesions (Compston and Coles
2008). The finding of OCBs in CSF remains the most reliable immunological test used 
to support the clinical and radiological features in establishing the diagnosis of MS 
(Weber and Hemmer 2010). However, OCBs are not disease specific and therefore 
can only be used in conjunction with other neurological tests. Variants of MS include 
neuromyelitis optica (NMO), Balo’s concentric sclerosis and acute MS (Marburg type) 
can also overlap substantially with MS by clinical, laboratory and imaging measures. 
Based on this important exclusion of other disorders is carried out by combining the 
clinical history, physical examination, MRI and presence of OCBs to establish a firm 
and clear diagnosis of MS (Polman et al., 2005).
1.3.3 Genetics and MS
There have been many studies carried out to investigate the genetics of MS within 
affected families. It is known that individuals belonging to a family with an affected 
individual carry an increased risk of developing the disease, with a familial recurrence 
rate of approximately 20% (Ebers et al., 1995; Sadovnick et al., 1996). Siblings, 
parents, and children carry an increased risk of developing MS if a family member is 
affected, of 3, 2 and 2%, respectively (Sadovnick et al., 1996). The age-adjusted risk of 
developing MS as a white northen European is 0.3% (Robertson et al, 1996). Studies 
in twins have also proven invaluable, with MZ twins showing a recurrence rate of 25- 
34% compared to 2-5% in dizygotic (DZ) twins, indicating a high heritability (Sadovnick 
et al., 1993; Wilier et al., 2003). Half-siblings have a lower age-adjusted risk of 
developing MS than full siblings, and this risk factor does not change whether they are 
reared together or apart from one another (Sadovnick et al., 1996). In children where 
both parents are affected by MS the recurrence risk is higher than in children who only 
have one affected parent (Robertson et al., 1997; Ebers et al., 2000).
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Figure 1.2: Clinical disease course in multiple sclerosis. There are four disease 
courses of MS. The most common disease course is relapsing remitting MS (RRMS) 
which is characterised by an acute attack followed by a full recovery and then 
subsequent attacks over time. The majority of patients with RRMS progress to 
secondary progressive MS (SPMS) which is characterised by fewer attacks and 
incomplete recovery as the disease becomes more progressive. Primary progressive 
MS (PPMS) is characterised by an increase in disability over time in the absence of 
any well-defined relapses and remissions. Progressive relapsing MS (PRMS) is the 
most rare disease course and is characterised by progressive disability from disease 
onset with clear relapses, in the absence and presence of a full recovery (Podojil and 
Miller 2006).
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There have been many genetic studies carried out to identify particular genes that may 
be associated with a risk of developing MS. The greatest achievement in genetics was 
the identification of variants in the HLA genes and associated risk of developing MS, in 
particular inheritance of the HLA-DRB*1501, DRB5*0101, DQBV0602, and
DQA1*0102 haplotypes (Bertrams et al., 1972; Naito et al., 1972; Fogdell et a l, 1995; 
Oksenberg and Barcellos 2005)
In a recent large-scale genetic study, DRB1 *15/08 genotypes were identified as high- 
risk for MS whereas DRB1*15/14 genotypes were identified as protective for MS 
(Barcellos et al., 2006). In addition, protective effects have been reported to be 
conferred by both HLA-5 and HLA-DRB1*11 (Ramagopalan et al., 2007; Yeo et al., 
2007; Dean et al., 2008). Additional genes have also recently been identified as having 
MS susceptibility loci associated with single nucleotide polymorphisms, including 
interleukin-7 receptor, interleukin-2 receptor, ecotropic viral integration site 5 and 
kinesin family member 1p (Hafler et al., 2007; Lundmark et al., 2007; Aulchenko et al., 
2008; Hoppenbrouwers et al., 2008).
1.3.4 Epidemiology
MS affects approximately 2.5 million people globally. It affects 1:1000 in the UK, 
costing £1.2 billion per year in the UK alone (Holmes et al., 1995; Compston and 
Confavreux 1998). Onset of disease is most common between the ages of 20 and 40 
years, reaching highest incidence at around 24 years of age, with females twice as 
likely to develop the disease than males (Noseworthy et al., 2000). In some countries 
this 2:1 ratio has increased, as demonstrated in Canada where a recent study showed 
that 3.2 women were affected for every man (Orton et al., 2006). Childhood MS is rare 
with disease onset occurring before the age of 18 in only 3-10% of cases (Banwell et 
al., 2007). Both the incidence and prevalence of MS appears to increase with 
increasing distance from the equator, with the most northern and southern countries 
identified as most high risk (Goldacre et al., 2004; Alonso and Hernan 2008). Clear 
increases in both the incidence and prevalence have been found in America (Noonan 
et al., 2002), Australia (Barnett et al., 2003), Canada (Orton et al., 2006), and the UK 
(Alonso and Hernan 2008) supporting the theory that there is an increase in countries 
furthest from the equator. This gradient of increasing MS risk with increasing latitude 
has been strongly linked with lack of UVR and vitamin D deficiency. It has been 
suggested that UVR exposure, which is the primary source of vitamin D, may offer 
protection against the development of MS, therefore accounting for this latitudinal effect 
of MS prevelance (Acheson et al., 1960; Kurtzke et al., 1979). In support of this a
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recent study found that individuals with MS have a much lower risk of developing skin 
cancer than individuals without MS (Goldacre et al., 2004).
1.3.5 Pathology of multiple sclerosis
1.3.5.1 White matter pathology
In 1868, Charcot first described the pathological hallmarks of MS, including focal 
demyelination, inflammation, formation of a scar, and varying degrees of axonal 
damage. There are two major types of plaques in MS: the active lesion and the chronic 
inactive lesion. The active lesion consists of active inflammatory demyelination, which 
is typically restricted to white matter and characterised by the accumulation of both 
lipid-laden macrophages and large reactive astrocytes, accompanied by varying 
degrees of perivascular inflammation. Luxol fast blue staining reveals loss of myelin 
with the preservation of axons in most cases, although where there is extensive 
damage, axons may become lost or fragmented (Lucchinetti et al., 2005). Typically 
macrophages become engorged with phagocytosed myelin remnants and debris, 
resulting in the appearance of classic Gitter cells. These cells are characterised by 
spherical round nuclei, vacuolated cytoplasm, and discrete cell bodies. Reactive 
astrocytes are also prominent, displaying polymorphic nuclei and an eosinophilic 
cytoplasm, and are distributed evenly throughout the active lesion (Lucchinetti et al., 
2005). By investigating the structural profile and degradation products within 
macrophages, demyelinating activity within a plaque can be determined: minor myelin 
proteins, including myelin oligodendrocyte (MOG) and myelin-associated glycoprotein 
(MAG), are rapidly degraded within 1 to 2 days following phagocytosis; whereas, major 
myelin proteins, including myelin basic protein (MBP) and PLP, can persist in 
macrophages for up to 10 days in biopsies; and in the later stages, macrophages 
contain sudanophilic and periodic acid-Schiff (PAS)-positive granular lipids that can 
persist in the lesion for several months (Bruck et al., 1995).
The chronic lesion involves predominantly the white matter and consists of 
demyelinating foci or plaques, which are found throughout the CNS, but most 
commonly develop in the periventricular white matter, varying in both size and number 
between individuals. These lesions also have a predilection for the optic nerves, 
brainstem, cerebellum and spinal cord. The chronic inactive plaque is sharply defined 
and hypocellular with no evidence of active demyelination or axonal loss (Lucchinetti et 
al., 2005). There is prominent fibrillary gliosis, along with a substantial reduction or 
complete loss of mature oligodendrocytes, with varying degrees of inflammation 
sometimes still present, particularly in the perivascular region (Prineas 1985). There
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can be obvious areas of remyelination but this is often incomplete and restricted to the 
plaque edge. However, more extensive remyelination throughout a chronic MS plaque 
may also be observed; referred to as shadow plaques (Lucchinetti et al., 2005). These 
remyelinated lesions can then become targets for further demyelination (Prineas et al., 
1993). Oligodendrocyte progenitor cells have been identified in completely 
demyelinated plaques devoid of mature oligodendrocytes (Wolswijk 1998), suggesting 
that remyelination may not be limited by an absence of oligodendrocyte progenitors but 
that damaged neurons may not be receptive to remyelination signals (Chang et al., 
2002).
At present MS lesions are classified based on either stage (for review see (Van der 
Valk and De Groot 2000) or underlying pathology (Lucchinetti et al., 2000). To date, 
four staging systems for MS lesions have been defined (for review see (Van der Valk 
and De Groot 2000)(Berger and Reindl 2007). The Bo/Trapp staging system 
encompasses the cellularity to determine the type of lesion, which is split into the 
following three categories: (1) active demyelinating lesions, defined as hypercellular; 
(2) chronic active lesions have a hypocellular centre with a hypercellular rim; and (3) 
chronic inactive lesions are hypocellular (Bo et al., 1994; Trapp et al., 1998). This 
system works best when applied to frozen sections and paraffin embedded tissue from 
post-mortem acquired lesions, but does not recognise early changes that occur in 
lesions. A modification of the Bo/Trapp staging system is the De Groot-van der Valk 
system which includes the following additional categories: (1) ‘pre-active’ lesions 
defined by clusters of microglial cells with little inflammation and no demyelination; (2) 
active demyelinating; (3) active but not demyelinating; (4) chronic active (as with the 
Bo/Trapp system); and (5) chronic inactive (as with the Bo/Trapp system). This system 
has been shown to work best on MRI-sampled material (Van Waesberghe et al., 1999). 
The Lassman/Bruck staging system used a high number of biopsy samples and 
therefore has been deemed most useful for classifying early lesions, and consists of 
five categories: (1) early active; (2) late active; (3) inactive; (4) early remyelinating; (5) 
late remyelinating (Briick et al., 1994; Bruck et al., 1995). The Vienna consensus was 
brought about at a conference in Vienna when a group of MS pathology experts 
convened to discuss staging of MS, led by Professor Hans Lassman (Ferguson et al.,
1997). The Vienna consensus incorporated both the Bo/Trapp and Lassman/Bruck 
staging system and identified six lesion types, as follows: (1) inflammatory and 
demyelinating; (2) inflammatory but not demyelinating; (3) hypocellular centre with 
inflammatory rim and demyelinating; (4) hypocellular centre with inflammatory rim, but 
not demyelinating; (5) no inflammation, but demyelinating; and (6) no inflammation and 
not demyelinating. The Vienna consensus is a more descriptive way to describe MS 
lesions rather than a staging system.
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1.3.5.2 Grey matter pathology
MS is traditionally thought of as a disease of the white matter, however, there is 
increasing interest in grey matter pathology, as demyelinating lesions have been found 
in both the cerebral cortex and the cerebellum of post-mortem tissue taken from the 
brains of patients with MS (Kutzelnigg et al., 2005; Kutzelnigg et al., 2007). The reason 
for this traditional view of MS as a disease of the white matter appears to be due to the 
fact that grey matter lesions are much more difficult to detect than those that occur in 
the white matter using traditional T2-weighted MRI scanning, for a number of reasons 
including location of lesion, size of lesion and the intrinsic properties of the grey matter, 
and therefore are often missed (Schmierer et al., 2010). A recent study also found that 
MRI for the detection of cortical lesions has a sensitivity of only 3-5% (Geurts et al., 
2005). In addition, although there is axonal injury, the global tissue texture is preserved 
better in grey matter lesions compared to white matter lesions, which can make it more 
difficult to determine cortical demyelination on visual inspection of the post-mortem 
brain or with MRI (Kidd et al., 1999).
In a study carried out by Lumsden and colleagues examining 60 MS post-mortem brain 
tissue cases, 93% of cases showed involvement of the cortex to a varying degree, with 
some showing involvement of only a few cortical lesions whilst in one case there were 
465 lesions (Lumsden 1970). Using post-mortem tissue from 52 patients with MS and 
30 control brains with immunohistochemistry, Kutzelnigg et al (2005) identified cortical 
demyelination as a characteristic feature of progressive MS. Demyelination in the 
cerebral cortex was mainly observed in tissue taken from patients with SPMS and 
PPMS, and was rare in patients with acute or relapsing disease course (Kutzelnigg et 
al., 2005). This has confirmed previous studies which also showed the presence of 
cortical demyelination in SPMS and PPMS patients (Brownell and Hughes 1962; 
Peterson et al., 2001).
Furthermore, in a more recent study, Gilmore and colleagues used 14 MS post-mortem 
MS cases and 3 control brain cases to quantify grey and white matter demyelination 
through staining for proteolipid protein (PLP) (Gilmore 2008). Overall, 28.8 % of the 
grey matter was demyelinated compared with only 15.6 % of the white matter, which 
was most extensive in the spinal cord and cerebellum. Consistent with the study by 
Kutzelnigg et al. (2005) this demonstrated that the cerebellar cortex is a predilection 
site for demyelination (Gilmore 2008). Grey matter lesions differ significantly from white 
matter lesions, as they are less inflammatory, with less infiltration by both macrophages 
and lymphocytes (Bo et al., 2006).
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1.4 Immune responses within the central nervous system
1.4.1 T cells
T cells arise from haematopoietic stem cells in the bone marrow and mature in the 
thymus, and play an important part in cell mediated immunity. Unlike B cells, T cells are 
only able to recognise peptide antigens that are displayed on MHC molecules 
expressed on other cells. All nucleated cells express MHC class I proteins, which are 
able to bind specifically to TCRs on T cells expressing the CD8 co-receptor (Friese and 
Fugger 2009). T cells expressing the CD4 co-receptor on their surface are restricted to 
interaction with MHC class II proteins, which are mainly expressed on specialised 
APCs (LaRosa and Orange 2008).
T cells can be divided into two main populations; effector and memory. Effector T cells 
encompass CD8+ T cells; CD4+ T helper (Th) 1, Th2, Th17, regulatory T cells (Tregs), 
whereas memory T cells consist of central memory (TCm) and effector memory (Tem) 
populations. CD4+ T helper cells produce the largest numbers of cytokines with Th1- 
type cytokines including IL-1(3, TNF-a and IFN-y producing pro-inflammatory responses 
specific for killing intracellular parasites and for exacerbating autoimmune responses, 
and Th2-type cytokines IL-4, IL-5 and IL-13, facilitating B-cell antibody responses, with 
IL-4 driving B-cell proliferation against extracellular pathogens and IL-4/IL-5 enabling 
production of IgE and eosinophilic inflammation, which is important for the clearance of 
helminth infections and atopy (Berger 2000; LaRosa and Orange 2008). CD4+ T cells 
differentiate into the different subsets upon priming and are distinguished by the 
cytokines they produce and their effector functions. Although not yet completely 
understood, it is thought that the cytokine milieu is the major factor that determines the 
differentiation of these subsets (LaRosa and Orange 2008).
T cells are able to enter the CNS in order to carry out immune surveillance, but are 
found in relatively low numbers in the CNS of healthy individuals (Hickey 1999), with 
higher efficiency in the spinal cord compared to the brain (Phillips and Lampson 1999; 
Yeager et al., 2000). The amount of immune surveillance in the CNS is much less than 
that occurring in other tissues.
Cytotoxic lymphocytes (CTLs) are found in low numbers in the CNS of healthy 
individuals, but are recruited during inflammation. CD8+ T cells are implicated in the 
direct killing of resident cells in host tissues through the release of perforin and 
granzymes which are toxic to the cells, resulting in specific killing of target cells 
(Shresta et al., 1998; Trapani et al., 2000; LaRosa and Orange 2008).
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1.4.2 B cells
B cells comprise the humoral part of the adaptive immune response, originating from 
haematopoietic stem cells in the bone marrow, and are imperative in controlling 
microbial infections (Cepok et al., 2006). B cells respond to protein targets in the GC of 
the lymph node, with the support of antigen-specific T cells. Upon contact with a 
specific protein presented on DCs B cells undergo affinity maturation during which high 
affinity receptors directed towards the target antigen are generated and eventually Ig 
class-switch is induced (see section 1.1.2.4). These high-affinity B cells can either 
mature into memory B cells or become antibody-secreting plasma cells, secreting 
antibodies of IgA, IgD, IgE, IgG or IgM class (Rajewsky 1996). These antibodies can 
bind specifically to antigens where they undergo phagocytosis by macrophages and 
can also activate the complement system (Dunkelberger and Song 2009). B cells can 
also act as APCs (Batista and Harwood 2009).
In non-inflammatory conditions, B cells are largely absent from the CNS and CSF, 
however, in acute and chronic inflammatory disease B cells can constitute up to 30% of 
cells of the CSF (Cepok et al., 2003; Cepok et al., 2005). These accumulated B cells in 
the CSF are predominantly lgM-lgD-CD27+ class switched memory B cells rather than 
short-lived immature plasma blasts (Cepok et al., 2006).
1.4.3 Glial cells
Virchow in 1846 was the first to coin the term neuroglia when he described cells other 
than neurons in the brain. This term has been used since the 1850s as a generic name 
for these cells, or in its shortened form ‘glia’. These major glial cell types were further 
characterised as the result of microscopic studies whereby Cajal first identified 
astrocytes, which was followed by Hortega identifying oligodendrocytes and microglia 
(Kettenmann and Verkhratsky 2008).
1.4.3.1 Microglia
Microglia are derived from myeloid cells in the periphery and are the resident long-lived 
macrophages of the CNS, accounting for approximately 12% of cells in the brain and 
10-20% of glial cells (Lawson et al., 1990; Gandhi et al., 2010; Zhang et al., 2010). 
There is significantly higher microglial density in white matter versus grey matter, with 
as little as 0.5% microglia in the grey matter compared to 16.6% in the white matter of 
the non-diseased human brain (Mittelbronn et al., 2001).
Microglia are responsible for the first line of defence against bacterial, viral, parasitic
and fungal infections in the CNS (Napoli and Neumann 2009). In order to carry out this
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task microglia have a large number of processes which cover the entire CNS 
parenchyma (Napoli and Neumann 2009). Traditionally microglia were thought to be in 
a “resting” state under normal physiological conditions, however, in vivo live imaging of 
fluorescently-tagged microglia in the rodent brain showed that microglia processes are 
very motile and are constantly surveying their environment through projection and 
retraction of their processes (Davalos et al., 2005; Nimmerjahn et al., 2005). This high 
motility enables microglial processes to immediately perceive their microenvironment 
and carry out important homeostatic activity in the normal CNS, including the constant 
phagocytosis of cellular debris and apoptotic cells (Napoli and Neumann 2009; 
Neumann et al., 2009). In this state, microglia are characterised by a ramified 
morphology and the expression of certain cell surface antigens, such as MHC 
molecules (Mittelbronn et al., 2001; Rock et al., 2004). Based on the above findings 
microglia are now thought of more as “surveillance” cells when not yet activated. 
Microglia are quickly activated following injury or infection and migrate towards the site 
of damage or infection within hours (Davalos et al., 2005; Haynes et al., 2006). In this 
state, microglia are characterised by an amoeboid morphology, along with up-regulated 
expression of cell surface markers, such as MHC molecules and chemokine receptors, 
and also the expression of CD14 which is not found on ramified microglia (Rock et al.,
2004).
Microglia express distinct types of receptors, which have a role in phagocytosis of 
pathogenic organisms through the expression of their Toll-like receptors (TLRs) or 
scavenger receptors which recognise phosphatidylserine (PtdSer) on the surface of 
apoptotic cells (Napoli and Neumann 2009).
The first line of defence in the elimination of microbes in the CNS is mediated by the 
recognition of pathogen associated molecular patterns (PAMPs) by TLRs expressed by 
microglia, which are widely expressed on many cells of the immune system and exist 
on both the surface and on internal membranes. TLRs respond rapidly to microbial 
pathogens through binding to these PAMPs (Napoli and Neumann 2009). TLRs are a 
type I transmembrane pattern recognition receptors (PRRs) that act as endogenous 
sensors for PAMPs produced by bacteria, viruses, parasites and fungi (Glezer et al.,
2007). Microglial cells express TLRs 1-9 and expression of these receptors is pivotal 
for generation of neuroimmune responses (Aravalli et al., 2007; Jack et al., 2007). 
Upon a PAMP binding to a specific TLR a downstream signalling pathway is initiated 
whereby adapter proteins are recruited leading to the activation of protein kinases and 
activation of transcription factors resulting in the secretion of pro-inflammatory 
cytokines (such as IL-1(3 and IL-6) and chemokines (such as CCL2 and CCL5) and 
production of reactive oxygen and reactive nitrogen species (ROS and RNS) (Takeda
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and Akira 2005; O'Neill 2008; O'Neill et al., 2009; Huang and Pope 2010). This results 
in both phagocytosis of infected cells and inflammation limited to the area of infection. 
TLR signalling plays a significant role not only in the innate immune response to CNS 
infections but also in inflammatory and demyelinating disorders including MS, 
ischaemic injury, and neurodegeneration (Aravalli et al., 2007; Lehnardt 2010). An 
example of this is injury to tissue within the CNS results in the release of DAMPs which 
are also recognised by TLRs and activate the same downstream signalling pathway as 
PAMPs.
In addition to TLRs, microglia express receptors able to detect pathogens, including 
nuclear oligomerisation domain-like receptors (NLRs) (Shaw et al., 2010; Bielig et al., 
2011; Kepp et al., 2011; Lamkanfi 2011). NLRs are located within the cytoplasm and 
recognise cytosolic viruses and bacterial products, which like TLRs bind many different 
ligands leading to gene transcription and production of pro-inflammatory cytokines, 
chemokines and proteases. However, NLRs also recruit cytoplasmic proteins to form 
an inflammasome capable of activating caspase-1, leading to the conversion of cellular 
proteins such as those transcribed by TLR activation (e.g. IL-1 [3 and IL-18) to their 
active forms that upon secretion contribute to the inflammatory cascade. These 
pathways involving TLRs and NLRs are important for helper T cell type I responses in 
killing of intracellular pathogens (Ross 2010). TLRs and NLRs both activate signalling 
pathways, however microglia also express PRRs which have immediate effects 
resulting in binding and subsequent internalisation of either pathogens or apoptotic 
cells without subsequent activation of signalling pathways (Ross 2010).
Dying cells in the CNS recruit phagocytes from both close proximity and greater 
distances, through the release of DAMPs. These signals facilitate the recruitment of 
microglia, include the release of nucleotides adenosine triphosphate (ATP) and uridine 
triphosphate (UTP) from damaged neurons, which have been shown to be key 
mediators in the recruitment of microglia through activation of puri no receptors following 
injury, leading to the removal of dying cells or their debris (Davalos et al., 2005; Haynes 
et al., 2006).
Within days following injury, microglia undergo a process called reactive microgliosis 
whereby microglia proliferate extensively and upregulate the expression of the stem 
cell-associated surface molecule CD34 (Ladeby et al., 2005). In comparison, cells 
undergoing apoptosis i.e. programmed cell death express signals which act as markers 
for microglia leading to ingestion and subsequent elimination of these cells. The most 
studied of these signals is PtdSer, which is redistributed to the outer leaflet of the 
plasma membrane to enable recognition by phagocytes followed by subsequent 
internalisation (Ravichandran 2003; Ravichandran and Lorenz 2007; Napoli and
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Neumann 2009). Apoptotic neurons have also recently been shown to upregulate their 
expression of TREM2 ligand (triggering receptor expressed on myeloid cells-2) 
resulting in efficient clearance of these damaged neurons by microglia expressing 
TREM2, without inducing gene transcription of pro-inflammatory mediators or up- 
regulating the expression of receptors involved in antigen presentation (Takahashi et 
al., 2005; Piccio et al., 2007).
Microglia are also important antigen presenting cells in the CNS and are able to 
interact with B and T cells through the expression of MHC class II and co-stimulatory 
molecules CD83 and CD40 (Benveniste 1997; Raivich and Banati 2004; Aravalli et al.,
2007).
Besides their role in both innate and adaptive immunity, microglia are also important in 
embryogenesis whereby cells of the immune system undergo developmental 
apoptosis, in particular twice as many neurons are produced then are retained in the 
mature individual. Microglia are thought to play a role in both promoting cell death and 
the phagocytosis of developing neurons (Marin-Teva et al., 2004; Bessis et al., 2006; 
Ransohoff and Perry 2009). In addition to this, microglia are also important as 
promoters of neurogenesis in adults through secretion of neurotrophic factors such as 
brain-derived neutrotrophic factor, insulin-like growth factor (IGF-1) and neurotrophin 3 
(Napoli and Neumann 2009; Napoli and Neumann 2010). Microglia are also thought to 
carrying out synaptic stripping in pathological processes (Bessis et al., 2006; Trapp et 
al., 2006). Therefore, microglia can be both neuro-protective and neuro-destructive 
(Aravalli et al., 2007).
1.4.3.2 Astrocytes
Astrocytes are the most abundant glial cells in the CNS and are defined by their 
characteristic star-shaped morphology and the expression of the intermediate filament 
GFAP within their cytoplasm (Eng 1985). Two types of astrocytes exist within the brain: 
(1) stellar fibrillary astroglia and (2) protoplasmic astroglia. The former have elongated 
cell processes and are predominantly found in the white matter of the brain (Bignami et 
al., 1972), whereas the latter have short and ramified cell processes and are usually 
found in the grey matter (Didier et al., 1986; Cammer and Tansey 1988). Until recently, 
these cells were thought to merely play a role as supportive cells within the brain and in 
forming a structural part of the blood-brain barrier (BBB). However, this view has now 
changed with recent publications showing that astrocytes play a number of important 
complex roles within the brain, including monitoring and modulating the neuronal 
microenvironment and information processing and signalling in the brain (for review 
see Penkowa et al., 2008).
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Astrocytes have a number of housekeeping duties within the CNS, including the 
formation and maintenance of the BBB as part of the glia limitans, which prevents the 
entry of potentially harmful molecules into the brain and facilitates the entry of essential 
nutrients into the CNS, in addition to the formation of tight junctions (TJs) between the 
endothelial cells (ECs) of the BBB (Aschner 2000). Astrocytes are able to preserve the 
stability of the extracellular environment by regulating extracellular pH and removing 
neurotransmitters, excess ions, ammonia, free radicals and water from the brain 
microenvironment (Tsacopoulos and Magistretti 1996; Benveniste 1997; Aschner et al., 
1999). Under normal conditions, astrocytes maintain homeostasis in the CNS to 
support survival and information processing functions of neurons through providing 
neurotrophic and protective factors (Ridet et al., 1997; Raivich et al., 1999).
Due to their large numbers within the brain and their extended processes, astrocytes 
are also important surveillance cells within the CNS and react to brain damage or 
disease by increasing in both their number and size in a process called reactive 
astrogliosis (Penkowa et al., 2008). Cell hypertrophy of these reactive astrocytes is a 
consequence of an increase in intracellular filaments and cytoskeleton proteins (Ridet 
et al., 1997) in order to stabilise the brain tissue surrounding the site of injury. In 
particular, there is an upregulation of the intermediate filament protein GFAP within the 
cytoplasm of the astrocytes, which is a hallmark of reactive astrogliosis and GFAP 
immunostaining is the most commonly used marker for reactive astrogliosis, and is a 
sensitive and early biomarker of astrogliosis following injury (O'Callaghan and Sriram
2005).
Trauma, ischaemia, infections and neurological diseases are all known to have the 
capacity to induce astrogliosis i.e. conversion of astrocytes into their “reactive” form 
(Malhotra et al., 1997; Okamoto et al., 2005; Sofroniew 2009; Wakasa et al.,
2009).()()() Reactive astrocytes initiate and regulate CNS inflammatory and immune 
response through the expression and secretion of a number of important 
neuroimmunological factors, including adhesion molecules, MHC class I and II, 
cytokines, neurotrophic factors, growth factors and signalling molecules (Penkowa et 
al, 2008). Reactive astrocytes modulate the CNS microenvironment by producing and 
secreting molecules of the extracellular matrix (ECM) (Eddleston and Mucke 1993; 
Aschner et al., 1999). In addition to the above roles, reactive astrocytes are also pivotal 
in the maintenance and repair of the BBB following CNS injury (Zhang et al., 2010).
Reactive astrocytes provide support for axonal growth and help improve the recovery 
of axons following injury (Privat 2003). Inititally astrocytes encase themselves around 
damaged neurons with thin sheet-like lamellar cell processes (Graeber and Kreutzberg 
1988) resulting in the loss of synapses, but then retract from the neurons prior to
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neuroregeneration, with neuronal surface membranes eventually re-establishing 
synapses (Raivich et al., 1999). However, following a particularly traumatic injury to the 
CNS, hypertrophic astrocytic processes encase the lesion site and deposit an inhibitory 
ECM, which results in the formation of a dense structure that prevents 
neuroregeneration and is referred to as a glial scar (Cafferty et al., 2007). CNS neurons 
are unable to neuroregenerate due to both an inhibitory physical and chemical barrier, 
as it is thought that astrocytes may also produce growth-inhibitory factors (Stichel and 
Muller 1998; Rolls et al., 2009).
Reactive astrocytes are also a major source of both pro- and anti-inflammatory 
cytokines, and are therefore able to activate other immune-responsive cells, such as 
monocytes/macrophages/microglia and lymphocytes to the site of injury (Hopkins and 
Rothwell 1995; Ridet et al., 1997; Raivich et al., 1999). Initially this production of pro- 
inflammatory cytokines can be beneficial in recruiting immune-responsive cells, such 
as micoglia and lymphocytes to the site of injury and attenuation of CNS damage, 
however, prolonged release of these cytokines may induce chronic inflammation and 
neurodegeneration, as these pro-inflammatory cytokines are harmful to both neurons 
and oligodendrocytes (Oleszak et al., 1998). Reactive astrocytes are also able to 
produce nitric oxide which causes damage to a number of cells, including neurons and 
oligodendrocytes (Estevez et al., 1998). In contrast, reactive astrocytes also produce 
anti-inflammatory cytokines which are likely to contribute to limiting the 
neuroinflammation in the affected area and aid in the regeneration of neurons (Nair et 
al., 2008). In addition, reactive astrocytes produce a number of growth factors which 
are able to promote oligodendrocytes to produce myelin (Moore et al., 2011). Reactive 
gliosis is thought to be an attempt by the CNS to isolate the injured area (Fitch and 
Silver 1997) and therefore protect the unaffected area, however, astrogliosis also 
prevents axonal regeneration.
1.4.3.3 Oligodendrocytes (OLGs)
OLGs are the glial cells of the CNS that are able to wrap long segments of axons with a 
multilayered sheath of extended cell membrane. This ability of oligodendrocytes to form 
the myelin sheath, provides electrical insulation around nerve fibres, thereby making 
rapid transmission of electrical signals in the brain possible (Jessen 2004). Myelin was 
first understood to enable 'saltatory' impulse propagation in axons more than 60 years 
ago before it was recognised by electron microscopy as a specialised outgrowth of glia 
(Geren and Raskind 1953). OLGs are able to myelinate several axons simultaneously. 
Mature oligodendrocytes make myelin by wrapping axons with their own cell 
membrane in a spiral shape, which eventually becomes a multilayered sheath covering
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a long segment of axon. These myelinated axons are flanked by nodes of Ranvier, the 
sites at which sodium channels are concentrated and the action potentials are 
generated (Nave 2010).
The proliferation and differentiation of OLG lineage cells is controlled by further growth 
factors and cytokines, including platelet-derived growth factor and brain-derived 
neurotrophic factor. This myelination of neurons prevents the consumption of large 
amounts of ATP, as in electrically active but unmyelinated fibers the restoration of ion 
gradients by sodium and potassium-ATPase consumes a large amount of available 
ATP. Myelination strongly reduces this energy consumption because action potentials 
and ion currents are restricted to less than 0.5% of the axon's surface. Furthermore, 
myelination of axons provides up to a 100-fold increase in conduction velocity (Nave 
2010). Additional functions of OLGs are still not fully elucidated, but there is evidence 
that these cells communicate lifelong with axons, and that glia are required for the long­
term integrity and survival of axons (Griffiths et al., 1998; Lappe-Siefke et al., 2003; 
Edgar et al., 2004; Kassmann and Nave 2008). Subsequently, OLGs may also be 
neurotrophic.
1.4.4 Endothelial cells (ECs)
Brain ECs comprise a key component of the BBB (Figure 1.3) and contribute to the 
immune response of the CNS by responding to, transporting and secreting cytokines. A 
unique feature of brain ECs is their ability to change cell membrane composition 
depending in whether the membrane is facing the blood or the brain, with their lipid, 
receptor and transport compositions differing depending on this (Verma et al., 2006). 
This polarisation is important in preventing harmful substances from entering the brain.
Brain ECs lack fenestrations, exhibit low pinocytic but high efflux transporter activity 
and this limits transcellular diffusion (Fenstermacher et al., 1988; Sedlakova et al., 
1999; Oldendorf et al., 2004; Verma et al., 2006). Brain ECs are exposed to an array of 
endogenous and exogenous neuromodulatory substances, immune cells, 
neurotransmitters and hormones, environmental stresses, and potentially toxic 
compounds at both the brain and blood side of the membranes. These brain ECs have 
the potential to receive signals from one compartment, e.g. the blood, and to secrete 
into the other, e.g. the brain (Verma et al., 2006). Brain ECs secrete an array of 
cytokines, with IL-1 a, IL-10 and granulocyte-macrophage colony-stimulating factor 
preferentially secreted from brain ECs facing the blood. Exposure of brain ECs to IL-1 (3, 
TNF-a, IFN-y, or LPS decreases the transendothelial electrical resistance allowing 
leukocytes to enter the brain (Wong et al., 2004).
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1.4.5 The blood brain barrier (BBB)
Cells at three key interfaces form barriers between the blood and the CNS; BBB, blood- 
CSF barrier and the arachnoid barrier, in order to limit and regulate molecular 
exchange at the interfaces between the blood and the neural tissue or its fluid spaces 
(Ransohoff et al., 2003; Abbott et al., 2010). In the brain and spinal cord the BBB is 
created by ECs that form the walls of the capillaries. The combined surface area of 
these microvessels constitutes the largest interface for BBB exchanges and is the 
major site of blood-CNS exchange (Abbott et al., 2010). A second interface is formed 
by the epithelial cells of the choroid plexus facing the CSF fluid, which forms the blood- 
CSF barrier (BCSFB). The CSF is secreted across the choroid plexus epithelial cells 
into the brain ventricular system (Brown et al., 2004), whilst the remainder of the 
interstitial fluid (ISF), is secreted across the capillary endothelium of the BBB (Cserr et 
al., 1981; Abbott 2004; Dolman et al., 2005).
The third interface is provided by the avascular arachnoid epithelium, underlying the 
dura, and completely enclosing the CNS; this completes the seal between the 
extracellular fluids of the CNS and that of the rest of the body (Abbott et al., 2006). 
Although the arachnoid also forms a barrier layer, it does not provide a significant 
surface for blood-CNS exchange due to its avasculature nature and relatively small 
surface area (Kandel et al., 2000). At all three interfaces, the barrier function is not 
fixed, but can be modulated and regulated, both in physiology and pathology (Abbott et 
al., 2006).
The BBB is composed of three cellular elements of the brain microvasculature: (1) 
ECs, (2) astrocyte end-feet and (3) pericytes (PCs) (Ballabh et al., 2004) (Figure 1.3). 
The brain ECs differ from ECs in the rest of the body by the absence of fenestrations, 
more extensive tight junctions (TJ), and sparse pinocytic vesicular transport. EC TJs 
limit the paracellular flux of hydrophilic molecules across the BBB. In contrast, small 
lipophilic substances, such as 0 2 and C 02 diffuse freely across plasma membranes 
along their concentration gradient (Grieb et al., 1985). Nutrients including glucose and 
amino acids enter the brain via transporters, whereas receptor-mediated endocytosis 
mediates the uptake of larger molecules, including insulin, leptin and iron transferrin 
(Pardridge et al., 1985; Zhang and Pardridge 2001).
TJ and adherens junction (AJ) proteins between adjacent ECs form a diffusion barrier 
which selectively prevents most blood-borne substances from entering the brain 
(Schulze and Firth 1993; Kniesel and Wolburg 2000; Mrass and Weninger 2006).
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Figure 1.3: Schematic diagram of the blood-brain barrier (BBB). Endothelial cells 
line the BBB with associated tight junctions, forming a barrier between the circulation 
and the brain parenchyma. This prevents the entry of lymphocytes, monocytes and 
neutrophils. A thin basement membrane surrounds the endothelial cells and pericytes. 
This prevents the infiltration of pathogens and restricts antibody-mediated immune 
responses from entering into the central nervous system, and thus protects against a 
full-blown immune response (adapted from Francis et al., 2003).
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Extremely tight ‘tight junctions’ are a key feature of the BBB and significantly reduce 
permeation of polar solutes between the ECs from the blood plasma to the brain 
extracellular fluid (Begley and Brightman 2003; Wolburg et al., 2009). AJs are essential 
for barrier formation of TJs and disruption of AJs results in barrier disruption (Wolburg 
and Lippoldt 2002). TJs are zipper-like structures that link two adjacent cells and are 
formed by the close interaction and the assembly into macromolecular complexes of at 
least three families of transmembrane proteins: claudins, occludin and junctional 
adhesion molecules (JAMs) (Wolburg and Lippoldt 2002; Wolburg et al., 2009).
Astrocytic end-feet tightly ensheath the vessel wall and appear to be critical for the 
induction and maintenance of the TJ barrier. Induction and maintenance of many BBB 
properties, including formation of TJs and the polarised expression of transporters in 
the enthdothelial membranes, depends on close association with astrocytes (Rubin et 
al., 1991; Wolburg et al., 2009).
PCs are cells that wrap around ECs of microvessels including capillaries, venules, and 
arterioles. They are thought to provide structural support and vasodynamic capacity to 
the microvasculature (Ballabh et al., 2004). PCs are the least studied cellular 
component of the BBB but appear to play a key role in angiogenesis, structural integrity 
and differentiation of the vessel, and formation of endothelial TJs (Balabanov and 
Dore-Duffy 1998; Allt and Lawrenson 2001). The BBB also consists of the capillary 
basement membrane (BM), in which PCs embed.
The BBB is present in all brain regions, except for the circumventricular organs, such 
as the pineal gland. Blood vessels in these areas of the the brain have fenestrations 
that permit diffusion of blood-borne molecules across the vessel wall (Ballabh et al., 
2004).
All components of the BBB are essential for the normal function and stability of the 
BBB. A number of CNS pathologies involve dysfuntion of the BBB, including MS 
(Correale and Villa 2007), Parkinson’s disease (PD) and Alzheimer’s disease (AD) 
(Desai et al., 2007; Zlokovic 2008), and hypoxia and ischaemia (Kaur and Ling 2008). 
The barrier dysfunction can range from mild and transient TJ opening to chronic barrier 
breakdown (Forster 2008).
1.4.5.1 BBB disruption and multiple sclerosis
Despite the presence of this highly regulated BBB, leukocyte entry into the CNS is an 
early event in MS. The entry of pro-inflammatory leukocytes into the CNS is thus 
considered an early phenomenon that can trigger early events leading to 
neuroinflammation, BBB disruption and MS plaque formation (Raine et al., 1990;
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Engelhardt 2006). Immune cells of MS subjects express inflammatory cytokines, ROS 
and enzymes that can facilitate their migration to the CNS by influencing barrier 
function, either directly or indirectly (Larochelle et al., 2011). Acute MS lesions, 
featuring areas of demyelination, axonal loss and immune cell infiltrates, display BBB 
disruption as evidenced by in vivo gadolinium uptake on MRI and post-mortem 
evidence of focal micro-vascular leakage (Larochelle et al., 2011).
Whether BBB dysfunction precedes immune cell infiltration or is the consequence of 
perivascular leukocyte accumulation remains to be established. While it has been 
suggested that BBB dysfunction can precede immune infiltration and demyelination in 
MS, leukocyte migration both directly and indirectly, modified BBB permeability 
(Larochelle et al., 2011). An example of this is the clinical use of Natalizumab, an anti- 
a4(31 integrin antibody known to restrict leukocyte migration to the CNS, which 
decreases lesion genesis and the number of lesions showing gadolinium enhancement 
(Polman et al., 2006). A number of different BBB dysfunctions have been reported in 
MS, including breakdown of the BBB (Minagar and Alexander 2003), TJ abnormalities 
(McQuaid et al., 2009), and down-regulation of laminin in the BM (Oki et al., 2004).
1.5 Autoimmune mechanisms in MS
The immunopathogenesis of MS is complex and involves a number of different immune 
cells, most notably T cells, B cells and macrophages (Frohman et al., 2006). Until 
recently, MS was considered to be a T cell mediated disease (Sospedra and Martin
2008). However, the role of B cells in MS pathogenesis is becoming increasingly 
apparent. In particular, deposition of antibody and complement is observed in the most 
common pathological pattern of MS lesions as well as the presence of oligoclonal IgG 
bands on IEF of CSF (Lucchinetti et al., 2000).
1.5.1 T cells in MS
CD4+ T cells reactive with epitopes of several myelin proteins, including MBP and 
other myelin antigens are found in the blood and CSF as well as in MS lesions 
(Frohman et al., 2006; Chitnis 2007; Sospedra and Martin 2008). This involvement of 
the CD4+ T cell-mediated process is consistent with the association of genetic risk with 
MHC class II molecules, with many studies confirming that HLA class II genes confer 
the largest genetic risk factor for MS (see section 1.3.3). CD4+ T cell reactivity is 
restricted by MS-associated MHC class II molecules (Sospedra and Martin 2005). 
However, the antigen specificity of T cells in patients with MS is very similar to that of T 
cells from healthy individuals (Sospedra and Martin 2005). It is possible that the HLA
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molecules associated with MS might contribute to T cell population expansion and 
antigenic spread because of preferential binding of certain myelin epitopes (McFarland 
and Martin 2007). This is supported by the substantial increase in the frequency of 
high-avidity CD4+ T cells which recognise myelin epitopes in patients with MS 
(Bielekova et al., 2000).
CD8+ T cells are easily demonstrated in inflammatory lesions (Traugott et al., 1983; 
Babbe et al., 2000). CD8+ T cells are present at the lesion edge as well as in 
perivascular regions, whereas CD4+ T cells are generally only present at the lesion 
edge (McFarland and Martin 2007). In addition, a higher frequency of CD8+ T cells 
recognising myelin proteins in patients with MS than in healthy controls, has been 
reported (Crawford et al., 2004). It is hypothesised that CD4+ T cells initiate the MS 
lesion, followed by the clonal expansion of CD8+ T cells, which amplify and mediate 
the damage. This is supported by a study which showed that CD8+ T cells can directly 
attach to and damage axons (Medana et al., 2001).
1.5.2 B cells in MS
B cells are important in the pathogenesis of MS, as they: (1) act as APCs for the 
activation of encephalitogenic T cells and therefore influence their differentiation; (2) 
are a precursor of plasma cells that secrete autoreactive antibodies and (3) are able to 
produce cytokines that activate macrophages and stimulate further proliferation of 
immune cells (Antel and Bar-Or 2006; Racke 2008).
Evidence of B cell activity associated with MS was first observed in 1950 when 
intrathecal Ig synthesis was reported in patients with MS (Kabat et al., 1950). These Igs 
are observed on IEF of CSF, whereby clear OCBs can be seen, and are observed in 
up to 90% of patients with definite MS, although are not specific for the disease 
(Compston and Coles 2002). Increased Ig levels in CSF in patients with MS is one of 
the important findings used in the diagnosis of MS (Berger and Reindl 2007; Weber 
and Hemmer 2010). The presence of OCBs are associated with a worse prognosis in 
patients than those without (Zeman et al., 1996; Villar et al., 2002). Furthermore, 
clonally expanded populations of memory B cells and plasma cells are found in MS 
lesions and in the CSF of MS patients with Serafini and colleagues being the first to 
report the formation of B-cell follicle-like structures in the brains of patients with MS 
(Zeman et al., 1996; Baranzini et al., 1999; Villar et al., 2002; Hauser et al., 2008).
The target antigen of these OCB antibodies has not yet been fully characterised, 
despite many attempts. Of the candidate autoantigens, MBP is the most extensively 
studied. MBP is one of the principal components of the myelin sheath and is the
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second most abundant protein in the CNS (Boggs 2006). MOG is present on the outer 
layer of the myelin sheath and is thus more accessible to antibody binding (Brunner et 
al., 1989). Both MBP and MOG can act as autoantigens to trigger an animal model of 
MS in rodents, experimental autoimmune encephalomyelitis (EAE) (Gold et al., 2006). 
Antibodies specific for MOG are present in active demyelinating lesions (Genain et al., 
1999). In terms of MS, changes in the structure of myelin through postranslational 
modification (PTM) of its component proteins including MBP and MOG may play an 
important role in disease pathogenesis, through the generation of novel epitopes to 
which the immune system is no longer tolerant. Citrullination is one possible PTM 
which may be responsible for these changes to the structure of proteins in MS.
1.5.3 Peptidylarginine deiminases (PADs) and citrullination
Citrulline is a non-standard amino acid and proteins containing citrulline can only be 
generated by PTM of arginine residues, in a process called citrullination or deimination, 
in which the guanidino group of arginine is hydrolysed to a ureido group and ammonia, 
yielding a deiminated amino acid (citrulline) (Anzilotti et al., 2010). This PTM is carried 
out by a family of five citrullinating enzymes known as peptidylarginine deiminases 1, 2, 
3, 4 and 6 (PADs), first described in 1977, the genes of which are located at a single 
locus on chromosome 1 at position 1p35-36 in the human genome, and are highly 
conserved showing 59-71% sequence homology at the protein level (Rogers et al., 
1977; Vossenaar et al., 2003; Chavanas et al., 2004). PAD1 and PAD3 are the most 
closely related isozymes, with 68% sequence homology (Vossenaar et al., 2003; 
Chavanas et al., 2004). These isoenzymes show a high level of tissue specific 
expression and require higher calcium levels than are normally physiologically present, 
to be active (Takahara et al., 1986; Vossenaar et al., 2003). The result of this 
citrullination is a reduction in the net positive charge of the protein, which can have 
dramatic effects on protein folding and protein-protein interactions due to interruption in 
electrostatic interactions (Tarcsa et al., 1996).
PAD1 is mainly expressed in the epidermis and uterus (Terakawa et al., 1991; Rus’d et 
al., 1999), and is thought to play an important role in terminal differentiation of 
keratinocytes, as during this process both keratins and the keratin-associated protein, 
filaggrin, are citrullinated (Senshu et al., 1996; Senshu et al., 1999). However, the 
exact role of citrullination in this process remains to be elucidated. PAD2 is the most 
widely expressed PAD, and is expressed in skeletal muscle, brain, spleen, secretory 
glands and macrophages (Watanabe et al., 1988; Akiyama et al., 1990; Urano et al., 
1990; Vossenaar et al., 2004). PAD2 is known to citrullinate both MBP in the CNS and 
vimentin in skeletal muscle and macrophages (Vossenaar et al., 2004). PAD3 is
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believed to play an important role in hair follicle formation due to its ability to deiminate 
trichohyalin, an abundant arginine-rich structural protein present in the inner root and 
medulla of hair follicles (Mechin et al., 2007).
PAD4 is the best characterised isoenzyme, and has been shown to be important in a 
number of processes, most importantly transcriptional regulation of genes. PAD4 is the 
only isoenzyme to carry a functional nuclear localization signal which enables it to 
translocate from the cytoplasm to the nucleus, and has been shown to regulate 
chromatin structure and function through its ability to deiminate histone proteins, and 
therefore plays an important role in transcriptional regulation (Hagiwara et al., 2002; 
Nakashima et al., 2002; Cuthbert et al., 2004; Wang et al., 2004)
1.5.3.1 PADs and citrullination in MS
In MS, PAD2 and PAD4 are of greatest interest due to their localisation in the brain and 
in macrophages. A number of PAD substrates that may be important in MS have been 
identified. These include MBP, GFAP, a number of nuclear proteins and, most recently, 
members of the CXC chemokine family. Several studies have documented that MBP in 
CNS tissue of MS patients is more highly citrullinated compared with MBP from control 
subjects (Moscarello et al., 1994; Wood et al., 1996). For example, MBP isolated from 
the CNS of MS patients was found to be more highly citrullinated than MBP isolated 
from CNS tissue of adults without neurological disease, and was similar in the extent of 
citrullination to that observed in children aged less than 4 years, indicating a role for 
citrulllination in the development of mature myelin (Moscarello et al., 1994; Wood et al., 
1996). By using MBP isolated from NAWM of patients with MS and controls, post 
mortem, and fractionation of the samples by column chromatography, Moscarello et al. 
found that 18% of MBP was citrullinated in control tissue compared with 45% of MBP in 
patients with MS (Moscarello et al., 1994). Further studies by the same group found 
that in Marburg’s disease as much as 90% of MBP is citrullinated, demonstrating that 
almost all the MBP is citrullinated (Wood et al., 1996). This study found that citrullinated 
MBP in both controls and patients with chronic MS contained six citrulline residues and 
13 arginine residues, whereas citrullinated MBP in patients with Marburg disease 
contained 18 citrulline residues and only one arginine residue.
Using immunoslot blots with antibodies specific to PAD2 and PAD4, Wood et al. (2008) 
found that levels of both PAD2 and PAD4 in myelin isolated from the NAWM of seven 
patients with MS was significantly higher than levels observed in six control subjects. 
The same method was also applied using an F95 antibody, specific for citrullinated 
proteins, which showed increased citrulline in the myelin isolated from NAWM of these 
patients compared with control tissue (Wood et al., 2008). In addition to this, the
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authors were able to demonstrate that MBP is citrullinated in vitro in the presence of 
recombinant PAD2 and PAD4 through measuring the specific activities of these 
enzymes following the addition of increasing amount of unmodified MBP (Wood et al.,
2008). By using mass spectrometric analysis of intact human MBP and its citrullinated 
forms, it was demonstrated that PAD2 can citrullinate 18 out of 19 arginine residues, 
whereas PAD4 can only citrullinate 15 out of the 19 arginine residues present in MBP 
(Wood et al., 2008).
By subjecting homogenates of NAWM from 12 MS patients and normal white matter 
from three controls to immunoslot blots, and measuring PAD2 levels using anti-PAD2 
antibody in both MS and control white matter, PAD2 in MS NAWM was found to be 
three-fold higher than in control subjects, with a two-fold increase in citrullination 
compared with control subjects (Mastronardi et al., 2007). To determine whether the 
increase in citrullination was due to citrullination of MBP, western blot analysis was 
carried out using whole MBP extracted from white matter and antibodies against MBP 
and citrulline, which confirmed the increase was consistent with increased citrullination 
of MBP (Mastronardi et al., 2007).
GFAP has now been identified as a second substrate of PADs and has been found to 
be citrullinated in higher amounts in the NAWM of patients with SPMS compared with 
equivalent control brain tissue (Nicholas et al., 2004). Using antibodies against 
citrullinated proteins and GFAP together, and with the aid of confocal microscopy, 
Nicholas et al. 2004 found that tissue taken from the NAWM of three patients with 
SPMS was highly citrullinated compared with NAWM taken from three patients with 
other neurological diseases (ONDs), and that this citrullination was demonstrated to co- 
localize with GFAP.
By fractionation of NAWM from MS patients and controls into a membrane-containing 
fraction, non-microsomal fraction and a nuclear fraction, followed by quantitation of the 
amount of PAD 1-4 antibody binding, PAD4 was found to be elevated in NAWM from 
17 patients with MS compared with nine control subjects (Mastronardi et al., 2006). The 
nuclear fraction contained a 3.5-fold increase in the level of PAD1-4 in patients with 
MS compared with controls. Through western blot analysis, using anti-PAD4 antibody, 
this was attributable to increased PAD4 in the MS NAWM. Using an antibody against 
citrullinated proteins, this increase in PAD4 was found to be accompanied by an 
increase in citrullinated proteins in tissue taken from patients with MS, whereby strong 
nuclear labeling in NAWM from MS patients was observed compared with the controls 
(Mastronardi et al., 2006). This increase in PAD4 was also accompanied by an 
increase in nuclear histone H3 citrullination, as demonstrated by staining MS and 
control tissue with an antibody against citrullinated protein, which revealed increased
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nuclear staining of cells in the MS white matter compared with the control white matter 
(Mastronardi et al., 2006). These findings were confirmed by western blot analysis, 
which showed a great abundance of citrullinated H3 in MS NAWM, with only traces in 
white matter from controls (Mastronardi et al., 2006). This citrullination of histones 
greatly affects the chromatin structure and function, as deimination of arginine residues 
of histones decreases their positive charge, which compromises their ability to interact 
with DNA and possibly result in apoptosis of affected cells (Wang et al., 2004; 
Moscarello et al., 2007)
Excess citrullination has been reported in the CNS in postmortem MS brain tissue 
(Nicholas and Whitaker 2002; Mastronardi et al., 2006). Recently, using proton MR 
spectroscopy, Oguz et al. (2009) found that citrulline peaks occurred more frequently in 
27 patients with early-onset MS compared with 23 control cases. This further suggests 
a role for increased citrullination of myelin proteins in MS and, possibly, other 
demyelinating diseases.
Chemokines are the most recently described substrates of PAD. Chemokines are a 
family of secreted proteins that activate and attract leukocytes to sites of inflammation 
and have been demonstrated to play a role in the recruitment of leukocytes across the 
BBB in MS (Rot and von Andrian 2004; Charo and Ransohoff 2006). Proost et al. were 
the first to identify citrullination of the chemokine CXC ligand 8 (CXCL8), expressed by 
human peripheral blood mononuclear cells (PBMCs) (Proost et al., 2008). Further 
chemokines have since been reported to be citrullinated, including CXCL10, CXCL11, 
CXCL12 and, most recently, Mortier et al. identified a further chemokine that is also 
citrullinated, CXCL5 (Loos et al., 2008; Struyf et al., 2009; Mortier et al., 2010). All 
these chemokines have been previously reported to play a role in the migration of T 
cells and monocytes into the CNS (Loos et al., 2008; Struyf et al., 2009; Mortier et al.,
2010), as well as CXCL12 having a proposed role in engraftment of neural stem cells 
(Carbajal et al., 2010). Thus, studies on citrullination of chemokines are highly relevant 
to understanding the pathogenesis of MS and other inflammatory neurological 
diseases. In general, the effect of citrullination of these chemokines leads to a 
decrease in their proteolytic cleavage, resulting in a reduction in their binding affinity 
and intracellular signaling through the corresponding chemokine receptor. The heparin- 
binding capacity of both citrullinated CXCL10 and CXCL11 are significantly reduced 
compared with their native form, and since sequestration of chemokines and the 
formation of a chemokine gradient is essential for inflammatory cell recruitment, 
reduced binding of the citrullinated forms to the glycosaminoglycan (GAG) in the 
extracellular matrix would also contribute to decreased inflammatory cell recruitment 
(Loos et al., 2008). In functional in vivo and in vitro assays, citrullination of chemokines
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led to decreased inflammatory cell migration when compared to the noncitrullinated 
proteins, suggesting that PAD enzymes play an anti-inflammatory role through 
citrullination of chemokines (Loos et al., 2008; Proost et al., 2008; Struyf et al., 2009; 
Mortier et al., 2010). Using freshly isolated monocytes and activated lymphocytes, 
Struyf et al. found that CXCL12-1Cit was significantly less chemotactic for both 
monocytes and lymphocytes, and that CXCL12-5Cit was inactive in vitro (Struyf et al., 
2009). The authors concluded that citrullination appears to reduce the activity of 
chemokines leading to downregulation of inflammation. Therefore, citrullination of 
chemokines may be a mechanism for resolution of inflammation. IFN-g-induced 
CXCL10 is expressed in actively demyelinating MS lesions, predominantly by 
macrophages within the plaque and by reactive astrocytes in the surrounding 
parenchyma and this promotes the recruitment of activated CD4+ T cells expressing 
CXCR3 across the BBB (Simpson et al., 2000a; Simpson et al., 2000b). Citrullination of 
locally expressed chemokines may therefore be an important mechanism to reduce 
further T-cell and monocyte migration into the CNS. Based on current findings, it 
appears that there may be many more CNS proteins that undergo citrullination in MS 
that have yet to be identified.
1.5.3.2 Citrullination and experimental autoimmune encephalomyelitis (EAE)
EAE has been widely used an an animal model for MS for many years. There are 
several variations of EAE induction by immunisation of the animal with either myelin 
proteins or by adoptive transfer of myelin-specific CD8+ T cells (Mix et al., 2010). MBP 
and MOG as well as smaller encephalitogenic peptides of MBP, MOG and PLP can act 
as autoantigens to trigger EAE (Gold et al., 2006; Mix et al., 2010). Transgenic animal 
models of spontaneous demyelination have also been developed in an attempt to 
imitate MS without the bias of a specific peptide for induction (Mastronardi et al., 1993; 
Ellmerich et al., 2005; Pollinger et al., 2009; Mix et al., 2010). Although EAE models do 
not directly mimic the complex pathogenesis of MS, their similarities have allowed the 
investigation of CNS inflammation and tests for potential MS therapies. There is now 
an emerging understanding of the role of protein deimination in the CNS derived from 
studies on EAE models of MS.
Using antibodies against citrullinated proteins, MBP and GFAP, it has been 
demonstrated that citrullinated proteins are present in both the brain and spinal cord of 
mice with MOG-induced EAE, and that citrullination co-localises with both MBP and 
GFAP, indicating both oligodendrocytes and astrocytes as cell types with citrullinated 
proteins (Nicholas et al., 2005). Raijmakers et al. 2005 were the first to report hyper- 
citrullination of CNS proteins in PLP-induced EAE. This study found that during
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development of EAE in mice, citrullination of proteins occurred in the spinal cord and 
correlated with areas of demyelination. The amount of citrullinated proteins was highest 
in the relapse phase of EAE, compared with acute-phase EAE, which was thought to 
be due to remyelination attempts, as increased citrullination is associated with 
myelination during development of the CNS (Cao et al., 1999). By using specific 
antibodies, the citrullinated proteins were identified as MBP and GFAP. Using 
immunoblotting of spinal cord tissue, it was determined that this increase in citrullina­
tion was not due to an increase in the levels of PAD2 and PAD4. No citrullination was 
found in control mice (Raijmakers et al., 2005). Based on this, the authors concluded 
that the hypercitrullination observed in EAE must be mediated by activating PAD2 and 
PAD4 already present in the CNS rather than de novo synthesis of the enzymes. In a 
study by Nicholas et al. 2005, GFAP was found to be citrullinated in higher amounts in 
the CNS of animals with EAE compared with equivalent control brain tissue (Nicholas 
et al., 2005).
Musse et al. (2008) investigated the role of PAD2 in demyelinating disease, by 
developing transgenic mice overexpressing PAD2. These mice displayed a more 
severe clinical disease course than spontaneously demyelinating transgenic mice, with 
clinical symptoms presenting at 6 weeks compared with 3 months. Levels of PAD2 
were compared with control mice, with PAD2 transgenic mice showing significantly 
increased PAD2 activity at 2 months of age, along with an approximately 2.5-fold 
increase in citrullinated MBP at 3 months of age. Histochemical staining with Luxol fast 
blue of the optic nerve of these mice showed areas of myelin breakdown, along with a 
reduction in myelin. All these changes were more pronounced in homozygous mice 
possessing 30 copies of the cDNA encoding the PAD2 gene, compared with the 
heterozygotes possessing only 15 copies of this gene. PAD2 mRNA levels showed 
similar changes with a four-fold increase in PAD2 mRNA in transgenic compared with 
non-transgenic mice, which increased to 5.3-fold in homozygous PAD2 transgenic 
mice. In addition, when assessing MBP isolated from PAD2 knockout mice, the authors 
demonstrated the ability of PAD4 to citrullinate MBP in the absence of PAD2 (Musse et 
al., 2008).
1.5.3.3 Proteolytic enzyme action on citrullinated MBP
Since citrullination alters the charge of the protein, as for each arginine converted to 
citrulline there is a loss of one positive charge, MBP becomes partially unfolded and its 
interaction with phospholipids is weakened following citrullination, therefore the myelin 
sheaths formed are not as tightly packed as in normal myelin (Beniac et al., 2000). 
Citrullination of MBP increases its susceptibility to degradation by proteinases, which
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are reported to be elevated in the CNS in MS, in particular around active plaques and 
in the CSF (Einstein et al., 1972; Cuzner and Davison 1973; Richards and Cuzner
1978). Macrophages and reactive astrocytes have been previously demonstrated to 
produce the proteinase cathepsin D (Prineas and Wright 1978; Allen and McKeown
1979). Studies carried out by Cao et al. (1999) showed that MBP-C6, the citrullinated 
isomer of MBP, which contains six citrulline residues, is digested four-times faster by 
cathepsin D than the unmodified form of MBP, and 35-times faster in MBP-C18, which 
contains 18 citrulline residues, releasing numerous peptides through cleavage at the 
Phe-Phe linkages in the MBP protein. The peptides generated by cathepsin D 
cleavage, which contain the immunodominant epitopes of MBP, have been detected in 
the CSF of patients with MS (Whitaker 1977; Whitaker and Granum 1980). By 
incubating various MBP species, containing different amounts of citrulline per mole of 
MBP, with cathepsin D, Pritzker and colleagues (2000) were able to demonstrate that 
the MBP species containing the greatest amount of citrulline per mole of MBP were 
digested at a much faster rate, as determined by mass spectrometric analysis of MBP 
peptides following digestion (Pritzker et al., 2000).
In addition, using a 3D-atomic structure model of human MBP, the authors were also 
able to test the effects of deimination of specific arginine residues to citrulline residues 
and found that the molecule became significantly more extended and open in structure 
the more citrullinated it was (Pritzker et al., 2000). Following this study, the authors 
concluded that this more open structure would allow cathepsin D better access to Phe- 
Phe linkages in MBP, which would account for the increased digestion of citrullinated 
MBP.
Using Cys scanning, spin labeling, electron paramagnetic resonance spectroscopy and 
site-specific proteolysis, Musse et al. (2006) were able to demonstrate that in the 
membrane-bound state the primary immunodominant epitope, V83-Y92, of 
recombinant murine MBP-C6 is more highly surface exposed than unmodified 
recombinant murine MBP. In addition, in the presence of cathepsin D, the recombinant 
murine MBP-C6 demonstrated enhanced proteolysis. These results suggest that citrul­
lination of MBP not only impedes membrane adhesion and assembly activity of this 
protein into myelin, but also exposes an immunodominant epitope in the membrane- 
bound protein to proteases. From this study, the authors concluded that greater surface 
exposure and greater cleavage of the citrullinated protein by enzymes would lead to 
increased release of the immunodominant epitope, which could prime the innate 
immune-derived cells of the CNS and sensitize peripheral T cells (Musse et al., 2006; 
Musse and Flarauz 2007).
1.5.3.4 Regulation of PAD and citrullination
It is not yet known whether excess citrullination is a primary or secondary event to the 
inflammatory process in MS, or whether the regulation of PAD isoforms may be part of 
the genetic susceptibility to MS. Single nucleotide polymorphisms in the PAD4 gene, 
associated with the autoimmune disease RA, increase mRNA stability, suggesting that 
this could result in more PAD4 protein expression and, therefore, increased 
citrullination of proteins (Suzuki et al., 2003). Increased PAD2 protein expression in 
human astrocytes in vitro has also been reported in response to increased intracellular 
calcium levels when cells were subjected to elevated pressure and in response to 
hypoxia (Sambandam et al., 2004; Bhattacharya et al., 2006a; Bhattacharya et al., 
2006b). A number of pathological processes, including excitotoxicity, occur in the CNS 
in MS, which would lead to raised intracellular calcium ions in neurons and glia 
(Shideman 2006; Smith 2007). Large numbers of activated macrophages are present 
in inflammatory demyelinating sites within MS lesions as well as activated microglia. 
Since these cells contain PAD enzymes and there is increased cell death owing to 
raised intracelluar calcium ions, this would lead to activation of PAD enzymes when 
released from dying cells (Bhattacharya et al., 2006a). Thus, myelin proteins may be 
citrullinated both intracellularly, during myelin degradation following phagocytosis, as 
well as extracellularly, following release of PAD enzymes from dying cells. In addition, 
significant hypomethylation of the PAD2 promoter has also been found to occur in MS 
NAWM compared with controls, which may lead to increased PAD2 expression and 
subsequent increase in citrullination, as hypomethylation leads to increased gene 
transcription (Mastronardi et al., 2007).
PAD enzymes are dependent on the presence of calcium. X-ray crystallographic 
structural analysis of human PAD4 in calcium-free and calcium-bound forms, suggests 
that binding of calcium to the C-terminal domain is critical for both substrate specificity 
and binding (Arita et al., 2003; Arita et al., 2004). The binding of calcium to PAD4 leads 
to conformational changes around the substrate binding site, which then allows PAD4 
to interact with arginine residues in other proteins (Arita et al., 2004). Only the crystal 
structure of PAD4 has been elucidated as yet, however, due to human PAD4 and 
PAD2 showing more than 50% sequence homology, it is assumed that PAD2 will have 
a similar crystal structure and mechanism for activity (Vossenaar et al., 2003). In the 
absence of high levels of intracellular calcium, PAD2 would not undergo these 
conformational changes which are essential for activation of the enzyme.
The cytosolic and nucleoplasmic calcium concentration is much too low (approximately 
100-fold) for PAD activity under normal physiological conditions (Takahara et al.,
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1986). However, there are numerous events which can lead to raised intracellular 
calcium. For example during cell death the integrity of the plasma membrane is lost 
(Schwab et al., 2002; Tombal et al., 2002), causing influx of calcium from the 
extracellular space and subsequent activation of intracellular PAD (Asaga et al., 1998; 
Hagiwara et al., 2002; Nakashima et al., 2002; Vossenaar et al., 2004). Artificially 
raising the cytosolic and nucleoplasmic calcium concentration by including calcium 
ionophores in the media of the cells should induce activation of PAD and subsequent 
citrullination of intracellular proteins (Vossenaar et al., 2003).
1.5.3.5 Citrullination in rheumatoid arthritis (RA)
RA is a common autoimmune disease characterised by chronic inflammation of the 
synovial joints, which leads to destruction of the joints (van Venrooij et al., 2011). 
Antibodies to citrullinated proteins have been reported in RA, since the 1960s 
(Nienhuis et al., 1964). Since this discovery multiple citrullinated protein targets have 
been identified that are specific to RA-related autoimmunity, including vimentin, 
fibronectin and filaggrin amongst others (Klareskog et al., 2008). Testing of ACPAs in 
individuals with RA is now one of the prime biomarkers used in the diagnosis of RA 
(Whiting et al., 2010). Furthermore, the detection of ACPAs in the sera of a blood donor 
may indicate that this individual will develop RA in later life (Rantapaa-Dahlqvist et al., 
2003; Jorgensen et al., 2008). The detection of ACPA production also precedes the 
initial inflammatory cytokine response seen in pre-morbid RA patient sera by several 
years (Jorgensen et al., 2008). It is also associated with a more destructive erosive 
form of the disease (van der Linden et al., 2009).
The conversion of arginine to citrulline has been shown to enable a high-affinity peptide 
interaction with the RA-associated HLA-DRB1*0401 MHC class II molecule (Hill et al., 
2003). In this study Hill et al (2003) demonstrated that converting arginine to citrulline 
significantly increases the vimentin-MHC affinity, leading to the activation of CD4+ T 
cells in HLA-DRB1*0401 transgenic mice. Unmodified vimentin did not induce T cell 
activation; however, citrullinated vimentin stimulated a strong proliferative response 
followed by the production of IFN-y, showing that citrullination is required in order to 
elicit a CD4+ T cell response to vimentin in these transgenic mice. Furthermore, genetic 
suspectibility to RA is associated with MHC class II molecules that contain an amino 
acid motif known as the shared epitope (Gregersen et al., 2005). Competition assays 
showed that the citrulline-containing vimentin bound with higher affinity to MHC class II 
molecules that contained this shared epitope compared to uncitrullinated vimentin. The 
authors concluded that this novel peptide-MHC interaction is dependent on both 
citrullination and a shared RA epitope (Hill et al., 2003).
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Following on from the above study, James et al (2010) were able to show that binding 
of arginine-substituted peptides to another RA-associated HLA-DRB1*1001 MHC class 
II molecule blocked peptide binding, suggesting that arginine is not accepted within the 
binding pockets of HLA-DRB1*1001. However, peptides with single citrulline 
substitutions bound to recombinant HLA-DRB1*1001 were accepted withinin the 
binding pocket, which was significantly enhanced by further citrulline substitutions 
(James et al., 2010). Unmodified and citrullinated joint-associated peptide sequences 
were synthesised and used to stimulate CD4+ T cells from RA patients and controls. 
Three of these sequences elicited CD4+ T cell responses. T cell clones specific for 
these sequences only proliferated in response to citrullinated peptides and not 
unmodified peptides. The author concluded this generation of “altered-self peptides 
suggests that citrullination must be an important factor in the initiation or progression of 
RA (James et al., 2010).
1.5.3.6 Citrullination in other neurological diseases (ONDs)
Citrullination has also also been shown to occur in ONDs including AD, PD and 
sporadic Creutzfeldt-Jakob disease (sCJD) (Ishigami and Maruyama 2010; Jang et al., 
2010; Nicholas 2011). AD is the most common neurodegenerative disease, leading to 
progressive dementia. Ishigami et al. (2005) showed, using western blot analysis with 
an anti-modified citrulline antibody, the presence of multiple citrullinated proteins in 
post-mortem hippocampal brain tissue from ten AD cases, whereas no citrullinated 
proteins were found in age-matched controls. Two-dimensional gel electrophoresis (2- 
DE) and subsequent MALDI-TOF mass spectrometry identified two of these proteins as 
vimentin and GFAP. Using immunohistochemistry citrullinated proteins were observed 
throughout the hippocampus in these AD cases with no citrullinated proteins detected 
in age-matched controls. PAD2 immunoreactivity was observed throughout both the 
AD and control hippocampal areas, although PAD2 enrichment did coincide with areas 
of positive citrullinated proteins. Dual immunofluorescence staining revealed that 
citrullinated proteins and PAD2 co-localised with GFAP-positive astrocytes. The 
authors of this study concluded that these results suggest a role for PAD and 
citrullination in AD (Ishigami et al., 2005). Furthermore, Satoh et al. (2010) more 
recently showed the presence of serum ACPAs in eight out of fourty-two patients with 
AD, using a commercially available enzyme-linked immunosorbent assay (ELISA) 
containing artificially engineered cyclic citrullinated peptides optimised for use in 
detecting RA-specific ACPAs, further implicating a role for citrullination in the 
pathogenesis of this disease (Satoh et al., 2010).
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PD is a neurodegenerative disease, characterised by a slow and progressive 
degeneration of dopaminergic neurons in the substantia nigra (SN) (Hirsch and Hunot
2009). Nicholas (2011) recently showed using dual immunofluorescence and an 
established monoclonal antibody against peptidyl-citrulline moieties, the presence of 
citrullinated proteins co-localised with GFAP-positive astrocytes in the SN of post­
mortem brain tissue from five PD cases and five age-matched controls. Interestingly, 
this same study showed that citrullinated proteins co-localised to the cytoplasm of 
neurons in the SN of brain tissue from these PD cases, whereas none of the neurons 
from control SN brain tissue expressed citrullinated proteins (Nicholas 2011). The 
significance of these findings are not yet known, however the author of this study 
concluded that the results indicate that citrullination may be involved in the 
pathogenesis of PD.
Prion diseases are a group of progressive neurodegenerative diseases that affect the 
CNS in humans and animals, with sCJD accounting for approximately 85% of human 
prion cases (Jang et al., 2010). Using western blot analysis Jang et al. (2010) showed 
that the expression of PAD2 was significantly increased in the frontal cortex of post­
mortem tissue from four sCJD cases compared to four controls. Furthermore, 
immunohistochemistry revealed increased immunoreactivity of PAD2 in the brains of 
sCJD compared to controls, and was co-localised to reactive GFAP-positive astrocytes. 
PAD2 activity was also shown to be significantly elevated by 3.1-fold in sCJD brains 
compared to control brains. Western blot analysis also showed a significant increase in 
citrullinated proteins in sCJD compared to control brains, with immunohistochemistry 
showing the co-localisation of PAD2 and citrullinated proteins with GFAP-positive 
astrocytes. Lastly, a number of citrullinated proteins were identified using 2-DE and 
MALDI-TOF, including vimentim, GFAP and enolase (Jang et al., 2010).
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1.5.4 Hypothesis
An increase in intracellular calcium levels in the CNS during inflammation and/or 
polymorphisms in the PAD2 or 4 genes, leads to increased citrullination of MBP and 
other CNS proteins by PAD enzymes in MS. This could directly lead to demyelination 
through affecting the structural conformation of the myelin sheath. Secondary to this, 
citrullination of CNS proteins by PADs could also result in the generation of novel 
epitopes, to which the immune system is not tolerised. This could result in an 
autoantibody response against self proteins, leading to demyelination. The resultant 
antibody response to citrullinated proteins could be a useful diagnostic indicator of MS.
1.5.5 Aim of the thesis
To determine the role of PADs and citrullination in the pathogenesis of MS.
1.5.6 Objectives of the thesis
1. To compare PAD2 and PAD4 expression by cells of the CNS in vitro and 
determine factors involved in their modulation.
2. To determine cell types expressing PAD2 and PAD4 in the CNS in vivo in 
control white matter, MS NAWM and MS lesional brain tissue, and determine 
the distribution of citrullinated proteins.
3. To identify, using mass spectrometry, citrullinated proteins in MS lesional brain 
tissue.
4. To develop an ELISA method for the detection of ACPA in MS serum or CSF, 
specifically targeted to citrullinated MBP, and or other citrullinated proteins 
isolated above using mass spectrometry.
5. To examine ACPA antibodies in paired serum and CSF samples from MS, 
ONDs and controls, using the above ELISA techniques, and from this determine 
whether antibody levels correlate with the diagnosis of MS on clinical and CSF 
criteria.
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Chapter 2
In vitro investigation of the effects of 
pro-inflammatory cytokines on the 
expression of PAD2 and PAD4
2.1 Introduction
Although increases in PAD expression and the subsequent increase in citrullination are 
implicated in the pathogenesis of MS, little is known about the regulation of these 
enzymes during inflammation. It is well-reported that a number of pro-inflammatory 
cytokines are up-regulated in MS, particularly in and around lesions. Therefore, the 
effect of a number of pro-inflammatory cytokines implicated in MS pathogenesis on the 
modulation of PAD2 and PAD4 were investigated as these may be important regulators 
of PAD gene expression.
IL-1 (3 is predominantly produced by monocytes and macrophages but is also produced 
by brain endothelial cells, B cells and activated T cells (Corsini et al., 1996), and has 
been found to be increased in the CSF of MS patients with active disease (Hauser et 
al., 1990). In MS lesions there is increased expression of IL-1 (3 (Cannella and Raine 
1995) and it is also up-regulated in the CNS during the induction of EAE (Kennedy et 
al., 1992; Bauer et al., 1993). TNF-a is produced by a number of cells including 
monocytes, macrophages, NK cells, astrocytes and microglia (Imitola et al., 2005). 
Expression of TNF-a in the CNS is up-regulated in MS lesions (Cannella and Raine 
1995; Algeciras et al., 2008), and it is expressed by macrophages, microglia, and 
astrocytes within the MS plaque border in chronic active MS lesions (Hofman et al., 
1989; Selmaj et al., 1991; Cannella and Raine 1995). TNF-a is also expressed by 
leukocytes within the perivascular cuff (Merrill 1992; Woodroofe and Cuzner 1993). An 
increased expression of TNF-a in the CSF of patients with active disease and in 
progressive forms of the disease compared to stable MS has been reported (Hauser et 
al., 1990; Sharief and Hentges 1991).
IL-6 is synthesised by various cells including macrophages, T cells, astrocytes and 
microglia (Imitola et al., 2005). In MS, the highest numbers of IL-6 expressing cells are 
found in inactive demyelinated lesions (Schonrock et al., 2000), with IL-6 expression 
also reported in the cells of perivascular cuffs (Woodroofe and Cuzner 1993). IFN-y, 
which is produced by activated T lymphocytes and NK cells (Ali Shokrgozar et al.,
2009), has been found to be increased in patient plasma preceding relapse (Beck et 
al., 1988; Lu et al., 1993) and has an activating role in sustaining inflammation in MS 
(Hofstetter et al., 2006). It has also been found within the cells of the inflammatory cuffs 
in post-mortem MS CNS tissue (Woodroofe and Cuzner 1993; Simpson et al., 2000b). 
IFN-y levels are significantly higher in clinically isolated syndrome (CIS) patients in the 
acute phase and during relapses in RRMS (Frisullo et al., 2008). IFN-y is expressed in 
the CNS at the onset of EAE and increases during peak disease and decreases during
remission (Issazadeh et al., 1995; Begolka and Miller 1998).
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Dysregulation of cytokine expression in MS is not restricted to pro-inflammatory 
mediators but is also observed in anti-inflammatory cytokines. IL-4 is produced by T 
cells and increased expression is found in both acute and chronic MS lesions (Cannella 
and Raine 1995). IL-10 is produced by monocytes, macrophages, B and T cells (Imitola 
et al., 2005). Peripheral blood mononuclear cells (PBMCs) from patients with RRMS 
have decreased levels of IL-10 mRNA prior to the onset of an exacerbation 
(Rieckmann et al., 1994). Levels of IL-10 mRNA are significantly lower in PBMCs from 
patients with SPMS compared to RRMS; however levels of IL-10 mRNA in RRMS 
decrease significantly six weeks prior to a clinical relapse (Van Boxel-Dezaire et al., 
1999).
TGF-p is produced by T cells, and has been shown to be significantly down-regulated 
in lymphocytes of MS patients with clinically active disease compared to stable MS 
(Mokhtarian et al., 1994) and has been observed in microglia within the plaque edge of 
acute active lesions (Peress et al., 1996) and surrounding the blood vessels within the 
extracellular matrix (ECM) of acute lesions (Cannella and Raine 1995). TGF-|3 mRNA 
in PBMCs of RRMS patients is significantly down-regulated compared to control 
PBMCs (Rieckmann et al., 1994). Increased expression of TGF-p is also associated 
with the recovery phase in EAE (Iwahashi et al., 1997).
This chapter describes the investigation of the in vitro effects of four pro-inflammatory 
cytokines (IL-1 (3, TNF-a, IL-6 and IFN-y) which, as outlined above, are up-regulated in 
MS, on the modulation of PAD2 and PAD4 gene expression in an astrocytoma cell line 
(U373-MG), three preparations of primary human astrocytes (MS16, EP14, EP15), a 
human foetal microglial cell line (CHME3), and a human brain endothelial cell line 
(hCMEC/D3). Initial experiments were undertaken to determine any effects of these 
cytokines on cell viability. In addition, the in vitro effects of three anti-inflammatory 
cytokines, IL-4, IL-10 and TGF-(3, which have differential expression in MS, on the 
proliferative capacity of a human foetal microglial cell line (CHME3), and modulation of 
PAD2 gene expression was also investigated.
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2.1.4 Aim of the study
To determine the gene expression of PAD2 and 4, their modulation and the subcellular 
localisations of PAD2 and PAD4 proteins.
2.1.5 Objectives of the study
1. Optimise the method of quantitative real-time polymerase chain reaction 
(qPCR) for the detection of PAD2 and PAD4 gene expression.
2. Determine the modulating effect of cytokine treatment on gene expression of 
PAD2 and PAD4 in all cell lines utilised in this study and assess the effect of 
single and co-treatment of cells with cytokines on proliferation or cell death.
3. Determine the subcellular localisation and distribution of PAD2 and PAD4.
57
2.2 Materials and methods
2.2.1 Suppliers used in this chapter
Abeam, 330 Cambridge Science Park, Cambridge, CB4 OFL, UK; Bioline UK Ltd, 16 
The Edge Business Centre, Humber Rd., London, NW2 6EW; Applied Biosystems, 
Lingley House, 120 Birchwood Boulevard, Warrington, WA3 7QH, UK; Fisher 
Scientific Inc, Bishop Meadow Rd., Loughborough, Leicestershire, LE11 5RG, UK; 
Invitrogen, 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK; Lonza, 
Muenchensteinerstrasser 38, CH -  4002, Basel, Switzerland; Millipore, Suite 3 & 5, 
Building 6, Croxley Green Business Park, Watford, WD18 8YH, UK; MWG-Biotech 
Ltd, Mill Cart, Featherstone Rd., Wolverton Mill South, Milton Keynes, MK6 5RD; 
NUNC, supplied through Fisher Scientific Inc; Peprotech EC Ltd, Peprotech House, 
29 Margravine Rd., London, W6 8LL, UK; Sigma-Aldrich, The Old Brickyard, New Rd., 
Gillingham, Dorset, SP8 4XT, UK; Vector Laboratories Ltd., 3 Accent Park, Bakewell 
Road, Orton Southgate, Peterborough, PE2 6XS, U.K; VWR International, Hunter 
Boulevard, Magna Park, Lutterworth, Leicestershire, LE17 4XN, UK.
2.2.2 Cell culture
The culture of mammalian cells in vitro is a technique which enables the investigation 
of specific cell behavior under particular conditions. An example of this is the treatment 
of cells with cytokines or drugs, and the effect of this on specific gene or protein 
expression within the treated cells compared to untreated cells. Mammalian cells are 
broadly grouped into two categories: primary and secondary cultures.
Primary cultures are cells that are taken directly from living tissues, such as biopsy 
material, and established for growth in vitro. These cells are more heterogeneous and 
have undergone very few population doublings and are therefore more representative 
of the true in vivo state of the tissue of origin. However, these primary cells can only be 
used for a limited number of passages (sub-culture) before dying.
Secondary cultures or cell lines are cells that are immortalised. Although these cells 
are not as representative of normal tissue as primary cells they are useful in producing 
reproducible data due to the fact that these cultures contain a more homogenous 
population of cells.
CNS tumour cells such as glioma cell lines used here are transformed cells which grow 
and divide indefinitely in culture.
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2.2.2.1 Collagen coating
For culture of hCMEC/D3 cell line, plasticware was coated with collagen type I from rat 
tail (3.41 mg/mL) (VWR, UK), which was diluted 1:30 in autoclaved distilled H20  
(dH20). Prior to use, the collagen solution was filtered through a 0.2 pm filter. Enough 
collagen solution was added to cover the bottom of a flask or a plate, and then 
incubated at 37°C for 1 hr. Following this, the excess collagen was removed and 
hCMEC/D3 cells were seeded.
2.2.2.2 Recovery of cryofrozen cells
Cells were stored long-term in 10% v/v dimethyl sulphoxide (DMSO) (Sigma, UK) in 
liquid nitrogen, until required for experimental work. Vials containing 1 mL of 1 x 106 
cells were removed from liquid nitrogen and placed in a 37°C incubator for 1-2 minutes 
to thaw. Following this, the contents of the vials were transferred into T25 flasks 
containing 9 mL of the appropriate, pre-warmed, complete cell culture medium and 
placed in a humidified incubator at 37°C containing 95% air and 5% C 02. The following 
day, cells had adhered to the bottom of the flask and medium was replaced.
2.2.2.3 Cell harvesting and serial passage of cells
A number of different primary and secondary cell lines were used for this study with 
specific media requirements (see table 2.1). Primary adult human astrocytes were 
isolated from either CNS NAWM obtained at autopsy from UK MS Society Tissue Bank 
(donor labelled MS16) or from normal tissue taken during temporal lobectomy 
resections for treatment of epilepsy at King's College Hospital (KCH, London; donor 
labelled either EP14 or EP15) (MS16, EP14 and EP15 were a kind gift from Dr I. 
Romero, Open University UK). The human foetal microglia cell line, CHME3, was 
obtained following transfection of human foetal-brain derived macrophages with a 
plasmid encoding for the large T antigen of SV40 (Janabi et al., 1995) (a kind gift from 
Prof. M. Tardieu, Faculte de Medecine Paris-Sud, France). The human brain 
endothelial cell line, hCMEC/D3, is a parent cell line obtained following lentiviral 
infection of pre-confluent human brain endothelial cells (Weksler et al., 2005).
Briefly, cells were cultured as monolayers in either 25cm2 or 75cm2 filter-cap flasks 
(Falcon, UK) containing specified media and kept in a humidified incubator at 37°C 
containing 95% air and 5% C 02. Cell media was changed twice weekly and cells were 
passaged when 80-90% confluent. Cells were passaged by aspirating medium from 
the flasks and washing twice with 5 mL or 10 mL (for T25 or T75, respectively) of 
Dulbecco's phosphate buffered saline (DPBS) without calcium and magnesium to
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remove remaining media. This was then followed by the addition of 3-5 mL of 0.5% 
trypsin and 0.2% ethylenediaminetetraacetic acid (EDTA) solution (Sigma-Alrich, UK) 
and incubation for 5 minutes in a humidified incubator at 37°C containing 95% air and 
5% C 02 to remove cells from the bottom of the flask. Trypsinisation was then stopped 
by neutralising trypsin/EDTA with 3-5 mL complete media, which was mixed with the 
cell suspension by gentle pipetting and then transferred to a sterile 15 mL centrifuge 
tube. Suspended cells were then centrifuged at 1000 rpm to pellet the cells, and the 
supernatant was aspirated to remove the trypsin/EDTA containing medium.
The cell pellet was then re-suspended in a known volume of fresh pre-warmed culture 
medium, and cells counted (see section 2.2.2.4) if required for experimental purposes, 
or suspended in the appropriate amount of complete media and seeded at a 1:6 split 
ratio to further propagate cells. Primary cells and cell lines were used between 
passages 5 and 8, except for U373-MG and hCMEC/D3 cell lines.
2.2.2.4 Cell counting
Cells were counted by removing 10 pL of cell suspension and adding to 10 pL of 0.4% 
Trypan blue, and mixed thoroughly. Trypan blue stain is based on the principle that live 
(viable) cells do not take up certain dyes, whereas dead (non-viable) cells do, as the 
dye can enter into cells with compromised membranes and is the method used with the 
Countess® automated cell counting platform (Invitrogen, UK). 10 pL of this mixture was 
then transferred onto a cell counting chamber slide and inserted into the Countess® 
Automated Cell Counter (http://www.invitrogen.eom/1/1/1306-trypan-blue-stain-0-4- 
use-the-countess-automated-cell-counter.htmL). The automated cell counter then 
counts the number of cells in total, the number of live cells/mL and the number of dead 
cells/mL. The number of live cells/mL is then used to calculate the amount of media to 
add to the cells to make the appropriate cell concentration for each experiment.
2.2.2.5 Reconstitution of cytokines
Recombinant cytokines IL-1 (3 (10 pg), TNF-a (50 pg), IL-6 (20 pg), IFN-y (100 pg), IL-4 
(20 pg), IL-10 (10 pg) and TGF-(3 (5 pg) (all from Peprotech, UK) were reconstituted 
from lyophilised powder in 100 pL, 500 pL, 200 pL, 1000 pL, 200 pL, 100 pL and 50 pL 
PBS, respectively, to give final stock concentrations of 100 pg/mL. These stock 
solutions of cytokines were stored in 20 pL aliquots at -20°C until required for further 
dilution on the day of experiments.
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2.2.2.6 Cytokine treatment of cells
For qPCR analysis, cells were seeded into 24-well plates at a density of 1x105 cells per 
well, in 1mL of complete media and left to adhere to the plate for 24 hours in a 
humidified incubator prior to treatment with cytokines. Following this, media was 
aspirated from the wells, and cells washed twice with DPBS to ensure no serum 
remained, as this could influence the results of the cytokine treatments. Subsequently, 
cells were treated in triplicate with serum free media (containing no FCS or human AB 
serum) containing 0, 1, 10 and 100 ng/mL of IL-1(B, TNF-a, IL-6 and IFN-y, respectively, 
for 24 hours in a humidified incubator.
Following this, media was aspirated from the untreated and treated cells and plates 
washed twice with DPBS. 0.33 mL Tri Reagent (Sigma Aldrich, UK) was added to each 
well of the treated and untreated cells and the triplicate samples were pooled. Total 
RNA was extracted from each cell lysate sample according to the manufacturers' 
instructions (see section 2.2.3.1). Three independent experiments were performed and 
in each experiment, treatments were carried out in triplicate to allow statistical analysis 
to be performed.
2.2.2.7 Cell viability and proliferation assay
When examining the effects of specific conditions on the behavior of mammalian cells 
in vitro, it is vital to determine if these conditions are having an effect on cell viability 
and proliferation. This can be determined through the use of a colourimetric MTS ([3- 
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium) assay, whereby MTS is bio-reduced by viable cells into a formazan 
product which is soluble in culture medium. The absorbance of the formazan product 
can then be measured directly enabling fold-change in cell numbers to be determined.
Cellular proliferation was determined using the MTS based assay (Figure 2.1) 
according to the manufacturers’ instructions (Promega, UK). MTS along with an 
electron coupling reagent, phenazine methosulphate (PMS), is bioreduced by 
dehydrogenase enzymes found in metabolically active cells to a formazan product. 
The absorbance of the formazan product at 490 nm is directly proportional to the 
number of living cells in culture.
Using the Cell Titer 96® Aqueous Cell Viability kit (Promega, UK), which is an MTS- 
based assay, cells were assessed for viability following treatment with pro-inflammatory 
cytokines. Briefly, cells were seeded into 96-well plates at a density of 2.5x104 cells per 
well in 100 pL complete media and left to adhere to the plate for 24 hours in a
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humidified incubator. Medium was then aspirated from the well, and cells were washed 
twice with 100 pL DPBS. Following this, cells were treated in triplicate with cytokines, 
100 pL per well, (see section 2.2.2.6) and left in a humidified incubator for 24 hours.
20 pL of MTS/ phenazine methosulphate (PMS) solution (1 mL of PMS solution in 20 
mL of MTS solution) was aseptically added to triplicate wells of the experimental 
samples. The plate was then incubated in a humidified incubator, and absorbance of 
the wells were measured at 490 nm using a Wallac Victor2 plate reader 
spectrophotometer every hour between 1 and 4 hours. Following optimisation, readings 
were taken at 2 hours, as this was determined to be when maximal reaction had 
occurred. These absorbance readings were then used in order to calculate fold-change 
in cell number following treatment with varying concentrations (1,10 and 100 ng/mL) of 
cytokines IL-1 (3, TNF-a, IL-6 and IFN-y, compared with untreated cells. Three 
independent experiments were performed.
2.2.3 The principles of standard polymerase chain reaction (PCR) and 
quantitative real-time PCR (qPCR)
Quantitative real-time polymerase chain reaction (qPCR) is widely used in gene 
expression studies in order to detect and quantify particular genes of interest, and is an 
improvement from traditional PCR. Prior to PCR, mRNA is converted to complementary 
DNA (cDNA) through the action of the enzyme reverse transcriptase, which elongates 
and copies the single-strand RNA using deoxynucleotide triphosphates (dNTPs) to 
make long single-stranded cDNA sequences of the entire length of RNA. This cDNA 
can then undergo traditional PCR or qPCR. In PCR primers are designed to bind to the 
3’ and 5’ ends of a specific DNA sequence initiating the activity of DNA polymerase, 
which copies the target sequence into double-stranded DNA. This double-stranded 
DNA product or amplicon then undergoes many repeats or cycles of thermal cycling, 
which consist of heating to denature the hydrogen bonds of the alpha-DNA helix thus 
separating the strands, and cooling to anneal primers and encouraging polymerization, 
resulting in the synthesis of over a billion copies of target DNA exponentially 
(http://gene-quantification.de/real-time-pcr-guide-bio-rad.pdf). The amplified product of 
known length, denoted by the distance between the primers on the target sequence of 
the gene, is produced and can be measured and semi-quantified by agarose gel 
electrophoresis. This traditional method of PCR has poor precision, low sensitivity, 
relies on good band resolution, and the use of hazardous chemicals, e.g. ethidium 
bromide. In addition, because traditional PCR measures the end-point of the assay, the 
results between replicates can be highly variable (Figure 2.2).
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Figure 2.2: qPCR amplification plot. PCR consists of three amplification stages; 
exponential, linear and plateau. In the exponential phase, reagents are in abundance 
with PCR product doubling every cycle. During the linear phase these reagents begin 
to deplete and the PCR reaction begins to slow down. Finally in the plateau phase all 
reagents are depleted and the PCR reaction stops. qPCR measures PCR amplification 
during the exponential phase which generates more precise and accurate data, 
whereas traditional PCR measures the amount of accumulated PCR product at the end 
of the PCR cycles (the plateau phase) which shows much greater variability between 
triplicate samples.
Key: CT; Cycle Threshold.
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qPCR measures amplification cycle by cycle in real-time, rather than at the end point of 
the assay, as occurs in traditional PCR, through the use of fluorescently labeled 
molecules which accumulate after each amplification cycle. In qPCR the PCR products 
are quantified in the exponential phase of the reaction where there is a doubling of the 
PCR product every cycle, which provides more precise and accurate data for 
quantification (Figure 2.2). Within this exponential phase two values are calculated: the 
threshold line and the cycle threshold (CT). The threshold line is the level where the 
reaction reaches a fluorescence intensity which is significantly higher than background 
levels, usually ten times the standard deviation of the baseline (Wong and Medrano 
2005), and the CT is the PCR cycle at which the sample reaches this threshold (Figure 
2.2).
There are two distinct detection chemistries employed in qPCR, namely probe- or non­
probe based chemistries, also referred to as ‘specific’ and non-specific’, respectively 
(Bustin and Mueller 2005). Probe-based detection methods use amplicon-specific 
fluorescent probes that only generate a fluorescent signal when bound to their 
complementary target sequence. This type of detection chemistry is very specific as a 
particular gene sequence must be present in order for the probe to bind. In 
comparison, non-probe-based methods rely on fluorescent dyes that intercalate to 
double-stranded DNA, when in free solution this dye exhibits little fluorescence but 
during DNA polymerisation increasing amounts of the dye binds to nascent DNA 
resulting in an increase in fluorescent signal. This method is much less specific 
because the dye binds to any double-stranded DNA, including any mispriming events 
or primer dimers as well as the target sequence and therefore requires verification of 
the PCR product through the generation of a melt curve of the amplicon where 
fluorescence is plotted as a function of temperature.
PCR products can either be quantified using absolute or relative quantification. 
Absolute quantification requires the use of standards of known target copy number to 
generate a standard curve from which the absolute quantity of the mRNA from a target 
gene of an unknown sample can be determined. This method of quantification is most 
commonly employed when determining viral load or tumour load in bodily fluids (Bustin 
and Mueller 2005). Relative quantification determines the changes in mRNA 
expression of a target gene across multiple samples and expresses it relative to an 
internal reference gene e.g. housekeeping gene. There are many mathematical 
algorithms that have been developed to produce the corrected relative expression ratio, 
the most common of which is the comparative delta CT method (Livak and Schmittgen 
2001). However, in order for the comparative delta CT method to be valid, the primer 
amplification efficiencies of each target and reference gene must be approximately
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equal, therefore it is important that primer efficiencies are determined prior to qPCR of 
unknown samples. Relative quantification is most commonly used when comparing 
expression levels of mRNA targets between different biological conditions and 
validating gene knockdown experiments.
qPCR using Taqman® probes
qPCR is used for the detection and quantification of gene expression. RNA is first 
reverse transcribed into complementary DNA (cDNA). The target DNA molecule is then 
amplified by PCR and quantified in real-time by the accumulation of fluorescence after 
each cycle of amplification (Figure 2.3). Taqman® probes have three levels of 
specificity to ensure that only the gene of interest is amplified. In addition to the forward 
and reverse primers of traditional PCR, an oligonucleotide probe designed to bind only 
to a portion of the target DNA sequence is also added to the reaction, which provides 
further specificity compared to standard PCR and non-probe dye intercalating 
chemistries, such as SYBR Green (Bustin et al., 2005).
The Taqman® probe is an oligonucleotide that contains a fluorescent reporter dye 
bound to the 5’ end and a quencher on the 3’ end (Figure 2.3). The probe is designed 
to bind to a specific region of the target DNA sequence downstream from the primer 
binding site. While the probe is intact, the proximity of the quencher dye greatly 
reduces the fluorescence emitted by the reporter dye by fluorescence resonance 
energy transfer (FRET). If the target sequence is present, the probe anneals 
downstream from the primer site. During amplification the DNA polymerase elongates 
cleaving the probe due to its 5’ nuclease activity, resulting in the separation of the 
reporter from the quencher, with a subsequent increase in the reporter dye 
fluorescence. As the primer extends, the probe is completely removed from the target 
strand enabling primer extension to the end of the template strand. This fluorescent 
signal is captured by the PCR instrument. With each cycle, additional reporter 
molecules are cleaved from their respective probes, resulting in an increase in 
fluorescence intensity. This increase in reporter fluorescence intensity is directly 
proportional to the number of amplicons generated.
2.2.3.1 Total RNA extraction
RNA was extracted from cells following cytokine treatment for 24 hours using Tri
Reagent following the manufacturers' instructions (Sigma-Aldrich, UK). Briefly, cells
were washed twice with DPBS followed by the addition of 0.33 mL of Tri Reagent to
each well for 5 minutes at RT, in order to lyse the cells (total of 1 mL Tri Reagent per
condition as 3 wells) and then transferred to sterile 1.5 mL microcentrifuge tubes.
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Subsequently, 0.2 mL of chloroform was added to samples, mixed vigorously and left 
to stand for 15 minutes at RT followed by centrifugation at 12,000 g for 15 minutes at 
4°C.
The colourless upper aqueous phase was then transferred into a RNA-free clean 
microcentrifuge tube and 0.5 mL of isopropanol was then added to precipitate the RNA, 
which was left to stand for 15 minutes at RT, followed by centrifugation at 12,000 g for 
15 minutes. The supernatant was removed and the RNA pellet was washed in 1mL of 
75% ethanol followed by vortexing and centrifugation at 12,000g for 15 minutes. Lastly, 
the 75% ethanol was removed and the RNA pellet was air-dried for 5-10 minutes and 
then resuspended in 10-30 pL of diethylpyrocarbonate (DEPC)-treated water for 
subsequent complementary DNA (cDNA) synthesis. DEPC inactivates any RNase 
enzymes which may be present in the water (Invitrogen, UK).
2.2.3.2 Agarose gel electrophoresis of total RNA
RNA samples were run on a 1% agarose gel to check the quality and purity of the total 
RNA extracted (e.g. no degradation or contamination of RNA). This separation is based 
on the principle that 28S rRNA will migrate at 5 kb and 18S rRNA will migrate at 2 kb, 
and are present in a 2:1 ratio (Sambrook and Russell 2001).
A 1% pre-stained agarose gel was prepared by the addition of 0.5 g agarose (Bioline, 
UK) in 50 mL Tris-acetate-EDTA (TAE) buffer (89 mM Tris-HCL pH 7.8, 89 mM borate, 
2 mM EDTA), followed by heating in a microwave oven for 1 min to dissolve the 
agarose. The solution was then allowed to cool, followed by the addition of 3.5 pL 
ethidium bromide (from 10mg/mL stock concentration), and poured into a sealed gel 
tray. An 8-well gel comb was inserted into the agarose solution and the gel was left to 
set for -30 minutes. Agarose gels were then submerged in an electrophoresis tank 
containing TAE buffer covering 2-3 mm above the gel. Experimental samples (2 pL 
RNA with 2 pL sample buffer) were then loaded into each well and run for 20 minutes 
at 100V. Gel images were captured using a UVP epi II dark room using Labworks 
software version 4.0.
2.2.3.3 cDNA synthesis
RNA extracted from both cytokine treated and untreated cells was converted to cDNA 
prior to carrying out qPCR. RNase-free filter tips and tubes were used throughout the 
cDNA synthesis procedure.
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Forward primer
Reverse primer
Figure 2.3: A schematic diagram showing the principles of qPCR using Taqman® 
probes, (a) Sequence-specific forward and reverse primers, along with a sequence- 
specific probe, hybridise to the DNA template, (b-c) During amplification, the 5’ 
nuclease activity of the Taq DNA polymerase cleaves the probe as the primer is 
extended, separating the reporter (R) dye from the quencher (Q) leading to an increase 
in the reporter dye signal, (d) Lastly, the probe is fully removed from the target DNA 
sequence, allowing primer extension to continue and synthesis of the full amplicon 
sequence. Adapted from http://www.clinchem.Org/content/46/1/24/F1.small.gif.
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Briefly, 4 |jL of 5x first strand buffer, 2 (jL of 0.1 M dithiothreitol (DTT) (Invitrogen, UK), 
1 gL of deoxynucleotide triphosphates (dNTPs) (Bioline, UK), 0.5 pL of RNase inhibitor 
(Invitrogen, UK), 0.5 pL of random hexamers (Invitrogen, UK), 9 pL of DEPC-treated 
water (Invitrogen, UK), 1 pL of reverse transcriptase (Invitrogen, UK) and 1 pL of RNA 
were mixed in RNase-free PCR tubes (Sigma, UK) on ice. Control samples were also 
prepared containing RNA without the addition of the RT enzyme and also a negative 
control containing no RNA sample. The samples were then placed on a heating block 
where they were heated for 2 hrs at 42°C, then 5 minutes at 95°C to inactivate the 
reverse transcriptase enzyme followed by 4°C and then stored at -20°C.
2.2.3.4 qPCR
Forward and reverse PCR primers along with probes for both housekeeping and target 
genes of interest were pre-designed and ordered from Applied Biosystems, UK (see 
Table 2.2 for full gene name, function and primer details).
PCR reactions were prepared on ice and performed in a volume of 10 pL, containing 
0.5 pL FAM-labelled probe, 2.5 pL DEPC-treated water (Invitrogen, UK), 5 pL 2x 
Taqman® mastermix (ABI, UK) and 1 pL cDNA template. Reactions were performed in 
duplicate and three independent experiments were performed for each culture 
condition.
Amplification was carried out in an ABI 7900 sequence detector, using the following 
programme: 50°C for 2 minutes, 95°C for 2 minutes, followed by 40 cycles of 
denaturation at 95°C for 15 seconds and an annealing/elongation step at 60°C for 1 
minute. At each step of the experiment, emitted fluorescence was measured in real­
time resulting in an amplification plot on the ABI Prism 7900HT sequence detection 
system software 2.2.1. The relative mRNA level of each target gene was then 
calculated using the resulting cycle threshold (CT) values and the 2- delta delta cycle 
threshold (2'AACT) (see section 2.2.3.5).
2.2.3.5 Relative quantification using comparative CT method
The comparative CT method is a mathematical model that calculates changes in gene 
expression as a relative fold difference between an experimental and control 
(calibrator) sample normalised to an endogenous reference gene (Livak and 
Schmittgen 2001; Wong and Medrano 2005).
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Prior to data analysis, the baseline and threshold was manually determined on each 
amplification plot for each target and reference gene. For data analysis, the means of 
each duplicate target and housekeeping CT value for each sample were first averaged 
to account for any inter-assay variability. Following this the target mean CT values for 
each sample were then normalised to the mean CT values of two housekeeping genes 
to give the ACT, as follows:
ACj = CT target gene -  CT reference gene
For relative or semi-quantitative analysis of mRNA expression, the CT values of the test 
samples in experimental conditions i.e. treated, were represented relative to their 
expression in control conditions i.e. untreated. An average ACT of control samples for 
each repeat was then taken as the ACT calibrator value from which the test sample ACT 
values were normalised. Test samples were presented as relative fold-change from 
controls. The AACT was then calculated as follows:
AACj = ACj calibrator -  ACT calibrator
AACj = ACj sample -  ACT calibrator
Following this, the untreated control sample or calibrator then has a AACT value which 
equals 0. In order to account for the exponential nature of the PCR reaction, these 
values are then converted into linear form, as follows:
2-aact
By raising the AACT to 2'AACT, this converts the AACT value of the calibrator to 1, so that 
the fold-change in gene expression relative to the untreated control, equals 1. For the 
treated samples, the 2'AACT indicates the fold-change in gene expression relative to the 
untreated control i.e. 1 (Livak and Schmittgen 2001).
2.2.3.6 Determination of primer efficiencies
In order for the comparative CT method to be valid (see section 2.2.3.5), the primer
efficiencies of the target genes and the reference or housekeeping genes must be
approximately equal, therefore it is imperative to determine the primer efficiencies prior
to data analysis (Livak and Schmittgen 2001). When primers are 100% efficient there
should be a doubling of PCR product every cycle within the exponential phase of the
reaction (Figure 2.1) (Livak and Schmittgen 2001). A sensitive method for determining
primer efficiency is to carry out serial template dilutions of cDNA and examine the
resultant ACT. The data collected during this exponential phase can be log-transformed
and plotted with slope of the regression line, which represents the samples
amplification efficiency (Wong and Medrano 2005). Generally, a primer efficiencv
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between 90-110% is considered acceptable, although all target genes and 
housekeeping genes should be within 5% of one another in order to use the 
comparative CT method (Livak and Schmittgen 2001).
In order to assess primer efficiencies a two-fold serial dilution of template cDNA 
ranging from 1:1 to 1:32 in DEPC-treated water was performed and subjected to qPCR. 
The resulting CT values of all target and reference genes were plotted against log 
dilution factor. A linear trend line was then added to the graph, and from this, the slope 
of the line was determined and then calculated into percentage primer efficiency. The 
linear correlation was also determined, which indicates how good one value is at 
predicting another, with an R2 value of >0.99 providing good confidence in correlating 
two values.
2.2.3.8 Selection of housekeeping genes
To achieve accurate, relative quantification of an mRNA target it is necessary to 
normalise to at least one reference gene, which is constitutively expressed and is not 
affected by the experimental treatment under study, and therefore can be used to 
correct for differences in the amount of total nucleic acid added to each reaction 
(Vandesompele et al., 2002). There is not one specific gene that meets this criterion, 
therefore it is imperative to validate the expression stability of at least one control gene 
with experimental samples, prior to use for normalisation (Andersen et al., 2004). 
Vandesompele et al. (2002) recommend the use of at least three internal control genes 
for normalisation. However, this is often impractical due to time and money constraints. 
Three commonly used reference genes; glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), cyclophilin A (PPIA), and hypoxanthine guanine phosphoribosyl transferase 
1 (HPRT1), were assessed by qPCR to determine which of these reference genes 
were most stable, under the experimental conditions used in this chapter.
The geNorm programme was then used to select the two most stable reference genes 
(Vandesompele et al., 2002). This programme determines the expression stability of 
reference genes on the basis of non-normalised expression levels. For each reference 
gene, the pair-wise variation with other reference genes is determined, resulting in a 
gene expression stability measure (M). Those with the lowest M values have the most 
stable expression, with increasing variation in ratio corresponding to decreasing 
expression stability. Prior to input into the geNorm programme, the CT values were 
transformed using the ACT method (see section 2.2.3.5). ACT was calculated by 
subtracting the lowest CT value from all other CT values, followed by the equation 2'AACT 
applied to each experimental sample. Following this, geNorm software then calculated 
the average M value for each reference gene in ranked order, followed by exclusion of
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the gene with the highest M value (i.e. least stable) resulting in the display of the two 
most stable genes. An M value of <1.5 is considered a stable reference gene.
2.2.4 Traditional PCR
Untreated control cDNA from EP14 primary human astrocytes and U373-MG 
astrocytoma cell line were subjected to standard PCR (see section 2.2.3). All reagents 
were purchased from Bioline, UK, except for PCR primers which were designed and 
ordered from Applied Biosystems, UK. PCR reactions were prepared on ice and 
performed in a volume of 25 pL, containing 2.5 pL ImmunBuffer, 0.5 pL 50 mM MgCI2, 
0.5 pL dNTP mix, 1 pL forward primer, 1 pL reverse primer, 0.5 pL Immolase DNA 
polymerase, 17 pL DEPC-treated water (Invitrogen, UK) and 2 pL cDNA template. 
Amplification was carried out in a Primus 96 Plus Thermal Cycler (MWG-Biotech, UK), 
using the following programme: 95°C for 10 minutes, followed by 35 cycles of: 95°C for 
30 seconds, 55°C for 30 seconds and 72°C for 90 seconds. Samples were then stored 
at 4°C until the products were run on a gel.
2.4.4.1 Optimisation of traditional PCR for PAD4
Initially two forward and reverse primer sets (Table 2.3) were used to test for the 
presence of PAD4 product using cDNA from U373-MG and EP14 cells. Optimisation of 
forward and reverse primer sets predominantly involved testing different concentrations 
of MgCI2 and different temperatures of the annealing and extension cycles, using cDNA 
from U373-MG astrocytoma cell line as a positive control for PAD4 as this cell line had 
been reported previously to express PAD4 mRNA (Chang and Han 2006).
2.4.4.2 Agarose gel of PCR products
PCR products were run on a 3% agarose gel to check that products were of the correct 
size specific to the primers. A 3% pre-stained agarose gel was prepared by the addition 
of 1.5 g of agarose to 50 ml_ of TAE buffer (see section 2.2.3.2). Samples (10 pL with 3 
pL sample buffer) and ladder (Bioline, UK) were loaded into wells and run for -90 
minutes at 80V. The gel was then visualised using the UVP image analysis programme 
for the presence of a band at the expected size indicating no DNA contamination and 
the specificity of the primers.
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2.2.5 Im m unocytochem istry
Antibodies are routinely used to detect the cellular localisation of proteins (or antigens) 
in cells, tissues or biological fluids. The detection of an antigen using antibodies in 
cultured cells is referred to as immunocytochemistry (ICC) whereas the detection of an 
antigen using antibodies in tissues is known as immunohistochemistry (IHC). In this 
chapter ICC was utilised.
Immunofluorescence is dependent on the coupling of fluorophores to antibodies, which 
when bound to the antigen of interest and excited by a light source, such as UV light, 
emits light, which can then be visualised using either a fluorescence or confocal 
microscope revealing the location of the antigen of interest. Prior to antibody 
application the cells and/or tissues are subjected to fixation, permeabilisation and if 
necessary blocking. Fixation preserves both the cellular and subcellular structure in 
addition to the antigenicity of the antigen(s) of interest. Fixatives either form cross- 
linkages to preserve the tissue structure e.g. aldehydes such as glutaraldehyde or 
formalin, or remove lipids and dehydrate cells whilst precipitating proteins and fixing 
them in their usual cellular localisation e.g. organic solvents such as acetone, ethanol, 
methanol (Delves et al., 2006).
Both fixation methods can result in denaturation of the protein/antigen of interest. 
Fixatives which form cross-linkages may reduce the access of antibodies to some cell 
components, and therefore ICC may require a permeabilisation step to allow access of 
the antibody to the target protein/antigen. Detergents, such as Triton X-100 or Tween- 
20, are used for this permeabilisation step. A blocking step is often employed using 
bovine serum albumin (BSA) or serum from the species in which the secondary 
antibody is made. This prevents non-specific binding of the labelled secondary 
antibody and particularly binding to endogenous Fc receptors (FcRs) present on the 
surface of some cells (Buchwalow et al., 2011).
Washing of the cells and/or tissues is performed following each of these steps to 
remove unbound reagents. There are two types of immunofluorescence: direct and 
indirect. In the direct method of immunofluorescence, the primary antibody directed 
against the antigen of interest is directly conjugated with a fluorochrome (Figure 2.4). 
Although this method involves fewer steps, the technique is limited as only a limited 
number of antibodies can access the antigen of interest leading to low sensitivity. 
Based on this, indirect immunofluorescence is often the preferred method utilised.
This method of immunofluorescence is most commonly employed and is called the 
double-layer technique because it uses two antibodies, the primary antibody, which
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recognises the antigen of interest; the secondary antibody, which is directed against 
the species of Ig in which the primary antibody was raised (Figure 2.4). An example of 
this is the application of a monoclonal mouse anti-GFAP IgG antibody to cells or 
tissues, which can then be visualised by the addition of a fluorochrome-conjugated 
rabbit anti-mouse IgG. There are a number of advantages to this technique, in 
particular: several fluorescently labelled secondary antibodies can bind to the primary 
antibody, increasing the intensity of fluorescence and therefore the sensitivity of 
staining is greatly increased compared to the direct method; a single secondary 
antibody can be used to detect a range of primary antibodies, thereby reducing overall 
costs. Dual labelling of cells or tissues for two antigens can be performed providing the 
primary antibodies are raised in different species, otherwise the secondary antibody will 
be unable to discriminate between the two primary antibodies. In addition, the emission 
wavelengths of each of the fluorophore conjugated secondary antibodies must also be 
different otherwise discrimination between the two antigens of interest will not be 
possible. For example, GFAP and PAD2 can be detected in the same cell by using a 
monoclonal mouse and polyclonal rabbit primary antibody, respectively. In addition, the 
fluorescently labelled secondary antibodies must also be species specific, so directed 
against mouse and rabbit IgG, respectively each labelled with a different fluorophore.
2.2.5.1 Indirect immunofluorescence
In order to determine the cellular and subcellular localisation of PAD2 and PAD4, ICC 
was carried out on U373-MG, EP14 and EP15 cells. Cells were seeded into 8-well 
chamber slides (NUNC, Labtech International, UK) at a density of 1x104 cells/mL and 
400 pL per well and left to adhere to the chamber slide for 24 hours in an incubator at 
37°C containing 95% air and 5% C 02. Following this, media was aspirated from the 
chamber slides and cells washed three times in PBS for 5 minutes each. Cells were 
then fixed with acetone for 5 minutes and subsequently left to air dry for 10-15 minutes 
at RT. Prior to this a number of fixatives were tested in the initial optimisation 
procedure and acetone was found to provide substantially better staining than ethanol, 
methanol, or 4% paraformaldehyde (PFA). The chamber slide dividers were then 
removed and a wax pen was used to draw around each well of the chamber slide to 
ensure antibody solution remained within each well. The cells were stained for S100-(3, 
GFAP, PAD2 and PAD4 using monoclonal mouse anti-human GFAP, polyclonal rabbit 
anti-human PAD2 and polyclonal rabbit anti-human PAD4, respectively (Table 2.4). 
Preliminary experiments were performed to determine the optimum concentration for 
ICC, with each antibody diluted within a range recommended by the supplier. Primary 
antibodies (20 pL per well, diluted in DPBS with 0.5% Triton® X-100) were applied to
78
each well and incubated in a humidified chamber for 2 hrs at RT. The negative controls 
with the primary antibody omitted were incubated with 20 pL PBS with 0.5% Triton® X- 
100. Cells were then washed three times in PBS, to remove any unbound antibody, for 
5 minutes each. In order to detect any bound antigen, secondary antibodies FITC 
conjugated to rabbit anti-mouse IgG (for mouse monoclonal antibodies) or Alexa Fluor 
568® conjugated to goat anti-rabbit IgG (for polyclonal antibodies) were then applied. 
Fluorochrome conjugated secondary antibodies (20 pL per well, diluted in PBS) were 
applied to each well and incubated in the dark in a humidified chamber for 90 minutes 
at RT. Following this, cells were washed three times in DPBS, to remove any unbound 
secondary antibody, for 5 minutes each.
Subsequently, slides were mounted using Vectashield™ hard-set mounting medium 
with 4', 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, UK), which stains the 
cell nuclei blue. The edges of the coverslips were then sealed with nail varnish, and 
slides wrapped in foil and stored at 4°C until analysed. Images were captured using an 
upright Olympus BX60 fluorescent microscope, equipped with a cool-snap pro 
(Cybernetics) digital camera to acquire images into Labworks™ where they were saved 
without further manipulation.
2.2.6 Statistical analysis
MTS assay data was analysed using one-way ANOVA followed by a Dunnett’s post- 
hoc test. Statistical significance was set at p < 0.05 and data are represented as mean 
± SEM. qPCR data was analysed using the non-parametric Kruskal-Wallis test followed 
by a Conover post-hoc test. In order to carry out statistical analysis, the 2'ACT was 
calculated to determine the relative gene expression. Each treated condition was then 
compared to the control. Statistical significance was set at p < 0.05 and data are 
represented as mean ± SEM.
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2.3 Results
2.3.1 Effect of pro-inflammatory cytokines on the viability of CNS cells
Due to preliminary qPCR data (not shown) indicating a down-regulation in the 
expression of PAD2 and PAD4 in cells following cytokine treatment, the effect of pro- 
inflammatory cytokines on the viability of cells was examined to ensure down- 
regulation was not due to significant apoptosis of cells.
2.3.1.1 U373-MG astrocytoma cell line
Treatment of an astrocytoma cell line (U373-MG) with 100 ng/mL of TNF-a for 24 hours 
resulted in a small 7% decrease in number of viable cells compared to untreated 
control, whereas treatment with 100 ng/mL of IFN-y resulted in a 16% decrease in 
number viable cells compared to control. Treatment with IL-1 (3 and IL-6 alone did not 
affect cell viability (Figure 2.5a). Treatment of U373-MG cells with 100 ng/mL of IL-1 (3, 
TNF-a or IL-6 alone for 48 hours resulted in only small, 5 to 8% decreases in the 
number of viable cells, whereas 100ng/mL of IL-1 (3 caused a 20% reduction in the 
number of viable cells (Figure 2.5b).
2.3.1.2 EP14 primary human astrocyte cells
Treatment of primary human astrocytes (EP14) with IL-1 (3, TNF-a, IL-6 or IFN-y for 24 
hours did not affect cell viability (Figure 2.6a). Co-treatment of EP14 cells with IL-1 (3 
and TNF-a or IL-1 (3 and IFN-y did not have an effect on cell viability, whereas dual 
treatment with 100 ng/mL of TNF-a and IFNy resulted in a small 6% reduction in the 
number of viable cells compared to control cells (Figure 2.6b).
2.3.1.3 EP15 primary human astrocyte cells
Treatment of primary human astrocytes (EP15) with IL-1 (3, TNF-a, IL-6 or IFN-y did not 
alter the viability of the cells (Figure 2.7a). Flowever, co-treatment of EP15 cells 
showed dramatic increases in cell proliferation (Figure 2.7b). Co-treatment of cells with 
IL-1 (3 and TNF-a resulted in a maximal 44% increase in cell number at 10 ng/mL 
(Figure 2.7b), similarly co-treatment with IL-1 (3 and IFN-y resulted in a maximal 100% 
increase in cell number at 100 ng/mL. Furthermore, a maximal 61% increase in viable 
cells was observed following dual treatment with 100 ng/mL of TNF-a and IFN-y.
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Figure 2.5: Effect of cytokine treatment on viability of an astrocytoma cell line 
(U373-MG). (a) 24 hour treatment with single cytokines IL-1 (3, TNF-a, IL-6 and IFN-y, 
and (b) 48 hour treatment with single cytokines IL-1 (3, TNF-a, IL-6 and IFN-y at 0-100 
ng/mL. Data presented as the mean ± SEM. Significant difference from control, 
*p<0.05, ** p<0.01, *** p<0.001 (ANOVA with Dunnett’s test, n=3).
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Figure 2.6: Effect of cytokines on the viability of primary adult human astrocytes 
(EP14). 24 hour treatment with (a) single cytokines IL-1 (3, TNF-a, IL-6 and IFN-y, and 
(b) dual cytokines IL-1 (3 + TNF-a, IL-1 (3 + IFN-y and TNF-a + IFN-y at 0-100 ng/mL. 
Data presented as the mean ± SEM. Significant difference from control, * p<0.05 
(ANOVA with Dunnett’s test, n=3).
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Figure 2.7: Effect of cytokines on the viability of primary adult human astrocytes 
(EP15). 24 hour treatment with (a) single cytokines IL-1 (3, TNF-a, IL-6 and IFN-y, and 
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Data presented as the mean ± SEM. Significant difference from control, *p<0.05, 
**p<0.01, ***p<0.001 (ANOVA with Dunnett’s test, n=3).
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2.3.1.4 MS16 primary human astrocytes
IL-1 (3 treatment of primary human astrocytes (MS16) resulted in an increase in cell 
number, with a maximal 66% increase observed at 1 ng/mL, similarly TNF-a treatment 
resulted in an increase in viable cells, with a maximal 40% increase at 100 ng/mL 
(Figure 2.8a). IL-6 treatment resulted in an increase in viable cells, with a maximal 20% 
increase observed at 1 ng/mL. Treatment with IFN-y did not alter the cell viability or 
proliferation. Co-treatment of MS 16 cells with IL-1 (3 and TNF-a resulted in an increase 
in cell proliferation at all concentrations, with a maximal 187% increase observed at 10 
ng/mL. Dual treatment with IL-1 (3 and IFN-y resulted in an increase in cell proliferation 
at all concentrations tested, with a maximal 136% increase observed at 100 ng/mL 
(Figure 2.8b).
2.3.1.5 CHME3 human foetal microglial cell line
Treatment of human foetal microglial cell line (CHME3) with IL-1 (3 at 100 ng/mL 
resulted in a 16% decrease in viable cells compared to control, similarly treatment with 
TNF-a at 100 ng/mL resulted in a 19% decrease in viable cells compared to control 
(Figure 2.9a). Treatment with 100 ng/mL of IL-6 resulted in a 17% decrease in viable 
cells. IFN-y treatment resulted in a decrease in the viability of cells at all concentrations 
tested, with a maximal 14% decrease observed at 100 ng/mL.
Co-treatment of CHME3 cells with IL-1 (3 and TNF-a or IL-1 (3 and IFN-y did not have an 
effect on cell viability (Figure 2.9b). A decrease in the number of viable cells was 
observed following dual treatment with 10 and 100 ng/mL of TNF-a and IFN-y, with a 
maximal 22% reduction observed at 100 ng/mL. Single treatment of CHME3 cells with 
IL-4, IL-10 and TGF-(3 did not alter cell viability.
2.3.1.6 hCMEC/D3 human brain endothelial cell line
Treatment of a brain endothelial cell line (hCMEC/D3) with IL-1 (3, TNF-a, IL-6 or IFN-y 
for 24 hours did not affect cell viability (Figure 2.10a). Following co-treatment of 
hCMEC/D3 cells with IL-1 (3 and TNF-a, a maximal 22% decrease in cell viability was 
observed at 100 ng/mL (Figure 2.10b). Co-treatment with IL-1 (3 and IFN-y did not alter 
cell viability. A decrease in cell viability was observed following dual treatment with 
TNF-a and IFN-y, with a maximal 20% decrease at 100 ng/mL.
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Figure 2.8: Effect of cytokines on the viability of primary adult human astrocytes 
(MS16). 24 hour treatment with (a) single cytokines IL-1 (3, TNF-a, IL-6 and IFN-y, and 
(b) dual cytokines IL-1 (3 + TNF-a, IL-1 (3 + IFN-y and TNF-a + IFN-y at 0-100 ng/mL. 
Data presented as the mean ± SEM. Significant difference from control, *p<0.05, 
**p<0.01, ***p<0.001 (ANOVAwith Dunnett’s test, n=3).
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2.3.2 RNA integrity
All RNA experimental samples showed clear bands at 5 kb and 2 kb indicating 28s and 
18s ribosomal RNA in a ratio of 2:1 indicating no degradation or contamination, 
showing their suitability to be transcribed into cDNA and subjected to qPCR (Figure 
2.11; Figure 2.12).
2.3.3 Selection of housekeeping genes
Three widely used housekeeping genes (GAPDFI, PPIA, and FIPRT1) were tested for 
their stability across the experimental conditions and hence suitability as reference 
genes for normalisation of target gene expression in qPCR experiments. Using geNorm 
(see section 2.2.3.8), the expression stability measure (M) of the two most stable 
genes were determined in each cell line following cytokine treatment. Ideally reference 
genes should have an M-value of less than 1.5, indicating that the expression is stable 
following cytokine treatment. Once determined these reference genes can then be 
used for normalisation (Vandesompele et al., 2002).
In separate experiments, astrocyte preparations (EP14, EP15, MS16), CFiME3, and 
hCMEC/D3 cells were treated with varying concentrations (1, 10 and 100 ng/mL) of 
single cytokines; IL-1 (3, TNF-a, IL-6 and IFN-y and dual cytokines; IL-1 (3 + TNF-a, IL-1 (3 
+ IFN-y, and TNF-a + IFN-y for 24 hours and then subjected to qPCR. The raw ACT 
values from each experiment were then transformed using the relative quantification 
ACt method (see section 2.2.3.5) and subjected to geNorm analysis (Table 2.5). 
Following this, it was determined that GAPDH was the least stably expressed gene in 
all cell lines tested. Following the elimination of GAPDH, the M-value of the two most 
stably expressed genes in the cells was calculated to be less than 1.5 (0.158, 0.425, 
0.323, 0.246 and 0.405, respectively). This demonstrated the suitability of PPIA and 
HPRT1 to be used as reference genes, therefore both PPIA and HPRT1 were used in 
subsequent qPCR experiments.
2.3.4 Primer efficiencies
Once appropriate housekeeping genes had been selected, the amplification efficiency 
of four primer pairs was determined. cDNA from CHME3 was subjected to a two-fold 
serial dilution followed by qPCR using the standard curve method (see section 2.2.3.6). 
The resulting primer efficiencies ranged from 90 (PPIA) to 95% (HPRT1 and PAD4), 
with correlation coefficients between 0.957 (PPIA) and 0.999 (PAD4) (Table 2.6; Figure 
2.13).
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Figure 2.11: RNA extractions of CNS cells following treatment with varying 
concentrations (0, 1, 10 and 100 ng/mL) of single cytokines; IL-1 p, TNF-a, IL-6 
and IFN-y. (a) U373-MG, (b) EP14, (c) EP15, (d) MS16, (e) CHME3 and (f) 
hCMEC/D3.
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Figure 2.12: RNA extractions of CNS cells following treatment with varying 
concentrations (0, 1, 10 and 100 ng/mL) of dual cytokines; IL-1P+ TNF-a, IL-1 p + 
IFN, and TNF-a + IFN-y. (a) EP14, (b) EP15, (c) MS16, (d) CHME3 and (e) 
hCMEC/D3.
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Table 2.5: Validation of reference genes using the GeNorm analysis programme.
EP14 PPIA & HPRT1 IL-1(3 0.150
TNF-a 0.194
IL-6 0.149
IFN-y 0.136 0.158
EP15 PPIA & HPRT1 IL-16 0.364
TNF-a 0.399
IL-6 0.430
IFN-y 0.507 0.425
MS16 PPIA & HPRT1 IL-1 (3 0.402
TNF-a 0.188
IL-6 0.312
IFN-y 0.392 0.323
CHME3 PPIA & HPRT1 IL-1 (3 0.266
TNF-a 0.212
IL-6 0.289
IFN-y 0.217 0.246
hCMEC/D3 PPIA & HPRT1 IL-1 (3 
TNF-a 
IL-6 
IFN-y
0.476
0.303
0.524
0.316 0.405
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Table 2.6: Summary of the primer efficiencies of all housekeeping and target 
genes used in qPCR.
GAPDH -1.0540 0.9815 95
PPIA -0.9014 0.9572 90
HPRT1 -0.9487 0.9942 95
PAD2 -1.0926 0.9918 91
PAD4 -1.0518 0.9992 95
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Figure 2.13: Standard curves showing the primer efficiencies following qPCR of 
serially diluted cDNAfrom CHME3. (a) GAPDH, (b) PPIA, (c) HPRT1, (d) PAD2 and 
(e) PAD4.
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In order for the comparative CT method to be valid the primer efficiencies of the target 
genes and reference (housekeeping) genes must be approximately equal (see section 
2.2.3.5) (Livak and Schmittgen 2001). It is generally recommended that to use the 
comparative CT method, primer efficiencies must be within 5% of one another. The 
primer efficiencies of the target genes and housekeeping genes in this case were 
within 5% of one another, therefore it was decided that the comparative CT method 
could be used for analysis of qPCR data. Once the primer efficiencies had been 
determined, the baseline and CT thresholds were set for each primer-probe pair 
(Figure 2.14).
2.3.5 Modulation of gene expression by pro-inflammatory cytokines
The effects of pro-inflammatory cytokines on the modulation of PAD2 and PAD4 were 
investigated in the cells of the CNS following treatment for 24 and 48 hours with both 
single (IL-1 (3, TNF-a, IL-6 and IFN-y) and dual cytokines (IL-1 p + TNF-a, IL-1 (3 + IFN-y, 
and TNF-a + IFN-y). Following this, qPCR was carried out to determine the influence of 
these cytokines on the expression of PAD2 and PAD4. The data obtained was then 
transformed and quantified through the comparative CT method (see section 2.2.3.5) 
using normalisation against two suitable housekeeping genes (see section 2.2.3.8). 
Treatments were applied to wells in triplicate and cells pooled together for qPCR, which 
was performed in duplicate. Three independent experiments were carried out for each 
cell type in order to perform statistical analyses to compare treated to untreated control 
samples.
2.3.5.1 Basal expression of PAD2 and PAD4 in cells of the CNS
The 2'ACT values obtained for untreated control cells of the CNS (Figure 2.15) show that 
PAD2 is most highly expressed in astrocytes from MS case (MS16) (2ACT=0.111), 
followed by considerably lower expression in control astrocytes (EP14) (2'ACT=0.006) 
and EP15 cells (2'ACT=0.002). CHME3 cells (2'ACT=0.003), hCMEC/D3 cells (2‘ACT=0.001) 
and U373-MG cells (2'ACT=0.0001) all showed low levels of PAD2 expression. The 2"ACT 
values obtained for untreated control astrocytoma cell line, U373-MG, shows that 
PAD4 is expressed at a considerably lower level than PAD2 (2'ACT=0.000005). PAD4 
was undetectable in all the primary human astrocytes tested (EP14, EP15, and MS16), 
therefore modulation of PAD4 following treatment with pro-inflammatory cytokines was 
not investigated in these cells.
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Figure 2.14: Amplification curves generated following qPCR of target and 
housekeeping genes, (a) GAPDH, (b) PPIA, (c) HPRT1, (d) PAD2 and (e) PAD4. CT; 
cycle threshold.
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Figure 2.15: Basal expression of PAD2 mRNA in different preparations of primary 
human astrocytes, a human foetal microglial cell line (CHME3) and a human 
brain endothelial cell line (hCMEC/D3). Data presented as the mean ± SEM. 
Significant difference between MS16 and other cells tested is indicated, *** p<0.001 
(Kruskal-Wallis with Conover-lnman, n= 21).
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2.3.5.2 U373-MG astrocytoma cell line
The expression of PAD2 in the astrocytoma cell line (U373-MG) was significantly 
down-regulated following treatment with IL-1 (3, at 1, 10 and 100 ng/ml_ (4.7-fold 
(P<0.0001), 3.2-fold (p=0.0002) and 2.9-fold (p=0.0006), respectively) (Figure 2.16a). 
Treatment with IL-1 (3 resulted in down-regulation of PAD4, but this only reached weak 
statistical significance at 1 ng/mL (1.8-fold (p=0.0468)). A concentration-dependent 
decrease in PAD2 expression was observed following TNF-a treatment, with statistical 
significance reached at 10 and 100 ng/mL compared to control (2.3-fold and 3.6-fold 
(p=0.0052 and p=0.0009) respectively). Down-regulation of PAD4 was observed 
following treatment with 100 ng/mL TNF-a, however, statistical significance was not 
reached. Down-regulation of PAD2 and PAD4 was observed following treatment with 
100 ng/mL IL-6, however, this was not significant. Treatment with IFN-y resulted in a 
significant down-regulation at 1, 10 and 100 ng/mL (1.7-fold, 3.0-fold and 5.2-fold 
(p=0.0243, p=0.002 and p=0.0002), respectively). Similarly, PAD4 was also down- 
regulated following treatment with IFN-y, resulting in statistical significance at 1, 10 and 
100 ng/mL (2.1-fold, 2.9-fold and 3.2-fold (p=0.0125, p=0.0157 and p=0.0125), 
respectively).
Unlike at 24 hours, treatment with IL-1 (3 for 48 hours in the astrocytoma cell line (U373- 
MG) cells showed down-regulation at 1 and 100 ng/mL and statistical significance was 
reached (Figure 2.16b). Treatment with IL-1 (3 did not alter the expression of PAD4 at 
48 hours, which was similar to the pattern observed at 24 hours. TNF-a treatment for 
48 hours resulted in a concentration-dependent decrease in the expression of PAD2, 
with statistical significance obtained at 10 and 100 ng/mL (1.2-fold and 2.3-fold 
(p=0.0455 and p=0.0033), respectively).
Similar to 24 hours, treatment with TNF-a for 48 hours resulted in a decrease in PAD4 
expression at 100 ng/mL (2.2-fold (p=0.0108)). The expression of PAD2 did not alter 
following treatment with IL-6 for 48 hours, whereas PAD4 showed a concentration- 
dependent decrease with statistical significance reached at 100 ng/mL (2.0-fold 
(p=0.0157)) which is similar to results from 24 hour treatment. Treatment with IFN-y for 
48 hours resulted in a concentration-dependent down-regulation in the expression of 
PAD2 similar to the pattern observed at 24 hours, with statistical significance at 10 and 
100 ng/mL (4.2-fold and 8.4-fold (p=0.0017 and p=0.0002), respectively). PAD4 down- 
regulation was also observed following treatment with IFN-y, with statistical significance 
reached at 10 and 100 ng/mL (2.9-fold and 2.7-fold (p=0.0053 and p=0.0091), 
respectively), which is similar to the pattern observed at 24 hours.
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Figure 2. 16: Relative fold change in mRNA levels of PAD2 and PAD4 in U373-MG 
astrocytoma cells following cytokine treatment. Cells were treated with varying 
concentrations of IL-1 (3, TNF-a, IL-6 and IFN-y for (a) 24 hours and (b) 48 hours. Data 
presented as the mean ± SEM. Significant difference from control, *p <0.05, **p <0.01, 
***p<0.001 (Kruskal-Wallis with Conover-lnman, n=3).
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2.3.5.3 Primary astrocytes derived from normal white matter (EP14 and EP15)
IL-1 (3 treatment resulted in down-regulation of PAD2 expression in primary human 
astrocytes (EP14 and EP15), with significance reached at 1 and 10 ng/mL compared to 
untreated control cells (5.60-fold (p=0.0157) and (4.36-fold (p=0.0216), respectively) 
(Figure 2.17a). Treatment with TNF-a resulted in down-regulation of PAD2 expression 
at all concentrations tested, however, statistical significance was only reached at 10 
ng/mL where there was a 6.4-fold decrease in PAD2 (p=0.0163). Statistical 
significance was not reached at 1 and 100 ng/mL. Down-regulation of PAD2 
expression was also observed following treatment with IL-6 at 1 and 10 ng/mL, 
although statistical significance was only reached at 10 ng/mL (3.8-fold (p=0.0483)). 
Treatment with IFN-y resulted in an apparent down-regulation of PAD2 expression at 
10 and 100 ng/mL, although statistical significance was not reached.
Treatment of primary human astrocytes (EP14 and EP15) with IL-1 (3 and TNF-a at 
1 ng/mL resulted in a 1.5-fold increase in PAD2 expression, however, a 1.6-fold and
2.7-fold decrease in PAD2 expression was observed at 10 and 100 ng/mL, 
respectively, although not statistically significant (Figure 2.17b). Down-regulation of 
PAD2 was observed following treatment with IL-1 (3 and IFN-y with statistical 
significance reached at 10 and 100 ng/mL compared to control (1.6-fold (P=0.0002 and
2.7-fold (p=0.0023), respectively). A concentration-dependent decrease in PAD2 
expression was observed following treatment with 1, 10 and 100 ng/mL TNF-a and 
IFN-y, with statistical significance reached at 10 and 100 ng/mL (7.3-fold (p=0.217) and 
34.7 (p=0.009), respectively).
2.3.5.4 Primary astrocytes derived from white matter from a case of MS (MS16)
Treatment of primary human astrocytes (MS16) with IL-1 (3 resulted in significant down- 
regulation of PAD2 expression at 1, 10 and 100 ng/mL compared to control (5.2-fold 
(p=0.0046), 3.2-fold (p=0.0098) and 3.6-fold (p=0.0142), respectively) (Figure 2.18a). A 
concentration-dependent decrease in PAD2 expression was observed following TNF-a 
treatment with statistical significance reached at 1, 10 and 100 ng/mL compared to 
control (4.5-fold (p=0.004), 5.4-fold (p=0.0013) and 7.5-fold (p=0.0005), respectively). 
IL-6 treatment did not affect the expression of PAD2 compared to control. Treatment 
with IFN-y resulted in a concentration-dependent decrease in the expression of PAD2 
resulting in significant down-regulation at 100 ng/mL (4.2-fold (p=0.0242)).
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Figure 2.17: Relative fold change in mRNA levels of PAD2 in primary astrocytes 
from two control cases (EP14 and EP15) following cytokine treatment. Cells were 
treated for 24 hours with varying concentrations (0, 1, 10 and 100 ng/mL) of (a) single 
cytokines IL-1 (3, TNF-a, IL-6 and IFN-y, and (b) dual cytokines IL-1 [3 +TNF-a, IL-(3 + 
IFN-y, and TNF-a + IFN-y. Data presented as the mean ± SEM. Significant difference 
from control, *p <0.05, **p <0.01, ***p <0.001 (Kruskal-Wallis with Conover-lnman, 
n=3).
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Figure 2.18: Relative fold change in mRNA levels of PAD2 in primary astrocytes 
from an MS case (MS16) following cytokine treatment. Cells were treated for 24 
hours with varying concentrations (0, 1, 10 and 100 ng/mL) of (a) single cytokines IL- 
1 p, TNF-a, IL-6 and IFN-y, and (b) dual cytokines IL-1 (3 + TNF-a, IL-(3 + IFN-y, and 
TNF-a + IFN-y. Data presented as the mean ± SEM. Significant difference from control, 
* p <0.05, **p <0.01, ***p <0.001 (Kruskal-Wallis with Conover-lnman, n=3).
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Co-treatment of primary human astrocytes (MS 16) with IL-1 (3 and TNF-a resulted in 
significant down-regulation of PAD2 expression at 1, 10 and 100 ng/mL compared to 
control (3.6-fold (p=0.0115), 4.2-fold (p=0.0024) and 3.8-fold (p=0.0079), respectively) 
(Figure 2.18b). Significant concentration-dependent down-regulation of PAD2 
expression was observed following co-treatment with IL-1 (3 and IFN-y at 1, 10 and 100 
ng/mL compared to control (4.7-fold (p=0.0099), 5.5-fold (p=0.0036) and 8.6-fold 
(p=0.001), respectively). Co-treatment with TNF-a and IFN-y resulted in significant 
down-regulation in PAD2 expression at 1, 10 and 100 ng/mL (4.55-fold (p=0.0036), 
10.1-fold (p=0.0003) and 10.8-fold (p=0.0002), respectively).
2.3.5.5 CHME3 human foetal microglial cell line
Down-regulation of PAD2 expression was observed following treatment of CHME3 
cells with 1,10 and 100 ng/mL IL-1 (3, with statistical significance reached at 10 and 100 
ng/mL (2.0-fold (p=0.0014) and 1.9-fold (p=0.0029), respectively) (Figure 2.19a). A 
significant concentration-dependent decrease in the expression of PAD2 was observed 
following treatment with TNF-a (1.6-fold (p=0.0311), 2.4-fold (p=0.001) and 3.2-fold 
(p=0.0001), respectively). Down-regulation of PAD2 expression was observed following 
treatment with IL-6 and IFN-y alone, but the decreases were not significant.
A concentration-dependent decrease in PAD2 expression following co-treatment of 
CHME3 cells with IL-1 (3 and TNF-a was observed at all concentrations tested, with 
significance reached at 1, 10 and 100 ng/mL compared to control (1.9-fold (p=0.0118),
2.8-fold (p=0.0009) and 3.6-fold (p=0.0005), respectively) (Figure 2.19b). A significant 
down-regulation in PAD2 expression was observed following co-treatment with 1, 10 
and 100 ng/mL IL-1 (3 and TNF-a compared to control (1.6-fold (p=0.0133), 2.5-fold 
(p=0.0002) and 2.2 (p=0.0004), respectively). Significant concentration-dependent 
down-regulation in the expression of PAD2 was observed following co-treatment with 
TNF-a and IFN-y at 1, 10, and 100 ng/mL compared to control (2.6-fold (p=0.0006), 
3.4-fold (p=0.0003) and 5.8-fold (p=<0.0001), respectively).
Treatment of CHME3 with IL-4 induced a non-significant up-regulation of PAD2 
expression at 1 and 10 ng/mL, with down-regulation observed at 100 ng/mL (Figure 
2.19c). Treatment with IL-10 resulted in down-regulation of PAD2 at 10 and 100 ng/mL, 
but statistical significance was not reached. A concentration-dependent decrease in 
PAD2 expression was observed following treatment with TGF-(3 resulting in significant 
down-regulation at 1, 10 and 100 ng/mL compared to control (1.9-fold (p=0.0289), 2.2- 
fold (p=0.0013) and 4.0-fold (p=0.0002), respectively).
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Figure 2.19: Relative fold change in mRNA levels of PAD2 in CHME3 following 
cytokine treatment. Cells were treated for 24 hours with varying concentrations (0, 1, 
10 and 100 ng/mL) of (a) single cytokines IL-1 (3, TNF-a, IL-6 and IFN-y, (b) dual 
cytokines IL-1 (3 + TNF-a, IL-(3 + IFN-y, and TNF-a + IFN-y, and (c) single cytokines IL- 
4, IL-10 and TGF-(3. Data presented as the mean ± SEM. Significant difference from 
control, *p <0.05, **p <0.01, ***p <0.001 (Kruskal-Wallis with Conover-lnman, n=3).
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2.3.5.6 hCMEC/D3 brain endothelial cell line
IL-1 (3 and IFN-y treatment of the brain endothelial cell line (hCMEC/D3) did not alter the 
expression of PAD2 (Figure 2.20a). However, a concentration-dependent decrease in 
the expression of PAD2 was observed following treatment with TNF-a, although 
statistical significance was only reached at 100 ng/mL (6.6-fold (p=0.036)). Treatment 
with IL-6 resulted in a concentration-dependent non-significant decrease in the 
expression of PAD2.
A concentration-dependent decrease in the expression of PAD2 in hCMEC/D3 was 
observed following co-treatment with IL-1 (3 and TNF-a reaching statistical significance 
at 100 ng/mL (5.6-fold (p=0.0424)) (Figure 2.20b). Co-treatment with IL-1 (3 and IFN-y 
resulted in a non-significant down-regulation of PAD2 at 10 and 100 ng/mL. A 
statistically significant decrease in the expression of PAD2 was observed following co­
treatment with TNF-a and IFN-y at 1, 10 and 100 ng/mL (4.3-fold (p=0.0018), 4.1-fold 
(p=0.0274) and 9.2-fold (p=0.0052), respectively).
2.3.6 Standard PCR of PAD4
Due to the inability to detect PAD4 mRNA in primary human astrocytes using qPCR, 
standard PCR was carried to confirm whether absence of PAD4 was due to a 
polymorphism preventing primers binding in qPCR or due to no PAD4 gene expression 
in these cells. Following optimisation of the standard PCR protocol, primer set 2 (Table 
2.3) was used for the detection of PAD4. Standard PCR confirmed a product of 600 
base pairs in the U373-MG astrocytoma cell line indicating presence of the PAD4 gene 
expression, whereas no product was found in the EP14 primary human astrocytes 
indicating the absence or undetectable levels of PAD4 gene expression (Figure 2.21).
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Figure 2.20: Relative fold change in mRNA levels of PAD2 in hCMEC/D3 
endothelial cells following cytokine treatment. Cells were treated for 24 hours with 
varying concentrations (0, 1, 10 and 100 ng/mL) of (a) single cytokines IL-1 (3, TNF-a, 
IL-6 and IFN-y, and (b) dual cytokines IL-1 (3 and TNF-a, IL-1 (3 and IFN-y, and TNF-a 
and IFN-y. Data presented as the mean ± SEM. Significant difference from control, *p 
<0.05, **p <0.01, ***p <0.001 (Kruskal-Wallis with Conover-lnman, n=3).
107
PCR products for PAD4
BPM U373-MG EP14 NTC
800 bp
600 bp
400 bp
Figure 2.21: Agarose gel electrophoresis of standard PCR products. The
presence of PAD4 in U373-MG cells (600 bp) and absence in EP14 cells is observed. 
BPM; base pair marker, NTC; no template control.
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2.3.7 Immunocytochemical detection of PAD2 and PAD4
ICC was performed on astrocytes (EP14, EP15) and U373-MG cells in order to identify 
the cellular localisation of PAD2 and PAD4 following fixation in acetone to enable the 
intracellular localisation of astrocyte-specific markers (GFAP and S-100(3) and PAD2 
and PAD4 (Figures 2.22 and 2.25).
Negative controls were also performed whereby the primary antibody was omitted. 
Fluorescence microscopy demonstrated characteristic staining of both the processes 
and cell bodies of astrocytes in EP14 cells with an anti-GFAP and anti-S100(3 antibody 
(Figure 2.22 a, b).
PAD2 showed strong cytoplasmic staining in EP14, EP15 and U373-MG cells (Figure 
2.23 a-c). PAD4 demonstrated weaker cytoplasmic staining and more intense nuclear 
staining in EP14, EP15 and U373-MG cells (Figure 2.24 a-c). A second PAD4 antibody 
was also tested using acetone and ethanol as fixatives, which showed weak 
cytoplasmic staining (Figure 2.25 a, b).
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Figure 2.22: Single label immunofluorescence for GFAP and S-100p in EP14 
primary human astrocytes. Cells were fixed in acetone and labelled for (a) GFAP 
using primary polyclonal rabbit anti-human GFAP antibody and secondary antibody 
Alexa fluor 568 goat anti-rabbit IgG, (b) S-100(3 using primary monoclonal mouse anti­
human S-100(3 antibody and secondary antibody FITC goat anti-mouse IgG, (c) 
negative control with secondary Alexa fluor 568 goat anti-rabbit IgG alone, and (d) 
negative control with secondary FITC goat anti-mouse antibody alone. Nuclei were 
counterstained with DAPI (x400 magnification).
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Figure 2.23: Single label immunofluorescence for PAD2 in different preparations 
of primary human astrocytes and an astrocytoma cell line. Cells were fixed in 
acetone and labelled for PAD2 using primary polyclonal rabbit anti-human PAD2 
antibody and secondary Alexa fluor 568 goat anti-rabbit IgG in (a) EP14, (b) EP15, (c) 
U373-MG and (d) negative control with secondary antibody only. Nuclei were 
counterstained with DAPI (x400 magnification).
Figure 2.24: Single label immunofluorescence for PAD4 in different preparations 
of primary human astrocytes and an astrocytoma cell line. Cells were fixed in 
acetone and labelled for PAD4 using primary polyclonal rabbit anti-human PAD4 
antibody and secondary Alexa fluor 568 goat anti-rabbit IgG in (a) EP14, (b) EP15, (c) 
U373-MG and (d) negative control with secondary antibody only. Nuclei were 
counterstained with DAPI (x400 magnification).
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Figure 2.25: Single label immunofluorescence for PAD4 using a different primary 
antibody from Sigma, UK in EP14 primary human astrocytes. Cells were labelled 
for PAD4 using primary monoclonal mouse anti-human PAD4 antibody and secondary 
Alexa fluor 568 goat anti-mouse IgG following fixation with (a) ethanol, (b) acetone, and 
negative controls with secondary antibody only following fixation with (c) ethanol, and 
(d) acetone. Nuclei were counterstained with DAPI (x400 magnification).
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2.4 Discussion
2.4.1 IL-1 p, TNF-a, IL-6 and IFN-y differentially affect cellular proliferation 
in an astrocytoma cell line, primary human astrocytes, microglial cell line 
and brain endothelial cell line
Preliminary qPCR results showed down-regulation of PAD2 mRNA following cytokine 
treatment, therefore the effect of cytokines on the viability of cells was investigated to 
ensure this down-regulation was not due to significant cell death occurring in response 
to cytokine treatment. MS 16 showed greater proliferation following treatment with 
single pro-inflammatory cytokines compared to normal astrocytes, EP14 and EP15 
(Table 2.7). The astrocytoma cell line, U373-MG, showed a decrease in viable cells. A 
previous study, using qPCR, has shown that both U373-MG and primary human 
astrocytes prepared from patients with epilepsy constitutively express mRNA encoding 
the IFN-y receptor (IFNGR). However, using post-mortem brain tissue from a patient 
with MS, strong up-regulation of IFNGR on activated astrocytes in affected areas in MS 
was seen compared to U373-MG and astrocytes extracted from patients with epilepsy 
(Hashioka et a!., 2009). Therefore, this increased proliferation in MS16 may be due 
greater sensitivity of these cells to IFN-y as a result of up-regulated expression of 
cytokine receptors on astrocytes in MS tissue. Although there are no studies reporting 
differences in receptor expression for IL-13 and TNF-a in astrocytes prepared from 
individuals with MS compared to controls, it could be hypothesised that these cytokine 
receptors may also be up-regulated in MS16. However, due to the astrocytes in this 
study being isolated from only one MS case and two control cases, it is difficult to make 
any firm conclusions, and more astrocyte preparations from a larger number of MS and 
control cases would have to be investigated. Furthermore, co-treatment with pro- 
inflammatory cytokines showed significant additive increases in proliferation of both 
MS16 and EP15 primary human astrocytes.
Single cytokine treatments caused some reduction in the percentage of viable cells in 
the human foetal microglia cell line, CHME3. Previous studies have shown microglia to 
express receptors for IL-1, IL-6 and TNF-a (Lee et a!., 2002). Co-treatment with TNF-a 
+ IFN-y resulted in a further additive reduction in the percentage of viable cells, 
whereas co-treatments with either IL-1 (3 + TNF-a or IL-13 + IFN-y did not affect the cell 
viability. Treatment with anti-inflammatory cytokines IL-4, IL-10 and TGF-3 did not 
affect the proliferation or viability of CHME3 cells. Single-cytokine treatments did not 
affect the proliferation or viability of human brain endothelial cell line, hCMEC/D3, 
except following treatment with TNF-a which resulted in a small decrease in the
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percentage of viable cells. Co-treatments with IL-1 (3 + TNF-a and TNF-a + IFN-y 
resulted in a similar reduction in the percentage of viable cells. This reduction was no 
greater than TNF-a alone, indicating only TNF-a is exerting an effect on cell viability. 
This suggests that hCMEC/D3 cell lines are only sensitive to TNF-a.
The use of housekeeping genes in subsequent qPCR experimental results enables any 
differences in cell number to be accounted for when quantifying the mRNA levels of 
PAD2 and PAD4 genes, as data is expressed relative to HK gene level.
2.4.2 IL-1 p, TNF-a and IFN-y differentially modulate the gene expression of 
PAD2 and PAD4 in an astrocytoma cell line, primary human astrocytes, 
microglial cell line and brain endothelial cell line
In this present study, following optimisation and validation of the qPCR method for 
detection of PAD2 and PAD4, it was found that PAD2 was constitutively expressed in 
an astrocytoma cell line, primary human astrocytes, a human foetal microglial cell line 
and a human adult brain endothelial cell line. This agreed with previous 
immunocytochemical studies which have shown expression of PAD2 in glial cells 
(Akiyama et at., 1990), in particular microglia (Vincent et at., 1992; Asaga et at., 2002; 
Asaga and Ishigami 2007) and astrocytes (Vincent et at., 1992; Asaga and Senshu 
1993; Asaga and Ishigami 2000; Asaga et at., 2001). This is the first study to report the 
expression of PAD2 mRNA in brain endothelial cells.
The most prominent initial finding was that the basal expression of PAD2 mRNA was 
significantly higher in primary human astrocytes isolated from the NAWM of an MS 
post-mortem case (MS16) than primary human astrocytes isolated from brains 
following a temporal lobectomy for the treatment of epilepsy (EP14 and EP15), and 
also compared to expression in the human foetal microglial and human brain 
endothelial cell lines. This higher level of PAD2 gene expression in astrocytes 
extracted from a patient with MS is not surprising, as previous studies have shown 
increased PAD2 activity in patients with MS compared to control individuals (Wood et 
a!., 2008), although this is the first study to show PAD2 mRNA expression is 
specifically increased in the astrocytes of an MS patient. However, this result should be 
considered with caution due to these cells being isolated from one MS case. For the 
result to be validated further studies would have to be carried to determine the basal 
expression of PAD2 mRNA in astrocytes extracted from the NAWM of a number of MS 
CNS cases, and other factors controlled for such as death to autopsy interval time, age 
and sex of the patient etc. This increase in basal PAD2 mRNA expression in MS16 
may be due to hypoxia of the post-mortem brain tissue prior to extraction of the
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astrocytes which has been shown to raise intracellular calcium levels resulting in 
increased expression of PAD2 mRNA (Sambandam et at., 2004). In comparison, EP14 
and EP15 primary human astrocyte preparations are extracted from living individuals 
undergoing surgery for treatment of epilepsy, and therefore would not be exposed to 
hypoxia to the same extent.
Initial experiments showed that PAD4 mRNA could only be detected in the astrocytoma 
cell line, U373-MG, and was undetectable in primary human astrocytes, EP14 and 
EP15. Due to the PAD4 gene being highly polymorphic, it was initially thought that the 
reason for this may be that the primary human astrocytes contained a polymorphism in 
the PAD4 gene which was preventing the original PAD4 primers from being able to 
bind and therefore amplify the PAD4 gene. Single nucleotide polymorphisms in the 
PAD4 gene are associated with the autoimmune disease RA (Suzuki et at., 2003). 
Therefore a further two primer and probe sets were tested covering different exon 
boundaries to see if amplification of PAD4 occurred using different primer sets, 
targeting a different region of the PAD4 gene. However, the PAD4 gene was still 
undetectable in primary human astrocytes. Lastly, standard PCR was carried out to 
amplify a larger portion of the PAD4 mRNA to determine if PAD4 was present at the 
mRNA level. Using U373-MG as a positive control, results showed that U373-MG 
expressed the PAD4 gene which was indicated by a product at 600 base pairs whereas 
again, this PAD4 product was undetectable in primary human astrocytes (EP14). This 
confirmed that PAD4 was either absent or not expressed at a level detectable using 
qPCR or standard PCR in the primary human astrocytes. It was not surprising that 
PAD4 was expressed at a high enough level to be detected by qPCR in the 
astrocytoma cell line, as previous studies have shown PAD4 to be significantly 
expressed in various cancers but not in corresponding normal tissues (Chang and Han 
2006; Wang et al., 2010). Chang et at. (2006) were able to show moderate expression 
of PAD4 at the protein level in human brain astrocytoma cells compared to no 
expression in normal tissues. Previous studies have shown PAD4 to be predominantly 
expressed by white blood cells, in particular neutrophils (Asaga et at., 2001), 
macrophages and monocytes (Vossenaar and van Venrooij 2004; Vossenaar et at., 
2004). Therefore, it was not surprising that PAD4 was not detected in primary human 
astrocytes.
Immunocytochemistry confirmed the expression of PAD2 protein in the astrocytoma 
cell line, U373-MG and the three different preparations of primary human astrocytes 
(EP14, EP15 and MS16). However, contrary to the qPCR findings in the present study, 
where no PAD4 mRNA was identified in the primary human astrocytes, the PAD4 
protein was found to be expressed in all preparations of primary human astrocytes
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(EP14, EP15 and MS16). PAD2 showed positive diffuse staining in the cytoplasm, 
whereas PAD4 showed strong punctate nuclear staining. This pattern of staining was 
expected as PAD4 is the only PAD to carry a nuclear localisation signal to translocate it 
to the nucleus of a cell (Nakashima et al., 2002). However, a recent study has also 
shown PAD2 to be present in the nucleus (Jang et al., 2011). In the present study, the 
conflicting data from qPCR and immunocytochemical studies does not allow for clear 
conclusions to be drawn. The staining was not caused by non-specific staining of the 
secondary antibody, as the negative control cells showed no positive staining. The 
staining pattern of PAD4 seemed specific to nuclear proteins, which was expected, as 
PAD4 is known to reside in the nucleus and is involved in the citrullination of histones 
(Hagiwara et al., 2002; Nakashima et al., 2002; Cuthbert et al., 2004; Wang et al., 
2004).
In terms of reliability of the qPCR data the PAD4 primer-probes are validated by the 
supplier, ABI, however, in-house validation by target detection would have been useful 
to confirm the reliability of the procedure. However, the fact that the PAD4 gene was 
also not detected in the primary human astrocytes using standard PCR whereas the 
astrocytoma cel! line as a positive control, where a band corresponding to PAD4 
appeared at 600 base pairs, further confirms the absence of PAD4 mRNA in primary 
human astrocytes. The correlation between mRNA and protein expression is not 
always invariant, and Gygi et al., (1999) described how mRNA is an insufficient 
predictor of protein expression. Post-transcriptional mechanisms controlling the 
translation rate of the proteins, the half-lives of specific mRNAs or proteins, and the 
intracellular location and molecular association of the protein products may all 
contribute to the disparity between mRNA and protein quantification (Gygi et al., 1999). 
Through isolation of PBMCs from the peripheral blood of patients with RA and controls 
followed by differentiation of monocytes into macrophages, Vossenaar et al. (2004) 
has shown the presence of PAD4 protein in the absence of PAD4 mRNA in 
macrophages, whereas PAD2 was expressed at both the mRNA and protein level in 
monocytes.
Due to PAD4 mRNA only being detected in the astrocytoma cell line and undetectable 
in the primary human astrocytes, it was decided that further qPCR experiments in the 
primary human astrocytes, human foetal microglial and human adult brain endothelial 
cell lines would focus on PAD2 expression. Therefore, all subsequent qPCR was 
carried out using PAD2-specific primers only, except in the astrocytoma cell line.
Under inflammatory conditions, PAD2 and PAD4 genes showed differential expression 
patterns in the astrocytoma cell line, U373-MG (Table 2.8). Single treatment with IL-1 (3,
TNF-a and IFN-y all resulted in the significant down-regulation of PAD2 mRNA
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following treatment for 24 hours. Down-regulation of PAD4 mRNA was also observed 
following treatment with IFN-y and to a lesser extent following treatment with IL-1 (3 for 
24 hours. No significant differences were observed by incubating the cells with 
cytokines for 48 hours compared to 24 hours, therefore, all subsequent cytokine 
experiments were carried out for 24 hours.
All primary human astrocytes and the human foetal microglial cell line, CFIME3, 
showed significant down-regulation of PAD2 mRNA following single cytokine treatment 
with either IL-1 (3 or TNF-a alone. Co-treatment with IL-1 (3 and TNF-a, IL-1 (3 and IFN-y, 
or TNF-a and IFN-y all resulted in significant down-regulation of PAD2 gene 
expression. Interestingly, co-treatment with TNF-a and IFN-y resulted in a similar down- 
regulation of PAD2 gene expression as observed following single treatment with TNF- 
a, suggesting the down-regulation is exerted by TNF-a. This pre-dominance of TNF-a 
actions was also observed following co-treatment with IL-1 [3 and TNF-a. Single 
treatment with IFN-y produced variable results with significant down-regulation of PAD2 
mRNA only reached following 100 ng/mL of treatment in the primary human astrocytes, 
MS16, which as suggested earlier could be due to increased expression of the IFNGR 
in MS.
In the human brain endothelial cell line, hCMEC/D3, only single treatment with TNF-a 
elicited significant down-regulation of PAD2 gene expression. Co-treatment with IL-1 (3 
+ TNF-a or TNF-a + IFN-y, showed significant down-regulation of PAD2 mRNA similar 
to the down-regulation observed following single treatment with TNF-a. Similar to the 
above observations, this implicates TNF-a as the single cytokine exerting effects on the 
expression of PAD2 mRNA.
This decrease in PAD2 and PAD4 mRNA expression following treatment with pro- 
inflammatory cytokines was unexpected, since previous studies have shown significant 
up-regulation of pro-inflammatory cytokines (for review see Imitola et al., 2005) along 
with an increase in the expression of both PADs and citrullinated proteins in MS brains 
by IHC (for review see (Bradford et al., 2009). It was anticipated that pro-inflammatory 
cytokines may initially up-regulate PAD mRNA expression resulting in increased PAD 
protein expression and activation followed by subsequent increase in citrullinated 
proteins. Therefore, it was expected that incubation of cells with pro-inflammatory 
cytokines in vitro to mimic the in vivo situation in MS would result in an up-regulation of 
PAD gene expression.
Due to this down-regulation of PAD2 in all primary cells and cell lines tested following 
treatment with pro-inflammatory cytokines, the effect of anti-inflammatory cytokines on 
the expression of PAD2 mRNA was briefly investigated as these anti-inflammatory
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cytokines are thought to have an opposing effect on PAD2 gene expression. Microglia 
are a major cell type known to express PAD2 (Vincent et al., 1992; Asaga et al., 2002; 
Asaga and Ishigami 2007), therefore the human microglial cell line, CHME3, was 
selected for anti-inflammatory cytokine treatment with IL-4, IL-10 or TGF-p alone. 
Treatment with either IL-4 or IL-10 did not modulate the expression of PAD2, whereas 
treatment with TGF-p resulted in down-regulation of PAD2 mRNA, by CHME3 cells.
A previous study has shown citrullination to be rapidly induced in HL-60 neutrophils 
following exposure to various inflammatory signals, including TNF-a, LPS, lipoteichoic 
acid and hydrogen peroxide (Neeli et al., 2008). However, there are very few studies 
that have investigated the effects of cytokines on the expression of PAD2 and PAD4 
directly as opposed to the resultant citrullinated proteins. One study has showed that 
TNF-a is essential for translocation of PAD4 to the nucleus (Mastronardi et al., 2006). 
This same study also showed that transgenic mice over-expressing TNF-a have 
increased levels of citrullinated histones and elevated nuclear PAD4 in the CNS prior to 
demyelination (Mastronardi et al., 2006). There are other studies which indicate a 
number of different factors are involved in the regulation of PADs, and therefore it is 
tempting to speculate that in order for the expression of PAD2 to become significantly 
up-regulated a number of other mediators have to be present, of these calcium seems 
to be most important.
Not only is calcium the indispensable factor in the environment of the deimination 
reaction (see section 1.5.3.6), but it is also considered as a major regulator of PAD 
genes at the transcriptional level (Ying et al., 2009). Using normal human keratinocytes 
(NHEK) Dong et al., (2005) have shown that the expression of PAD2 mRNA is 
enhanced 2-fold when these cells are cultured in 1.2 mM calcium compared to cells 
grown in media containing only 0.15 mM of calcium. It is thought that calcium could 
control the binding of transcriptional factors to the promoters of the PAD2 gene. In 
particular, the level of Sp1 and/or Sp3 recruitment to the promoter and the Sp1/Sp3 
ratio has been shown to change according to the calcium concentration in the culture 
medium (Dong et al., 2005). Studies of PAD1 in NHEK cells have shown that mutations 
of the binding sites of MZF-1- or Sp-1 transcription factors markedly reduced PAD1 
promoter activity (Dong et al., 2007). Interestingly, MZF1 -binding sites have not been 
identified in the promoter region of PAD2, which shows that PAD isoforms are 
differentially regulated at the transcription level (Dong et al., 2005). In this study, the 
culture media contained approximately 1.8 mM of calcium, which according to the 
above studies should be sufficient to induce the binding of transcriptional factors to the 
promoters of the PAD2 gene, and explains why PAD2 mRNA expression was observed 
in untreated cells used in this study. However, the subsequent down-regulation of
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PAD2 observed following cytokine treatment suggests that the balance between anti- 
and pro-inflammatory cytokines does not control PAD2 expression in vitro which 
indicates that additional mediators and mechanisms must be involved in the modulation 
of PADs in vivo.
Additional mechanisms have also been shown to be important to the transcriptional 
regulation of the PAD2 gene. Methylation of the PAD2 promoter results in silencing of 
the PAD2 gene (Cedar 1988; Yeivin and Razin 1993) whereas hypomethylation of the 
PAD2 promoter increases transcription. A study by Mastronardi et al. (2007) has shown 
significant hypomethylation of the PAD2 promoter in MS NAWM compared with 
controls, which would allow for increased transcription of PAD2, leading to increased 
expression and subsequent increase in citrullination (Mastronardi et al., 2007). PAD2 
protein was shown to be up-regulated in MS NAWM compared to control white matter 
(Mastronardi et al., 2007). This hypomethylation of the PAD2 promoter has also been 
shown to occur in PBMCs from patients with MS along with an increase in PAD2 
mRNA expression (Calabrese et al., 2012).
In this study only expression of PAD2 at the mRNA level under the influence of pro- 
inflammatory cytokines was studied. It would have been useful to have carried out 
western blotting to determine the expression of PAD2 at the protein level, as mRNA 
levels do not always reflect protein levels (Bhattachyra et al., 2006). Furthermore, 
although this study showed the presence of PAD2 enzymes in astrocytes, microglia 
and brain endothelial cells, it would have been useful to detect the presence of 
citrullinated proteins within these cells using immunocytochemistry and/or western 
blotting which would indicate whether PAD2 was active in these cells or to directly 
measure PAD2 activity in these cells.
In addition to the direct role of calcium in the transcription of PADs, activation of the 
PAD enzymes are dependent on the presence of calcium. X-ray crystallographic 
structural analysis of human PAD4 in calcium-free and calcium-bound forms, suggests 
that binding of calcium to the C-terminal domain is critical for both substrate specificity 
and binding (Arita et al., 2003; Arita et al., 2004). The binding of calcium to PAD4 leads 
to conformational changes around the substrate binding site, which then allows PAD4 
to interact with arginine residues in other proteins (Arita et al., 2004). Only the crystal 
structure of PAD4 has been elucidated as yet, however, due to human PAD4 and 
PAD2 showing more than 50% sequence homology, it is assumed that PAD2 will have 
a similar crystal structure and mechanism of activity (Arita et al., 2004). In the absence 
of high levels of intracellular calcium, PAD2 would not undergo these conformational 
changes which are essential for activation of the enzyme.
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The cytosolic and nucleoplasmic calcium concentration is much too low (approximately 
100-fold) for PAD activity under normal physiological conditions (Takahara et al., 
1986). However, there are numerous events which can lead to raised intracellular 
calcium. For example during cell death the integrity of the plasma membrane is lost, 
causing influx of calcium from the extracellular space and subsequent activation of 
intracellular PAD. Artificially raising the cytosolic and nucleoplasmic calcium 
concentration by including calcium ionophores in the media of the cells should induce 
activation of PAD and subsequent citrullination of intracellular proteins (Vossenaar et 
al., 2003). Calcium ionophores, such as ionomycin, facilitate a sustained calcium influx 
from the extracellular to the intracellular environment (Schwab et al., 2002).
In addition to the presence of calcium, a number of other environmental or chemical 
factors have been shown to increase the expression of PAD2 mRNA and/or protein. 
Hypoxia has been previously shown to lead to an increase in PAD2 mRNA followed by 
an increase in PAD2 protein expression in primary human astrocytes (Sambandam et 
al., 2004). Furthermore, this increase in PAD2 at both the mRNA and protein level 
correlated with an increase in the amount of citrullinated GFAP as a product of 
increased PAD2 enzymatic activity. Interestingly, kainic acid-evoked 
neurodegeneration in the rat brain has been shown to increase the expression of PAD2 
protein in activated microglia but not in astrocytes (Asaga et al., 2002). This shows 
differential activation of PADs depending on the cell type in which they are expressed.
Prostaglandin D2 has been shown to induce PAD activity in a macrophage cell line (Lee 
et al., 2006). Activation of the prostaglandin D2 receptor also results in intracellular 
calcium influx (Boie et al., 1995). Exposure of a human monocytic cell line, THP-1, to 
silica has been shown to lead to increased PAD activity and increased citrullination, 
with the addition of a PAD inhibitor shown to significantly reduce PAD activity and 
citrullination. A raised intracellular calcium concentration was shown to occur in cells 
exposed to silica, with the addition of a calcium blocker shown to inhibit protein 
citrullination (Mohamed et al., 2012).
Pressure has been shown to increase the expression of PAD2 protein in human 
astrocytes compared to untreated cells and is associated with an increase in 
intracellular calcium. However, PAD2 mRNA levels were similar between pressure- 
treated and untreated astrocytes, suggesting posttranscriptional control of PAD2 
expression (Bhattacharya et al., 2006b). Furthermore, another study by the same 
group showed pressure-treated rat astrocytes exhibited elevated PAD2 protein and 
citrullination without an apparent change in PAD2 mRNA (Bhattacharya et al., 2006a).
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Interestingly, recent publications have also suggested an anti-inflammatory role for 
PADs and subsequent citrullination of proteins. Ji et al. (2011) have shown the up- 
regulation of microRNA, in particular miR-34a, in RA synovial monocytes, which targets 
the PAD4 gene, leading to decreased expression of PAD4 in RA synovial monocytes 
compared to normal PBMCs, which would lead to decreased PAD4 expression in RA. 
Therefore, microRNAs may be important regulators of PADs in RA and other 
autoimmune disease, such as MS (Ji et al., 2011). The authors of this paper suggested 
that this decrease in PAD4 expression may be responsible for aggravating RA activity, 
implicating an anti-inflammatory role for PAD. Two reports have recently demonstrated 
that citrullination reduced the pro-inflammatory activity of several chemokines, including 
CXCL8, CXCL10 and CXCL11, thus suggesting an anti-inflammatory role for PAD 
(Loos et al., 2008; Proost et al., 2008; Loos et al., 2009).
Furthermore, activated PAD2 has been shown to suppress NF- kB kinase activity in 
LPS-stimulated macrophages, which would lead to the down-regulation of pro- 
inflammatory gene expression induced by LPS (Lee et al., 2010). The authors of this 
study propose that activation of PAD2 in inflammation might serve to self-limit 
inflammatory responses. These studies suggest that PADs may piay an anti­
inflammatory role in autoimmune diseases.
In the in vivo situation, it is also important to consider reciprocal communication 
between different cells, such as neurones and astrocytes (Carmignoto 2000), which 
may also be responsible for the modulation of PADs. Furthermore, it has been shown 
in vitro that when human monocytes come into contact with stimulated T cells, both 
PAD2 and PAD4 are up-regulated at both the mRNA and protein level (Ferrari-Lacraz 
et al., 2010).
2.4.3 Conclusion
PAD2 was shown to be down-regulated following incubation with pro-inflammatory 
cytokines in different preparations of primary human astrocytes (MS16, EP14, EP15), a 
human foetal microglial cell line (CFIME3) and a brain endothelial cell line (hCMEC/D3) 
in vitro. This indicates that the balance between pro- and anti-inflammatory cytokines 
does not control PAD expression and additional mechanisms must be involved in the 
up-regulation of PADs reported by others in MS tissue. Furthermore, additional studies 
investigating the PADs at the protein level in addition to activity would provide further 
insight. Evidence provided here suggests that the transcription of PAD2 is regulated at 
multiple levels, and may involve a number of regulatory mechanisms which are difficult 
to mimic in vitro. Lastly, PAD2 protein expression and subsequent activation may be
controlled at the translational level independent of transcriptional regulation.
Table 2.7: Summary of significant effects of cytokines, single and co-treatment on proliferation of CNS cells.
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Chapter 3
In vivo investigation of citrullinated
proteins and PAD expression in 
post-mortem brain tissue
3.1 Introduction
Citrullination has been shown to be increased in NAWM of patients with SPMS 
compared to patients with other neurological diseases in a small scale study using 3 
MS and 3 control cases (Nicholas et al., 2004). Citrullination co-localised with GFAP, 
indicating astrocyte proteins as targets for citrullination (Nicholas et al., 2004). Earlier 
studies documented MBP in CNS tissue of MS patients as more highly citrullinated 
compared with MBP from control subjects, indicating oligodendrocytes as cell types 
which also have citrullinated proteins (Moscarello et al., 1994; Wood et al., 1996). 
Citrullinated proteins have been identified in the brain and spinal cord of mice with 
MOG-induced EAE, and co-localised with MBP and GFAP (Nicholas et al., 2005). 
Hypercitrullination occurs in the CNS during induction of EAE (Raijmakers et al., 2006).
The enzymes which perform this citrullination, PAD2 and PAD4, have also been 
reported to be increased in MS tissue compared to controls (Mastronardi et al., 2007; 
Wood et al., 2008). Both PAD2 and PAD4 isolated from myelin in NAWM of MS cases 
had significantly higher levels than observed in myelin from control subjects (Wood et 
al., 2008). Transgenic mice overexpressing PAD2 displayed a more severe clinical 
EAE disease course associated with increased citrullinated MBP and demyelination 
(Musse et al., 2008). Based on these studies it is clear that citrullination is important in 
MS. Apart for the small-scale study by Nicholas and colleagues (2004) using three MS 
brains with chronic lesions, extensive immunohistochemical studies have not been 
carried out investigating the distribution of citrullinated proteins and PAD2/PAD4 in 
active and chronic-active lesions in MS. This study builds from the previous chapter 
where PAD2 was shown to be expressed in primary human astrocytes, human adult 
brain endothelial cells and a microglial cell line.
This chapter describes the detailed investigation of the expression of citrullinated 
proteins and PADs in active and chronic active lesions, to further elucidate the role of 
citrullination of CNS proteins in MS pathogenesis.
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3.1.1. Aim of the study
To determine the expression and distribution of citrullinated proteins and PAD2 in 
different lesion types in MS tissue.
3.1.2 Objectives of the study
1. Investigate the expression of citrullinated proteins in MS tissue compared to 
control tissue.
2. Investigate the cellular distribution of citrullinated proteins in different lesion 
types in MS tissue compared to control tissue.
3. Confirm the identity of proteins that are citrullinated through SDS-PAGE and 
western blotting.
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3.2 Materials and methods
3.2.1 Suppliers used in this chapter
Abeam, 330 Cambridge Science Park, Cambridge, CB4 OFL, UK; Applied 
Biosystems, Lingley House, 120 Birchwood Boulevard, Warrington, WA3 7QH, UK; 
Invitrogen, 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK; 
Millipore, Suite 3 & 5, Building 6, Croxley Green Business Park, Watford, WD18 8YH, 
UK; Sigma-Aldrich, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT, UK; 
LI-COR Biosciences Ltd, St. John’s Innovation Centre, Cowley Road, Cambridge, 
CB4 OWS, UK; Vector Laboratories Ltd., 3 Accent Park, Bakewell Road, Orton 
Southgate, Peterborough, PE2 6XS, U.K; VWR International, Hunter Boulevard, 
Magna Park, Lutterworth, Leicestershire, LE17 4XN, UK.
3.2.2 Source of MS and control tissue and ethical approval
Eighteen blocks of snap-frozen autopsy CNS tissue from 12 clinically and 
neuropathoiogicaiiy confirmed MS cases, together with 9 blocks from six normal control 
cases, obtained from the UK Multiple Sclerosis Society Tissue Bank, Imperial College, 
London, were investigated for the presence of citrullinated proteins. Informed consent 
and ethical approval for this study was obtained from the Multi-Centre Research Ethics 
Committee (MREC) (See Appendix I). The MS cases included 10 females, mean age 
67.7 years (range 37-86) and 2 males, mean age 58.5 years (range 55-62) (Table 3.1). 
The control cases included 3 females, mean age 69 years (range 60-78) and 3 males, 
mean age 58 years (range 35-75) (Table 3.2). Tissue was received fresh from autopsy 
<24 h death-autopsy interval for 11 out of 12 MS cases. All of the MS cases had a 
confirmed diagnosis of SPMS. Control and MS blocks were matched for CNS location 
as far as possible.
The UK Multiple Sclerosis Society Tissue Bank initially prepared the tissue used in this 
study. Tissue blocks were prepared by cutting the whole brain into anterior and 
posterior halves by a single cut through the mamillary bodies. One centimetre thick 
coronal slices were then cut through the entire brain. The slices were then numbered 
based on whether they were taken anteriorly to the mamillary bodies and therefore 
from the frontal pole or posteriorly to the mammillary bodies and therefore from the 
occipital pole. The former were numbered A1, A2 etc and the latter were numbered P1, 
P2 etc. The coronal slices were then laid on a grid and divided into 2cm2 blocks, frozen 
by immersion in isopentane, pre-cooled on dry ice and then stored in air-tight 
containers at -85°C (Dr. Abhi Vora, The UK Multiple Sclerosis Tissue Bank).
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Each patient is given an ID code and the four digits following that relate to the coronal 
section and the grid reference where the tissue block was taken from, e.g. MS058 
P1C3, is patient ID: MS058, and the coronal section is P1 and therefore derived from 
the first section posterior to the mamillary bodies, and the block was taken from grid co­
ordinates C3 (Figure 3.1).
These brain blocks were then mounted using Cryo-M-bed mounting media and cut into 
10 pM sections using a cryostat and transferred onto polysine coated glass slides 
(VWR, UK) where they were left to dry for approximately 30 minutes. Slides were then 
stored at -80°C until required.
3.2.3 Characterisation of tissue blocks
In order to characterise each tissue block, cryostat sections (10pm) were processed for 
haematoxylin and eosin (H&E), oil red-0 (ORO), myelin oligodendrocyte glycoprotein 
(MOG), MHC class II (HLA-DR), CD3 (T cell) and CD20 (B cell) to evaluate general 
histology and extent of cellular activation within each block. H&E stain was utilised to 
determine the extent of inflammation. Both ORO and MOG were used in order to 
assess the extent of demyelination. An antibody directed against HLA-DR was 
employed to determine the state of activation of microglia and macrophages, in 
addition to B and T cells (anti-CD3 and CD20).
3.2.3.1 Haemotoxylin and eosin (H&E)
H&E is the most common stain used in histology and exploits the different acidic and 
basic properties of the cell’s nucleus and cytoplasm (Ross and Pawlina 2006). 
Haematoxylin stains the nucleus whereas eosin stains the cytoplasm and the 
connective tissue, therefore allowing excellent insight into the overall tissue 
architecture as well as demonstrating any inflammatory processes which may be taking 
place (Bancroft and Gamble 2008). Dyes used in histology are broadly classified into 
two groups; acidic or basic. An acidic dye carries a net negative charge on its coloured 
portion whereas a basic dye carries a net positive charge on its coloured portion. 
Haematoxylin is used to stain the nuclei of cells, but first requires oxidation either 
naturally or through chemical oxidising agents, followed by combining with a mordant 
which gives the dye-mordant complex a positive charge, as haematoxylin stains poorly 
itself (Bancroft and Gamble 2008). This then enables the dye-mordant complex to bind 
to anionic sites within the tissue, in particular nuclear chromatin, which results in a 
deep blue to a black colour of nuclei within tissue sections.
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Harris’s haematoxylin is the most commonly used haematoxylin that has undergone 
oxidation through the use of mercuric oxide. Following nuclear staining, the cytoplasm 
and connective tissue is counterstained with eosin, which is an acidic dye, which gives 
varying shades and intensities of pink, orange and red (Ross and Pawlina 2006). Eosin 
Y is the most widely used eosin (Bancroft and Gamble 2008).
Prior to staining, frozen sections were fixed in 4% paraformaldehyde (PFA) for 1 hr at 
4°C. Following fixation, slides were immersed in Harris’s haematoxylin for 1 min and 
then rinsed in tap water until the water ran clear. Slides were then immersed in eosin Y 
for 40 secs and then rinsed in tap water until the water ran clear. Following this, slides 
were subjected to dehydration in increasing concentrations of ethanol (50, 70, 80, 95 
and 100%) for 2 minutes in each concentration, followed by xylene for 5 minutes. This 
last step was then repeated a further time. Lastly, slides were then mounted using DPX 
mounting medium. Slides were then left to harden in the fume hood for at least 30 
minutes and then examined using light microscopy with an Olympus BX60 microscope 
with a CoolSNAP-Pro (Media Cybernetics) imaging system.
3.2.3.2 Oil Red O (ORO)
In demyelination there is release of proteins and lipids, which undergo enzymatic 
degradation, mainly within macrophages but also in some astrocytes (Li et al., 2008). 
Active MS lesions are characterised by the presence of lipid-laden foamy 
macrophages, which acquire their distinctive morphology by ingestion and 
accumulation of vast amounts of myelin-derived lipids (Li et al., 1996; Boven et al., 
2006). In order to visualise these breakdown products within macrophages, ORO is 
used. ORO is a fat-soluble dye used to stain neutral triglycerides and lipids on frozen 
sections (Ross and Pawlina 2006). This technique relies on the fact that the dye is 
soluble in the lipid in the tissue (Bancroft and Gamble 2008).
Prior to staining, an ORO solution was prepared by adding 1 g of powder (Sigma 
Aldrich, UK) to 60 mL of triethyl phosphate (TEP) and 40 mL of dH20, placed on a 
stirrer and heated to 100°C for 5 minutes. Following this, the ORO solution was then 
filtered through filter paper (Whatman, UK) whilst still hot and a second time when cold.
Prior to staining, frozen sections were fixed in 4% PFA at 4°C for 1 hr. Following 
fixation, slides were washed in tap water, rinsed in 60% TEP, and stained in the filtered 
ORO solution for 10-15 minutes at RT. Once stained, the slides were briefly rinsed in 
60% TEP, and then in tap water. Nuclei were then counterstained with Harris’s 
haematoxylin (diluted with dH20  to 20% v/v) and then briefly washed in dH20. Lastly,
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slides were mounted using aqueous mountant glycerol gelatin, as any alcoholic or 
organic mountant will dissolve the lipids from the tissue.
3.2.3.3 Sudan black B staining
Sudan black B (SBB) is a fat-soluble dye used for staining of neutral triglycerides and 
lipids on frozen tissue sections, and is most commonly used to reduce 
autofluorescence of tissue due to the presence of lipofuscin (Schnell et al., 1999). 
Lipofuscin is a fluorescent pigment which accumulates with age in the cytoplasm of 
cells, and because of its broad excitation and emission spectra often overlaps with 
those of all commonly used fluorophores, which is detrimental when using fluorescence 
microscopy (Viegas et al., 2009). Using a concentration of 1% SBB has previously 
been shown to be sufficient to quench this lipofuscin autofluorescence (Schnell et al., 
1999).
Prior to staining, a 1% SBB solution was freshly prepared by adding 1 g of powder 
(Sigma Aldrich, UK) to 100 mL of 70% ethanol, placed on a stirrer in the dark for 2 
hours at RT. Following this, the SBB solution was filtered through filter paper 
(Whatman, UK), wrapped in foil and kept at 4°C until it was used in 
immunohistochemistry (see section 3.2.5).
3.2.4 Tissue grading
3.2.4.1 H&E and ORO stains
In order to examine levels of inflammation, H&E stained slides were graded according 
to the extent of perivascular cuffing observed, using a five-point scale (negative, +, ++, 
+++, ++++) with + indicating a few immune cell infiltrates around the blood vessel 
through to a ++++ indicating a large collection of immune cell infiltrates several layers 
deep around the blood vessel (Figures 3.2 and 3.3).
ORO was used in order to assess the extent of myelin loss and sections were graded 
using a four-point scale, with negative indicating complete absence of ORO-positive 
cells through to 3+ where ORO-positive cells were present throughout the lesion area 
(Figure 3.4). Blocks displaying ORO-positive cells throughout the lesion were classified 
as active, whereas blocks displaying ORO-positive cells around the lesion edge were 
classified as chronic-active (Lucchinetti et al., 2005).
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Figure 3.3: Haematoxylin and eosin staining showing the hypercellular border 
surrounding a lesion and the hypocellular centre of the same lesion (MS058 
P1C3). The black arrows indicate the hypercellular lesion edge where there is a 
gathering of leukocytes. The upper panel shows a lower magnification and the lower 
panel show a higher magnification of the same region.
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3.2.4.2 HLA-DR expression
In order to determine the extent of cellular activation, an antibody against HLA-DR was 
utilised. HLA-DR is a cell surface receptor encoded by the MHC II complex on 
chromosome 6 region 6p21.31. There are usually very low levels of MHC class II 
expression in healthy control tissues, whereas in autoimmune diseases the expression 
of MHC class II can greatly increase (Power et al., 1993). An example of this is in 
active lesions in MS where there is an abundance of MHC class II positive cells in and 
around the lesion (Woodroofe et al., 1986; Boyle and McGeer 1990).
Lesions were classified based on a study by Bo and colleagues (1994), in actively 
demyelinating lesions HLA-DR positive cells are evenly distributed within the lesion, 
whereas in chronic active lesions HLA-DR positive cells are located at lesion edges 
rather than centrally (Bo et al., 1994). Lastly, in chronic inactive lesions there is little or 
no HLA-DR positive cells either inside the lesion, at the edges of, or outside the 
demyelinated lesions.
3.2.4.3 MOG expression
In order to assess the extent of myelin loss an antibody against MOG was used. MOG 
is a type I membrane glycoprotein preferentially localised at the outermost surface of 
the myelin sheath and oligodendrocytes (Brunner et al., 1989). MOG is a useful marker 
for classifying the type of lesion in MS based on the extent of demyelination and also 
remyelination. In a chronic inactive plaque there is no evidence of active myelin 
breakdown, whereas in an active lesion there is substantial pallor of myelin staining 
(Lucchinetti et al., 2005). Therefore MOG can be extremely useful in determining 
whether the plaque is chronic inactive or active.
3.2.4.4 Classification of lesion type
H&E, ORO, HLA-DR and MOG staining were all used in order to classify the MS 
lesions as active, chronic active or chronic inactive. In this study no blocks were found 
to contain chronic inactive lesions. MOG was used in order to assess the extent of 
demyelination. If there was complete MOG loss the lesion was classified as chronic 
whereas if MOG was disrupted along with inflammation as shown through H&E staining 
the lesion was classified as active. HLA-DR was used to assess cellular reactivity. In 
the case of positive HLA-DR staining at the lesion edge in the chronic lesion the lesion 
was classified as chronic-active whereas if positive HLA-DR staining was observed 
throughout the tissue the lesion was classified as active.
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In some instances ORO staining of lipid-laden macrophages was also used in the 
classification of lesions. In the chronic-active lesion, lipid-laden macrophages are 
sometimes observed around the edge of the lesion whereas in active lesions there are 
lipid-laden macrophages throughout the lesion.
3.2.5 Immunohistochemistry
This procedure was similar to ICC performed on cells in vitro. For full details refer to 
chapter 2 (see section 2.2.5).
3.2.5.1 Single label immunofluorescence
Prior to staining, sections were fixed in ice-cold acetone in Coplin jars for 10 minutes at 
RT, and then air-dried for 20 minutes. Sections were then treated with 5% goat 
serum/1 % BSA in phosphate buffered saline (PBS) for 30 min at room temperature 
(RT) to prevent non-specific binding of the primary and secondary antibodies. Table 3.2 
provides a summary of the primary and secondary antibodies used in the study. 
Primary antibodies were initially optimised by selecting a range of dilutions based on an 
initial recommendation by the manufacturer, except anti-HLA-DR and vWF which was 
previously optimised by Dr. H. Denney and anti-MOG which was given as a gift from 
Dr. Stephen McQuaid and used at his recommended dilution. Following this, sections 
were then incubated with the primary antibody diluted in 0.3% goat serum in PBS 
overnight at 4°C, washed in PBS and incubated in the appropriate secondary antibody 
diluted in 1% BSA in PBS for 1 h at RT. Cell nuclei were counterstained with diamidino- 
2-phenylindole (DAPI), included in the mountant (Vector Laboratories, UK). For 
controls, the primary antibody was replaced with either an isotype control (IC) or 
omission of the primary antibody to ensure the absence of non-specific binding from 
the secondary antibody (Table 3.3). Where there was more than one primary antibody 
with the same isotype, the IC was used at the most concentrated primary antibody 
dilution
Following this, sections were blocked with 3% BSA plus 0.3% Triton X-100 in PBS (pH
7.4) (180 pL per section) for 30 minutes at RT. Sections were then washed in PBS
three times, 10 minutes per wash. Primary antibodies (180 pL per tissue section,
diluted in PBS in 0.3% Triton® X-100) were applied to each section and incubated in a
humidified slide tray for 2 hrs or overnight (O/N). The negative controls with the primary
antibody omitted were incubated with 180 pL PBS with 0.3% Triton® X-100. Following
this, slides were then washed three times in PBS, to remove any unbound antibody, for
10 minutes per wash. Secondary antibodies (180 pL per tissue section, diluted in PBS
with 0.3% Triton® X-100) were applied to each tissue section and incubated as before
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for 1 hr at RT. Slides were then washed three times in PBS, to remove any unbound 
antibody, for 10 minutes per wash. Lastly, slides were immersed in 1% Sudan Black B 
(SBB) for 5 minutes in the dark at RT, and then rinsed briefly in PBS, 8-10 times. Slides 
were mounted using Vectashield™ hard-set mounting medium with 4', 6-diamidino-2- 
phenylindole (DAPI). The edges of the coverslips were sealed with nail varnish, slides 
were wrapped in foil and stored at 4°C until analysed.
3.2.5.2 Dual labeling immunofluorescence
Prior to carrying out dual immunostaining, serial sections were single-labeled with each 
mouse or rabbit primary antibody followed by secondary antibodies to anti-rabbit Ig and 
anti-mouse Ig respectively to ensure that no cross-reactivity was observed between the 
primary antibody and the inappropriate secondary antibody. To determine the cellular 
localisation of citrullination, the following sequential dual-label immunofluorescence 
protocol was carried out.
Sections were co-incubated with both a monoclonal and polyclonal antibody overnight 
at 4°C and then detected by co-incubating the appropriate secondary antibodies 
against mouse and rabbit immunoglobulins for 1 h at RT. Following three 5 min washes 
in PBS, sections were placed in 1% SBB for 5 minutes, followed by 8-10 washes in 
PBS and then mounted in Vectorshield mountant with DAPI (Vector Laboratories, 
Peterborough, UK).
Dual staining was performed with polyclonal antibodies to the astrocytic marker, glial 
fibrillary acidic protein (GFAP), endothelial marker von Willebrand Factor (vWF), PAD2 
and PAD4 with mouse IgM anti-human citrullinated proteins (F95). Rabbit polyclonal 
anti-PAD2 and anti-PAD4 were used in dual staining with the marker for activated 
macrophage/microglial cells with mouse monoclonal anti-HLA-DR, T cells with mouse 
monoclonal anti-CD3, endothelial cells with mouse monoclonal anti-vWF and 
astrocytes with mouse monoclonal anti-GFAP, respectively. Prior to carrying out dual 
staining, serial sections were single-label immunostained with each mouse or rabbit 
primary antibody with secondary antibodies to anti-rabbit Ig and anti-mouse Ig 
respectively to ensure that no cross-reactivity was observed between the primary 
antibody and the inappropriate secondary antibody. Omission of either primary 
antibody from the protocol but with the secondary antibody resulted in no signal 
detection in the channel used to detect that antigen, indicating no non-specific binding 
of the secondary antibody. Due to cross-reactivity when carrying out dual staining with 
mouse IgM anti-human citrullinated proteins and mouse anti-human HLA-DR, CD3 and 
MOG these markers were stained using single label immunofluorescence of serial 
sections.
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Table 3.3: Details of the primary and secondary antibodies used in immunohistochemistry.
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
7jf;EfjfcjE
1 in 250 
1 in 500
1 in 500 
1 in 1000
1 in 500 
1 in 1000
1 in 500 
1 in 1000
1 in 500 
1 in 1000
1 in 500 
1 in 1000
M
pjlh'
FITC
Alexa 568
Alexa 568
Alexa 568
Alexa 568
Alexa 568
Alexa 568
I
Goat
Goat
Goat
Goat
Goat
Goat
Goat
Mouse IgM 
Mouse IgM
Mouse IgG
Mouse IgG
Mouse IgG
Mouse IgG
Rabbit IgG
Dr. A. 
Nicholas
BD
Biosciences
Novocastra
Dako
Dako
Dako
1 in 250 (unknown)
1 in 500 (unknown)
1 in 1000 (unknown)
_iEZLLOCNCOOLOc
1 in 50 (500 ng/mL)
1 in 200 
1 in 400 
1 in 600
n
rED)ZLN;CMOo
1:250
1:500
1:1000
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(IgM)
Monoclonal 
(lgG1 kappa)
Monoclonal
(lgG2b)
Monoclonal
(lgG2a
kappa)
Monoclonal 
(lgG1 kappa)
Polyclonal
(igG)
Mouse
0wo
Mouse
00o
Mouse
Rabbit
Citrullinated
protein
(F95)
COQO
HLA-DR
oCMQO
vWF
vWF
ooCDLLT3CCD_QCDCDO)cCDCD>oo3CD<_lI>»0)*
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Table 3.3 (continued): Details of the primary and secondary antibodies used in immunohistochemistry.
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Invitrogen
Invitrogen
Invitrogen
Invitrogen
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3.2.5.3 Semi-quantification of citrullination immunoreactivity
Sections of MS and control white matter were anonymised by coding by a third party 
and then scored by two independent blinded observers. Single-labelled 
immunostaining for F95 on these sections was graded on a five-point scale: sections 
devoid of F95-immunoreactivity were graded 0, sections displaying low level punctate 
F95 staining were graded +, sections showing slightly more elongated fibre staining 
were ++, with more intensive staining were given +++ and sections with extensive 
staining were graded ++++ (Figure 3.5).
3.2.6.1 Image analysis and capture
Confocal laser scanning microscopy (CLSM) is a powerful tool in the biological field, 
mainly in the imaging of single optical sections from fixed and immunofluorescently 
labelled specimens, in particular cells and tissues (Paddock 1999b). Furthermore, 
CSLM can also be used for time-lapse imaging of living cells (Paddock 2000). These 
cells or tissues can been labelled with up to three fluorescent probes, which can then 
be excited or illuminated by either a multi-wavelength laser or multiple lasers capable 
of excitation at several wavelengths. The use of more than one fluorescent probe in a 
single specimen is often utilised for mapping the relative distribution of three proteins 
within cells and tissue (Paddock 1999a). Only light emitted from a particular focal plane 
reaches the detector due to the presence of mirrors and filters which only direct specific 
light to the detector (Figure 3.6). In fluorescence microscopy approximately 90% of the 
fluorescence signal elicited by illuminating a spot in the plane of focus comes from out- 
of-focus light along with scattered light, which can interfere with the in-focus detail, 
greatly reducing the contrast and creating a high background level (Conchello and 
Lichtman 2005).
However, this is overcome in confocal microscopy through the use of a pinhole in front 
of the detector which rejects both out-of-focus light collected by the objective and 
scattered light around the illuminated spot (Conchello and Lichtman 2005). This 
removal of out-of-focus and scattered light in each image plane enables the acquisition 
of images of thin sections of a thick specimen, providing greater contrast and 
resolution. Through computationally combining data from a series of images of these 
thin sections a three-dimensional high resolution image can be constructed (Conchello 
and Lichtman 2005).
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Figure 3.5: Levels of citrullinated protein (pep cit) in control, NAWM and multiple 
sclerosis lesions by single staining immunofluorescence and confocal 
microscopy. DAPI counterstaining (blue) shows the location of cell nuclei.
Levels of peptidyl-citrulline staining were graded (a) 1+ single astrocytes were 
observed (C022 P1C2), (b) 2+ levels of staining became more diffuse (C022 P1C3), 
(c) 3+ pattern is more dense and filamentous (MS90 A1E6) and (d) 4+ widespread 
filamentous staining was observed together with an increase in intensity of staining 
(MS58 P1C3). Scale bar is 20 /jm.
146
Light Source
Photomultiplier —  Detector
LaserExcitationSource
I
Aperture 
Specimen
Focal I 
Planes 1
— Objective
Excitation Light Ray
In-Focus Fluorescence Emission Light Ray
DetectorPinholeAperture
Out-of-Focus Fluorescence Emission Light Ray
DichromaticMirror
Figure 3.6: Schematic diagram showing the optical pathway and principal 
components in a laser scanning confocal microscope. Light emitted by the laser 
passes through a light source pinhole aperture and is reflected by a dichromatic mirror 
towards the microscope objective and into the sample. The microscope objective 
focuses the laser to a particular focal plane in the specimen that becomes confocal with 
the pinhole apertures of the light source and detector (Claxton et al., 2006). On 
excitation at the correct wavelength the sample fluoresces and the emitted light passes 
through the dichromatic mirror and is focused into the detector pinhole aperture 
(Claxton et al., 2006). Refocusing the objective moves the excitation and emission 
points in a specimen to a new plane. Emitted fluorescence that occurs at points above 
and below the objective focal plane is obstructed from detection as it is unable to pass 
through the detector pinhole aperture. Therefore, only information from the focal region 
of interest reaches the detector (Paddock 1999a). Focused light that passes through 
the detector pinhole aperture is detected by a photomultiplier detector, which produces 
a signal directly proportional to the brightness of the light. This signal is then converted 
to an image directly processed by the adjoining computer, which builds up the image a 
pixel at a time resulting in a high-resolution image representative of the objective focal 
slice. From http://www.olvmpusconfocal.com/theorv/LSCMlntro.pdf
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3.2.6.2 Light and fluorescence microscopy
For grading of sections an upright Olympus BX60 microscope was used. Images of 
ORO and H&E on sections were also taken using an upright Olympus BX60 
microscope, equipped with a cool-snap pro (Cybernetics) digital camera to acquire 
images into labworks™ where they were saved without further manipulation.
3.2.6.3 Confocal scanning laser microscopy
All immunofluorescent images were captured using a Zeiss 510 CSLM equipped with a 
krypton/argon laser. Fluorophores were excited at wavelengths of 488 or 568 nm. 
Colocalisation studies of the dual-labelled samples utilised the colocalisation software 
available with the Zeiss 510 CSLM. Individual pixels were scanned for each channel 
within set intensity thresholds. Colocalised pixels were represented as yellow in the 
composite image.
3.2.3 qPCR using Taqman® probes
RNA was isolated from homogenised CNS tissue (2 x 30 pm sections) collected from 
12 MS and 6 control blocks using TRI-reagent, followed by cDNA synthesis and 
subjected to qPCR. For full details refer to chapter 2 (section 2.2.3).
3.2.3.1 Statistical analysis for qPCR data
qPCR data was analysed using a non-parametric Kruskal-Wallis test followed by 
Conover-lnman multiple comparisons test. To carry out this test, 2'ACT for each sample 
was calculated to determine the relative gene expression. Comparisons were then 
made between control, NAWM and MS lesional tissue. Significance was set at p <0.05.
3.2.4 Western blotting
Western blotting, also called immunoblotting, is a widely used analytical technique in 
the detection of specific proteins in a given sample of tissue homogenate or cell extract 
(Kurien and Scofield 2006). It uses gel electrophoresis to separate native proteins by 
three-dimensional structures or denatured proteins by the length of the polypeptide 
chain (Figure 3.7). These separated proteins are then transferred onto a membrane 
where they are probed with antibodies specific to the target protein. Specific antibody 
binding is then detected using a range of methods, most commonly 
chemiluminescence with an enzyme-labelled secondary antibody, or a fluorescently 
labelled secondary antibody.
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The most commonly employed type of gel electrophoresis is sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli 1970). In SDS-PAGE 
proteins are first denatured by the addition of SDS and reduced through the use of 
reducing agents to remove the secondary and tertiary structure of the protein, enabling 
the proteins to be separated based on their molecular weight. These proteins then 
become negatively charged by SDS binding and move towards the positively charged 
electrode through the acrylamide of the gel. Smaller proteins migrate faster whereas 
larger proteins migrate slower, thus separating the proteins based on their size.
In order to make these proteins accessible to antibodies for detection, they are 
electroblotted using an electric current to pull the proteins from the gel onto a 
nitrocellulose or polyvinylidene difluoride (PVDF) membrane. Although there are a 
number of membranes available, including nitrocellulose and PVDF, nitrocellulose is 
the most commonly used. PVDF membranes have high protein binding capacity and 
are strong; however they are expensive and have a short shelf-life. Nitrocellulose 
membranes have a lower binding capacity and are often brittle when dry, but are 
relatively inexpensive and have the longest shelf-life. Supported nitrocellulose 
membranes, such as Hybond-C extra, have improved mechanical strength thereby 
making them less brittle.
Once electroblotting is complete, it is often useful to check the effectiveness of the 
protein transfer through staining the membrane with Ponceau S, which enables 
visualisation of the protein bands (Salinovich and Montelaro 1986). Ponceau S is highly 
sensitive, detecting as little as 250 ng protein, and is water-soluble therefore can be 
easily removed through washing with tap water without affecting with probing of the 
membrane (Salinovich and Montelaro 1986).
Following electroblotting, the membrane is blocked in order to prevent non-specific 
binding of the primary antibody with either bovine serum albumin (BSA) or non-fat milk 
powder dissolved in Tris-buffered saline (TBS) with a detergent such as Tween 20 or 
Triton X-100. These proteins then bind to membrane in areas where the transferred 
proteins have not attached. This prevents non-specific binding of the primary antibody. 
The membrane is then probed with a primary antibody against the target protein of 
interest, such as a mouse anti-human GFAP, followed by the addition of a secondary 
antibody, such as a goat anti-mouse IgG, which is either tagged with an enzyme e.g. 
horseradish peroxidase (HRP) or a fluorescent molecule. With the addition of a 
substrate, HRP catalyses the oxidation of luminal to 3-aminophthalate, which results in 
the emission of luminescence measured through X-ray film exposure, the intensity 
produced is directly correlated with the amount of protein on the membrane. A second 
method of detection involves the use of secondary antibodies directly conjugated with
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near infrared (IR) fluorophores. These antibodies are available with an excitation at 
679nm and emission at 700, and an excitation at 778 nm and an emission at 800 nm, 
therefore, allowing simultaneous detection of two targets on the same blot (Schutz- 
Geschwender et al., 2004). The Odyssey Infrared Imaging System (LI-COR 
Biosciences, UK) instrument is equipped with two separate lasers and detectors, which 
allows simultaneous detection of both fluorescent signals at the same time (Figure 3.8).
3.2.4.1 Protein extraction
Protein was extracted, using Tri Reagent, according to the manufacturers’ instructions. 
Briefly, 2x30 pm tissue sections from each block were placed in 1 ml_ of Tri Reagent in 
an Eppendorf tube and then vortexed for approximately 5 minutes in order to lyse cells. 
Subsequently, this cell lysate was transferred into clean 1.5 ml_ microcentrifuge tubes 
where 0.2 ml of chloroform was added per ml of Tri Reagent, mixed vigorously and left 
to stand for 15 minutes at RT followed by centrifugation at 12,000 g for 15 minutes at 
4°C. The colourless aqueous phase containing RNA was then transferred into new 
Eppendorf tubes.
The remaining white cloudy phase containing DNA was then precipitated by adding 0.3 
ml_ of 100% ethanol per ml of Tri Reagent used in the original sample preparation, 
followed by gentle inversion and leaving at RT for 2-3 minutes. Samples were then 
centrifuged at 2,000 g for 5 minutes at 4°C, leaving a pellet containing DNA and 
supernatant containing protein. The DNA pellet was then removed and protein was 
precipitated by the addition of 1.5 ml of 2-isopropanol per ml of Tri Reagent. Samples 
were then left at RT for 10 minutes, followed by centrifugation at 12,000 g for 10 
minutes at 4°C. The supernatant was removed and the pellet containing protein was 
washed three times in 2 ml of 0.3 M guanidine hydrochloride/95% ethanol per ml of Tri 
Reagent. During each wash, samples were left for 20 minutes at RT followed by 
centrifugation at 7,500 g for 5 minutes at 4°C. Following this, 2 ml of 100% ethanol 
was added per ml of Tri Reagent and the protein pellet was vortexed and left to stand 
at RT for 20 minutes. Samples were then centrifuged at 7,500 g for 5 minutes at 4°C, 
followed by removal of the ethanol. Protein pellets were air-dried in a fume hood for 5- 
10 minutes and then dissolved in 70 pL 1% sodium lauryl sulphate (SDS) through 
gently pipetting up and down. Samples were then stored at -20°C overnight. The 
following day samples were placed on a 60°C heatblock for 10 minutes and dissolved 
further. Protein samples were then stored at -80°C until required.
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Figure 3.8: Schematic diagram showing the principal components of the 
Odyssey Infrared Imaging System (LI-COR Biosciences, UK), (a) Beams from the 
685 nm and 785 nm lasers are focused to form an excitation spot simultaneously on 
the scanning surface where the blot is placed, (b) A microscope objective focusses the 
excitation spot and collects light from the fluorescent infrared dyes at the same time, 
(c) This light then passes through a dichroic mirror where it is split into two separate 
fluorescent signals, (d) Each fluorescent signal then passes through two independent 
light paths, where it is focused on separate avalanche photodiodes and detected. This 
information is processed in real-time by the adjoining computer, resulting in two 16-bit 
red and green images depicting fluorescent bands of proteins of interest. These images 
can be viewed one channel at a time or together overlaid, with signal bands in the 
same position given a yellow colour.
Adapted from http://psf.cobre.ku.edu/Odyssey.pdf
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3.2.4.2 Bicinchoninic Acid (BCA) assay for measurement of protein 
concentration
Prior to western blotting, protein samples underwent protein concentration 
determination using the BCA protein assay kit according to the manufacturers’ 
instructions. This method relies on the formation of a Cu2+-protein complex under 
alkaline conditions, followed by the reduction of Cu2+ to Cu1+. The amino acids 
cysteine, cystine, tryptophan, and tyrosine, along with the peptide bonds are 
responsible for this reduction from Cu2+ to Cu1+. The amount reduced is proportional to 
the amount of protein present. BCA forms a purple-blue complex with the reduced 
Cu1+, which exhibits a strong linear absorbance at 570 nm with increasing protein 
concentrations. A standard curve can be constructed using known concentrations of 
protein, such as BSA, the readings of which can be used to construct a graph. The 
concentration of unknown samples can then be determined directly from the graph 
using the slope of the line. The BCA assay is a highly advantageous method for protein 
determination based on its ability to form a stable colour complex and ability to be used 
in determining a broad range of protein concentrations 
(http://www.sigmaaidrich.com/life-science/proteomics/protein- 
quantitation/bicinchoninic-acid-kit.html).
Briefly, BSA protein standards of concentrations ranging from 0.1 to 200 mg/mL were 
prepared, with dilutions made in 1% SDS. BCA reagent (10 mL BCA solution + 200 pL 
copper (II) sulphate pentahydrate solution (4% w/v)) was then prepared and stored in 
the dark until use. 200 pL of the BCA working reagent was added to 20 pL of each 
protein standard and blank in triplicate and the unknown protein samples in duplicate in 
a 96-well plate, mixed and left to incubate in the dark for 30 minutes at RT.
Following this the absorbance of each well was measured at 570nm using a Wallac 
Victor plate reading spectrophotometer. These readings were then used to plot a 
standard curve (Figure 3.9) and unknown protein concentrations were determined 
using linear regression analysis, as follows:
y = mx + c
y = absorbance; m = gradient; x = protein concentration; c = y intercept.
3.2.4.3 Optimisation of western blotting
Prior to carrying out western blotting of all the MS, NAWM and control block extracted 
protein samples various parameters were optimised (Table 3.4).
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Protein standard curve
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Figure 3.9: An example of a standard curve used in the determination of the 
protein concentration of unknown samples using BSA as a standard. The
concentration (x value) of protein in an unknown sample can be determined through 
using the absorbance value at 570 nm (y value) and rearranging the equation to x=(y- 
0.0297)/0.4432.
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3.2.4.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
Protein samples (30 pg) were fractionated on a pre-cast 10% Bis-Tris gel using Sodium 
Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) first developed by 
Laemmli (Laemmli 1970). All reagents for SDS-PAGE were purchased from Invitrogen, 
UK, unless stated ptherwise. Protein samples were prepared by adding 50 pL protein 
sample to 25 pL LDS sample buffer, 10 pL sample reducing agent, and 15 pL dH20. 
Samples were then reduced by placing on a heat block at 100°C for 5 minutes. Pre­
cast mini gels were placed into a Novex electrophoresis tank containing NuPage 
MOPS SDS running buffer (25 mL 20X NuPage MOPS SDS running buffer, 475 mL 
dH20, 250 pL NuPage anti-oxidant). 30 pg of each protein sample was loaded per well 
along with 10 pL of 2-colour protein marker standard (LI-COR, UK), and 
electrophoresis carried out at 150V and 300 mA for approximately 90 minutes, until the 
dye front reached the bottom of the gel.
3.2.4.5 Protein electroblotting
Fractionated proteins were transferred onto Hybond-C Extra nitrocellulose membrane 
(NCM). A piece of NCM was soaked for 10 minutes in cold transfer buffer (150 mL 
methanol, 1275 mL H20  and 1500 pL anti-oxidant), along with two pieces of blotting 
paper and two pieces of sponge per mini-gel. The transfer cassette was then 
assembled whilst submerged in the transfer buffer to ensure no air bubbles were 
allowed to form in any of the layers. One sponge was placed on the open transfer 
cassette, followed by a piece of blotting paper and the NCM, the gel, a second piece of 
blotting paper and another sponge. The cassette was then closed and placed into the 
tank containing the transfer buffer, ensuring the NCM was positioned closest to the 
anode. Protein was transferred from the SDS-PAGE gel to NCM at 100 V for 60 
minutes on ice.
To verify the proteins had transferred successfully onto the NCM, blots were briefly 
immersed in Ponceau S red in order to visualise the proteins, following by rinsing under 
running tap water to remove the stain.
3.2.4.6 Immunoprobing
Prior to probing with antibodies, blots were blocked for 90 minutes with gentle agitation, 
in 5% BSA in Tris-buffered saline (TBS) and 0.05% polyoxyethylene sorbitan 
monolaurate (Tween-20). Following this, the membrane was washed three times for 10 
minutes each in TBS with 0.05% Tween-20 (TBS-T), with gentle agitation. The primary
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antibody was then diluted to an appropriate concentration in TBS-T with or without non­
fat milk powder (Table 3.3) and incubated overnight at 4°C. For negative controls, 
primary antibody was omitted, and the membrane was incubated with TBS-T alone. 
The next day, the membrane was washed three times for 10 minutes each in TBS-T, 
with gentle agitation, to remove any unbound antibody. Labelled secondary antibodies 
were then diluted to an appropriate concentration in TBS-T (Table 3.3) and placed onto 
the blots and incubated for 2 hours with gentle agitation. The membrane was then 
washed twice for 5 minutes each in TBS-T on the shaker followed by one final wash for 
5 minutes in TBS only with gentle agitation. The blot was then visualised using the Ll- 
COR Odyssey® Imaging System (see section 3.2.4) whereby the optimum exposure 
time for each laser was determined and then set for all subsequent western blots.
3.2.4.7 Statistical analysis of western blot data
Densitometric data was analysed using a non-parametric Kruskal-Wallis test followed 
by Conover-lnman test. Comparisons were then made between control, NAWM and 
MS lesional tissue. Significance was set at p <0.05.
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3.3 Results
3.3.1 Tissue classification
Initially 40 MS and control blocks were assessed for level of inflammation and those 
displaying the greatest inflammation were chosen for the study. The majority of MS 
patient tissue blocks displayed varying degrees of perivascular cuffs except for two 
blocks which displayed no inflammation (MS051 A1B6 and MS057 A2D5) (Table 3.4). 
Most blocks displayed cuffs graded at +/++, except for four blocks which displayed 
cuffs graded ++/+++ (MS058 P1C3; MS092 P1B1; MS092 P1D1 and MS159 P1B) and 
two blocks which displayed cuffs at +++/++++ (MS058 P1D3 and MS 159 P1B2). The 
majority of tissue blocks were negative for ORO lipid-laden macrophages. However, 
five blocks displayed weak ORO positive staining which was very sparse and were 
graded as +. Only one block displayed more extensive ORO positive staining and was 
graded at ++ (MS051 A1B6) and a further patient block showed widespread ORO 
positive staining and was graded at +++ (Table 3.4). Five blocks were classified as 
containing active lesions, i.e. ongoing demyelination with or without ORO positive 
macrophages and increased HLA-DR staining in the absence of a hypocellular region. 
13 blocks were classified as containing chronic-active lesions, i.e. MOG loss with or 
without ORO positive macrophages and a rim of HLA-DR positive cells bordering the 
lesion with hypercellularity. 5 blocks were classified as NAWM, i.e. displayed minimal 
inflammation, no ORO positive macrophages, normal MOG and resting microglia (as 
shown by HLA-DR staining). Control blocks were negative for both pervascular cuffs 
and ORO positive macrophages and displayed resting microglia with low levels of HLA- 
DR staining along with normal MOG staining.
3.3.2 Isotype and negative controls
In order to determine the level of background staining isotype controls (IC) were tested 
on the NAWM of an MS tissue block. The IgM IC corresponding to the F95 monoclonal 
antibody showed a non-specific homogenous green hue (Figure 3.10a). The lgG1K IC 
corresponding to GFAP, CD3, VWF and NF monoclonal antibodies produced a very 
faint red hue (Figure 3.10b). The HLA-DR IC, lgG2b, showed a general widespread red 
hue which was not specific (Figure 3.10c). No specific staining was observed in tissues 
incubated with the CD20 IC, lgG2a (Figure 3.10d). No isotype control was available for 
the monoclonal antibody for MOG, therefore omission of the antibody served as a 
negative control. Omission of the primary antibody for MOG did not show any 
background staining from the secondary antibody (Figure 3.10e).
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Table 3.5 (continued): Tissue classification of MS and control blocks based upon H&E, ORO, HLA-DR and MOG staining. For each block the 
classification given by the MS Society Tissue Bank is documented and then the score for each of the staining criteria with re-classification of lesion 
type. H&E was graded for perivascular cuffing indicating extent of inflammation using a five-point scale (-, +, ++, +++, ++++) and ORO was graded 
using a four-point scale indicating extent of ORO positive cells (negative, +, ++, +++). MOG staining was assessed based upon whether it was
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The rabbit polyclonal antibodies for GFAP, PAD2 and PAD4 were all the same class, 
however, were tested individually at their specific concentrations due to the use of 
different secondary antibodies. The rabbit IgG IC concentration corresponding to the 
anti-GFAP antibody showed some non-specific staining (Figure 3.1 Of). The IgG IC 
concentration corresponding to PAD2 antibody showed significant cell-specific staining, 
which was also seen to a lesser extent in the lower concentration IgG IC corresponding 
to PAD4 antibody (Figure 3.1 Of; Figure 3.10g).
3.3.3 Expression of citrullinated proteins in MS, NAWM and control tissue
Levels of citrullinated proteins were graded from 1+ to 4+ (Figure 3.15 a-d). Intense 
immunoreactivity for citrullinated proteins was seen in both active and chronic active 
lesions of MS tissue blocks, as compared to NAWM and control white matter tissue. 
The highest levels of citrullination (3+ and 4+) were observed in lesions, whereas both 
control and NAWM were rated predominantly 2+ except for one control case which was 
graded 1+ (Figure 3.11). Strong peptidyl-citrulline immunoreactivity was observed in 
active lesions with ongoing demyelination, and was associated with areas of activated 
microglia (Figure 3.12 a-c). Using dual label immunofluorescence for peptidyl-citrulline 
and GFAP, the intensity of GFAP staining was markedly upregulated in MS specimens, 
and was colocalised with F95 immunoreactivity (Figure 3.12 d). Strong peptidyl- 
citrulline immunoreactivity was also observed in active lesions with thinning of the 
myelin sheath, as assessed by disrupted MOG staining, and was associated with areas 
of activated microglia HLA-DR, with GFAP colocalised with F95 immunoreactivity 
(Figure 3.13 4a-d). Citrullination was absent in lesions with complete myelin loss 
(Figure 3.13 a, c; Figure 3.14 a, c). In chronic active lesions, peptidyl-citrulline 
immunoreactivity was either weak or absent in areas of complete myelin loss and no 
microglia, with strongest peptidyl-citrulline immunoreativity observed in areas with 
intact or thining myelin and activated microglia at the lesion edge (Figure 3.15 a-d). 
NAWM showed weak peptidyl-citrulline immunoreactivity, with strongest 
immunoreactivity observed at the abluminal region of blood vessels (Figure 3.16 a-d). 
Control white matter showed areas with peptidyl-citrulline immunoreactivity, with co­
localisation with GFAP positive astrocyte cell bodies (Figure 3.17 a-d). Myelin was 
intact and normal in these cases, with microglia associated with these areas of 
peptidyl-citrulline immunoreactivity being resting with fine processes (Figure 3.17 a-c).
3.3.4 Expression of PAD2 in MS, NAWM and control tissue
PAD2 consistently showed high immunoreactivity within the lumen of blood vessels, 
but was not colocalised with endothelial cells (Figure 3.18 a,b). PAD2 did colocalise
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with activated microglia (Figure 3.18 c,d). However, PAD2 was shown not to be 
associated with either GFAP or with citrullinated proteins in astrocytes (Figure 3.18 e- 
h). In addition to this, PAD2 was not expressed by CD3+ T cells or in myelin (Figure 
3.18 i-l). There were no obvious differences in intensity or distribution of PAD2 
immunoreactivity between control, NAWM and lesions except within lesions where the 
green background hue was stronger. The IC for PAD2 antibody showed a high level of 
staining within the tissue, but was weaker than staining with the PAD2 antibody 
(Figure 3.19 a-b). PAD4 staining was difficult to detect and was similar to the staining 
pattern observed when using the corresponding IC (Figure 3.19 c-d).
3.3.5 qPCR analysis of mRNA expression of PAD2 and PAD4 in MS, 
NAWM and control tissue
PAD2 was shown to be expressed at the mRNA level in control white matter, MS 
NAWM and MS lesion brain tissue (Figure 3.20). There was significantly less PAD2 
mRNA in the MS NAWM compared to both control white matter and MS lesional brain 
tissue (p=0.0093 and p=0.0369, respectively).
3.3.6 Western blot analysis of expression of citrullinated proteins in MS, 
NAWM and control tissue
Following initial optimisation, western blot analysis of proteins from control white 
matter, MS NAWM and MS lesions all showed multiple bands for citrullinated proteins 
using the F95 antibody to detect peptidyl citrulline moieties (Nicholas and Whitaker 
2002) (Figure 3.21b). In control white matter, MS NAWM and MS lesions, seven major 
bands were detected, including one at the expected 50 kDa molecular weight for GFAP 
and one at 18.5 kDa molecular weight suggestive of citrullinated MBP (Figure 3.21b) 
(Harauz et al., 2004; Boggs 2006). The remaining unidentified bands were seen at 250, 
75, 15 and 10 kDa. Among these bands from brain tissue, two bands at -48 and -50 
kDa were most prominent, which were positively identified as citrullinated GFAP 
isoforms by overlay of the two antibodies (F95 and anti GFAP) (Figure 3.22a) 
(Ferguson et al., 2009). Densitometric analysis of these bands showed no significant 
differences in the proportion of these citrullinated proteins between control white matter 
and MS NAWM, or control white matter and MS lesion (Figure 3.23 a, b). A strong 
single band at 75 kDa (Ishigami et al., 2002) was observed when proteins extracted 
from MS lesional and control tissue were immunoprobed with the PAD2 antibody, 
confirming the specificity of the antibody (Figure 3.22b).
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Figure 3.11: Level of citrullinated proteins scored from each block of control 
white matter, NAWM and lesions from MS cases. Anonymised blocks were blindly 
graded by two independent researchers (control white matter, n=9; MS NAWM, n=5; 
MS lesion, n=14). Any discrepancies between blocks were reviewed again and a 
consensus agreement reached between the two raters. Levels of citrullinated proteins 
were highest in MS lesions compared to control white matter and MS NAWM.
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Figure 3.12: Citrullinated protein expression in areas of demyelination in an 
active MS lesion. Citrullination (pep cit; green), myelin (MOG; red), microglia (HLA- 
DR; red) and GFAP (red) in an active MS lesion (MS51 A1B6), visualised using single 
and dual staining immunofluorescence microscopy of serial tissue sections combined 
with DAPI (blue) demonstrating cell nuclei, (a) Ongoing demyelination was observed 
along with (b) activated microglia and (c) associated with strong immunoreactive 
staining for citrullination. (d) Citrullination (green) was predominantly co-localised 
(yellow) to within astrocytes (GFAP; red) at the centre of the lesion. Scale bar is 50 ym.
Figure 3.13: Differential citrullinated protein expression in an active MS lesion.
Citrullination (pep cit; green), myelin (MOG; red), microglia (HLA-DR; red) and GFAP 
(red) in an active MS lesion (MS58 P1D3), visualised using single and dual staining 
immunofluorescence microscopy of serial tissue sections combined with DAPI (blue) 
demonstrating cell nuclei, (a) Ongoing demyelination was observed along with (b) 
activated microglia and (c) strong immunoreactive staining for citrullination. Areas with 
complete myelin loss were associated with absence of citrullinated proteins, (d) 
Citrullination (green) was predominantly co-localised (yellow) to within astrocytes 
(GFAP; red). Scale bar is 50 ijm.
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Figure 3.14: Citrullinated protein expression in areas of demyelination in an 
active MS lesion. Citrullination (pep cit; green), myelin (MOG; red), microglia (HLA- 
DR; red) and GFAP (red) in a chronic active MS lesion (MS58 P1D3), visualised using 
single and dual staining immunofluorescence microscopy of serial tissue sections 
combined with DAPI (blue) demonstrating cell nuclei, (a) Complete myelin loss was 
observed along with (b) activated microglia and (c) absence of immunoreactive 
staining for citrullination. (d) Low levels of citrullination (green) was observed in 
absence of extensive astrocyte processes (GFAP; red). Scale bar is 50 /jm .
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Figure 3.15: Citrullinated protein expression in a chronic active MS lesion.
Citrullination (pep cit; green), myelin (MOG; red), microglia (HLA-DR; red) and GFAP 
(red) in a chronic active MS lesion (MS58 P1D3), visualised using single and dual 
staining immunofluorescence microscopy of serial tissue sections combined with DAPI 
(blue) demonstrating cell nuclei, (a) In areas of intact myelin (b) activated microglia 
were observed along with (c) strong immunoreactive staining for citrullination which 
was predominantly (d) co-localised (yellow) to within astrocytes (GFAP; red). Areas of 
complete myelin loss were associated with absence of both microglia and citrullination. 
Scale bar is 50 /jm.
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Figure 3.16: Citrullinated protein expression in MS NAWM. Citrullination (pep cit; 
green), myelin (MOG; red), microglia (HLA-DR; red) and GFAP (red) in MS NAWM 
(MS71 P2C3), visualised using single and dual staining immunofluorescence 
microscopy of serial tissue sections combined with DAPI (blue) demonstrating cell 
nuclei, (a) Intact myelin (b) with resting microglia were observed along with (c) weak 
immunoreactive staining for citrullination (2+) which was predominantly (d) co-localised 
(yellow) to within astrocytes (GFAP; red). Scale bar is 50 fjm.
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Figure 3.17: Citrullinated protein expression in control white matter. Citrullination 
(pep cit; green) in control white matter (C022 P1C3; visualised using single and dual 
staining immunofluorescence microscopy of serial tissue sections combined with DAPI 
(blue) demonstrating cell nuclei, (a) Intact myelin was observed throughout with (b) low 
level of resting microglia along with (c) weaker immunoreactive staining for citrullination 
which was predominantly (2+) (d) co-localised (yellow) to within astrocytes (GFAP; 
red). Scale bar is 50 ijm.
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Figure 3.18: Localisation of peptidylarginine deiminase 2 (PAD2) in MS lesions, 
visualised using double staining immunohistochemistry and confocal 
microscopy, (a, b) Strong immunoreactivity for PAD2 within the lumen of a blood 
vessel, (c, d) PAD2 co-localised with HLA-DR positive cells within a white matter 
lesion, as indicated by red arrow, (e, f) No immunoreactivity for PAD2 within astrocytes 
in a white matter lesion, (g, h) No co-localisation of PAD2 with citrullinated proteins in a 
white matter lesion, (i-j) Strong PAD2 immunoreactivity within the lumen of a blood 
vessel not associated with CD3+ T cells, (k, I) Strong PAD2 immunoreactivity within 
the lumen of a blood vessel not associated with areas of MOG staining. Scale bar is 20 
nm.
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Figure 3.19: Expression of PAD2 and PAD4 in MS NAWM (MS103 P1D3). (a) Low
level PAD2 expression was observed throughout the tissue but the expression pattern 
was similar to (b) the corresponding isotype control (IC). (c) Specific PAD4 staining 
was difficult to detect and was similar to (d) the corresponding IC. Scale bar is 50 /jm .
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Figure 3.20: qPCR analyses showing PAD2 and PAD4 mRNA expression in 
control, NAWM and lesion brain tissue (Log scale). mRNA expression of (a) PAD2 
and (b) PAD4. Note the difference in scale bars, showing much greater expression of 
PAD2 compared to PAD4. Data are represented as the mean (control white matter, n= 
9; MS NAWM, n=5; MS lesion, n=14) ± SEM. Statistically significant differences 
between control white matter, MS NAWM and MS lesional tissue are marked by 
asterisks (*p < 0.05, **p < 0.01).
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Figure 3.23: Levels of citrullinated GFAP and MBP in control white matter, MS 
NAWM and MS lesional brain tissue. Densitometric analysis values expressed as the 
density ratio of target (citrulline) to loading control (p-actin) in arbitrary units in (a) 
GFAP and (b) MBP of control white matter, MS NAWM and MS lesional brain tissue. 
Data are presented as the mean (n= control 9 blocks; NAWM 5 blocks; lesion 14 
blocks) ± SEM. No significant differences in levels of citrullinated GFAP and MBP were 
observed between control, MS NAWM and MS lesional tissue.
Control Lesion
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3.4 Discussion
3.4.1 The expression of citrullinated proteins is increased in MS
In this study, high levels of citrullinated proteins were found in areas of ongoing 
demyelination and myelin thinning. In comparison, much lower levels of citrullination 
were consistently found in the NAWM of MS and control white matter tissue where 
there is no demyelination. This suggests that the process of citrullination is intimately 
linked with that of demyelination, which is the hallmark of MS. A striking finding from 
this study is the increased expression of citrullinated GFAP in both active and chronic 
active lesions in brain tissue taken from patients with MS. It is not known whether 
these findings represent an increase in the amount of naturally occurring citrullinated 
GFAP overall, or if more arginine residues in these GFAP proteins are citrullinated in 
the disease state.
Citrullination was not shown to be associated with MOG, which was unexpected as 
MOG is a predicted target of citrullinated proteins. However, this inability to detect 
citrullinated MOG may be due to under exposure during image capture, as iow 
exposure times were used to capture images of citrullinated GFAP due to the 
brightness of citrullinated GFAP. By over-exposing the images citrullinated MOG may 
have been detectable. Unfortunately, interpretation of results regarding citrulline and 
MOG co-localisation was difficult due to the inability to carry out dual-staining as a 
result of cross-reactivity of secondary antibodies when carrying out staining on the 
same section. Furthermore, the majority of previous studies have identified MBP as 
citrullinated in MS (Wood and Moscarello 1989; Moscarello et a/., 1994; Wood et at., 
1996). Therefore, it may also have been useful to have carried out dual-staining with 
anti-human MBP and anti-human peptidyl-citrulline, although interpretation may have 
also been difficult due to these two antibodies only being available as monoclonal 
antibodies.
Due to increasing histological evidence indicating that non-lesional NAWM in MS 
patients has underlying pathology (Nicholas et a!., 2004; Kutzelnigg et at., 2005; 
Frischer et al., 2009; van der Valk and Amor 2009), the NAWM was also examined for 
the presence of citrullinated proteins. However, in this study we were unable to identify 
a difference in levels of citrullination between control white matter and MS NAWM 
compared to MS lesional brain tissue. This finding was unexpected as previously 
Nicholas and colleagues (2004), using three control and three MS blocks, were able to 
show increased expression of citrullinated GFAP in the NAWM of brain tissue taken 
from patients with SPMS. However, our study examined both active and chronic active
179
plaques as opposed to old chronic active plaques, which may account for this 
difference. In addition, in this study additional markers were used to assess the 
underlying pathology of the lesion and surrounding NAWM, most importantly cellular 
activation of microglia, myelin thinning and demyelination.
Western blotting showed the presence of multiple citrullinated proteins, with bands at 
-48 and -50 kDa, identified as GFAP isoforms and a band at -18.5 kDa identified as 
MBP (see chapter 4) (Harauz et at., 2004; Boggs 2006; Ferguson et a!., 2009). 
Additional bands of unidentified citrullinated proteins were observed at 250, 75, 15 and 
10 kDa. Western blot analysis and subsequent densitometry of bands corresponding to 
citrullinated GFAP and citrullinated MBP did not show a difference between levels of 
citrullination in the three tissue groups. However, this is most likely due to carrying out 
western blotting using brain extracts of the whole tissue section, as only a small area of 
the section demonstrated high levels of citrullination microscopically. Using 
immunoprecipitation with F95 antibody to isolate the citrullinated proteins, as has been 
used in previous studies (Nicholas et at., 2004; Nicholas et at., 2005) would address 
this issue. In addition, in immunostaining only a few citrullinated proteins are needed to 
provide a positive signai, whereas in western blotting a much greater amount of the 
protein of interest is needed (Keilhoff et al., 2008).
Although previous studies have identified citrullination of MBP in MS, this is the first 
study that has shown directly that high levels of citrullination are associated with areas 
of ongoing demyelination and not in areas of complete myelin loss. These findings 
provide evidence to suggest that citrullination of MBP precedes the actual loss of 
myelin. Previously, using MBP isolated from NAWM of MS cases and controls, and 
fractionation of the samples by column chromatography, Moscarello et al. (1994) found 
that 18% of MBP was citrullinated in control tissue compared to 45% of MBP in patients 
with MS. Further studies by the same group found that in Marburg’s disease, as much 
as 90% of MBP is citrullinated (Wood et al., 1996). This study found that citrullinated 
MBP in both control and patients with chronic MS contained 6 citrulline residues and 13 
arginine residues, whereas citrullinated MBP in patients with Marburg disease 
contained 18 citrullinine residues and only 1 arginine residue (Wood et al., 1996). A 
number of studies have shown that deiminated MBP is unable to compact lipid bilayers, 
causing membrane destabilisation, thereby, possibly promoting demyelination (Brady 
et al., 1981; Wood and Moscarello 1989; Boggs et al., 1999; Beniac et al., 2000). In 
addition, deiminated MBP is more susceptible to proteolytic digestion by myelin- 
associated proteases (Cao et al., 1999; Pritzker et al., 2000; D’Souza and Moscarello 
2006; Musse et al., 2006). This greater surface exposure and greater enzymatic 
cleavage of the citrullinated protein would lead to increased release of the
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immunodominant epitope, which could prime the innate immune cells of the CNS and 
sensitize peripheral blood T cells (Musse et al., 2006; Musse and Harauz 2007). 
Furthermore, proteolytic breakdown of MBP would allow access of PAD2 to the MBP 
protein, enabling citrullination to take place more readily than when myelin is intact. 
During demyelination there may be an increase in extracellular calcium, as a result of 
cell death, leading to activation of PAD2. These results reported in this thesis support 
previous studies as at sites of ongoing demyelination there is an increase in 
citrullinated proteins.
GFAP is the main intermediate filament protein in mature astrocytes and is involved in 
a number of structural and functional processes, including motility, proliferation, vesicle 
trafficking, autophagy and synaptic interactions with neurons (Middeldorp and Hoi 
2011). GFAP is also thought to play an important role in astrocyte motility, with motility 
of GFAP-/- astrocytes shown to be greatly reduced compared to GFAP-expressing 
astrocytes (Lepekhin et al., 2001). Vesicle trafficking has also been shown to be 
reduced in astrocytes from mice with double knock-out of GFAP and vimentin (Potokar 
et al., 2007; Potokar et al., 2008). Neuronal activity is closely linked to the release and 
uptake of the neurotransmitter glutamate, which requires the interaction between 
astrocytes and neurons. Glutamate transporters have been identified on neuronal and 
astrocytic membranes and are important for removal of extracellular glutamate (Pines 
et al., 1992; Storck et al., 1992; Rothstein et al., 1994). GFAP plays a key role in 
modulating astrocytic and neuronal glutamate transporter trafficking and function and in 
the control of glutamine production. In cortical and hippocampal synaptosomal 
preparations from adult GFAP-/- mice a reduced glutamate uptake was found together 
with decreased glutamate transport activity (Hughes et al., 2004). GFAP is subjected to 
multiple post-translational modifications that have important consequences for its 
structure and functions. Although the exact effect of citrullination of GFAP in astrocytes 
is currently unknown, it may have detrimental effects on a number of these 
physiological processes described above, such as reducing astrocyte motility and 
vesicle trafficking, preventing the phosphorylation of GFAP during cell proliferation 
(Inagaki et al., 1994), or affect the ability of astrocytes to effectively remove glutamate 
from the extracellular environment leading to neuronal glutamate excitotoxicity, 
contributing to pathological processes in MS (Bak et al., 2006).
Traditionally MS is believed to be induced by primarily targeting myelin sheaths and/or 
oligodendrocytes (Noseworthy et al., 2000). However, recent studies into other 
demyelinating diseases, such as neuromyelitis optica (NMO), have shown that direct 
targeting of myelin or oligodendrocytes is not essential and that initial antibodies 
targeting the astrocytic antigen aquaporin-4 (AQP-4) result in destruction of astrocytes
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which is then followed by degeneration and primary demyelination (Lennon et al., 2004; 
Lennon et al., 2005; Roemer et al., 2007). Astrocyte injury has also been suggested as 
an important early step in the cascade of lesion formation in brain inflammation, and 
that this may also be the case in the development of lesions in MS (Sharma et al., 
2010). At present potential pathological alterations of astrocytes in MS lesions have not 
received major attention; however, the high levels of citrullinated GFAP in MS lesions 
requires further investigation of how this might affect astrocyte function in the 
pathogenesis of MS.
3.4.2 PAD2 protein expression is associated with microglia and the lumen 
of blood vessels
PAD2 mRNA was shown to be expressed in control white matter, MS NAWM and in 
MS lesions. Interestingly, there was significantly less PAD2 mRNA in the MS NAWM 
compared to both control white matter and MS lesional brain tissue. These results are 
not unexpected as the expression of mRNA is an insufficient predictor of protein 
expression (see chapter 2) (Gygi et al., 1999). However, PAD2 protein expression 
within control white matter, MS NAWM and lesional tissue showed the strongest 
immunoreactivity within the lumen of the blood vessels and in microglia. No staining for 
PAD2 was observed in GFAP-positive astrocytes. Previous studies have shown PAD2 
to be present in both GFAP-positive astrocytes (Inagaki et al., 1994; Ishigami et al., 
2005; Jang et al., 2008; Jang et al., 2011) and microglia (Asaga et al., 2002). Ishigami 
et al. (2005) were able to demonstrate co-localisation of PAD2 with GFAP-positive 
astrocytes in brain tissue from patients with Alzheimer’s Disease (AD). Another group 
have shown PAD2 to be widely distributed in both astrocytes and neurons in brain 
tissue from scrapie-infected mice (Jang et al., 2008; Jang et al., 2011). These studies 
also showed PAD2 to co-localise with citrullinated GFAP-positive astrocytes (Ishigami 
et al., 2005; Jang et al., 2008; Jang et al., 2011). However, despite testing of several 
concentrations of anti-PAD2 antibody, blocking steps and fixatives, specific staining of 
astrocytes was not obtained. Western blotting of control and MS lesional brain tissue 
produced a single band at -75 kDa which confirmed the antibody did recognise PAD2 
as previous studies have shown PAD2 to be 665 amino acids in length with a predicted 
molecular mass of 75 kDa (Ishigami et al., 2002; Ishigami et al., 2005). The inability to 
detect PAD2 in frozen sections, as used in this study, may be due to the fact that in 
previous successful studies paraffin embedded tissue was used. Unlike previous 
studies which have shown increased expression of PAD2 in MS brain tissue compared 
to control brain tissue (Mastronardi et al., 2006; Wood et al., 2008), in this study there 
were no obvious differences in expression levels between control, MS NAWM and MS
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lesional tissue, except for a higher background staining level in lesions, which may 
indicate PAD2 localisation to myelin. However, this requires further investigation.
In order for PAD2 to become active, raised intracellular calcium ions must be present. 
There are many physiological and pathological conditions that could lead to raised 
intracellular calcium and subsequent activation of PAD2 in both neurons and glia, 
including hypoxia and excitotoxicity (see chapter 2) (Sambandam et al., 2004; 
Shideman et al., 2006; Smith 2007). If large numbers of activated macrophages 
containing PAD enzymes are present at inflammatory demyelinating sites in MS white 
matter, this could result in increased cell death in these areas, due to raised 
intracellular calcium ions, which would activate PAD enzymes, present both 
intracellularly and extracellularly, when released from dying cells (Bhattacharya et al., 
2006a; Bhattacharya et al., 2006b). In addition, the PAD2 promoter has been found to 
be hypomethylated in the white matter of subjects with MS compared to control 
subjects. Recently this hypomethylation of the PAD2 promoter has also been found to 
occur in peripheral blood mononuclear cells taken from patients with MS and is 
associated with significantly increased peripheral PAD2 expression in these individuals 
as compared to controls (Mastronardi et al., 2007; Calabrese et al., 2012). Taken 
together it seems that hypomethylation of the PAD2 promoter could be a principal 
event in inducing the transcription of PAD2 and subsequent increased activity of the 
enzyme through increases in intracellular calcium ions leading to citrullination of CNS 
proteins in MS. A recent study has also shown that upon contact with stimulated T 
cells, expression of PAD2 is upregulated in human monocytes (Ferrari-Lacraz et al.,
2010), which may also be the case in lesions when macrophages and microglia come 
into contact with activated T cells. Therefore, there are many factors within the MS 
tissue, particularly the lesion, which could lead to activation of PAD2 and subsequent 
citrullination of CNS proteins.
3.4.3 Conclusion
In conclusion, the increase in citrullinated proteins in areas of myelin thinning and loss 
within and surrounding MS lesions, along with co-localisation of citrullinated proteins 
with GFAP-positive astrocytes, supports the hypothesis that citrullination of proteins is 
important in the pathogenesis of MS, both in terms of citrullination of MBP preceding 
demyelination and citrullination of GFAP and its possible effect(s) on astrocyte 
function(s). It is difficult to draw any firm conclusions regarding the expression of PAD2 
in MS brain tissue compared to control tissue due to the inability to detect expression in 
GFAP-positive astrocytes, although this has been reported by others previously.
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Chapter 4
Investigation of the presence of anti- 
citrullinated protein antibodies in MS 
and other neurological conditions
4.1 Introduction
Self-reactive antibodies have been implicated in the pathogenesis of MS for many 
years, since intrathecal Ig synthesis was reported in patients with MS (Kabat et al., 
1950) and has remained a hallmark finding in the diagnosis of the disease (Berger and 
Reindl 2007). Since this discovery, many studies have been carried out to identify the 
target antigens, with limited success. Whilst the presence of antibodies in the CSF is 
associated with the diagnosis of MS, it is still unclear whether these Igs actively 
contribute to the pathogenesis or progression of the disease (Weber et al., 2011). 
Antibodies are also frequently observed in acute lesions of MS patients (Weber et al.,
2011). Furthermore, in newly diagnosed patients, histopathological biopsy studies 
demonstrate heterogeneity of acute lesions between individual patients suggesting at 
least four distinct patterns of acute demyelinating lesions exist (Lucchinetti et al., 2000; 
Lassmann et al., 2001). The most frequent pattern is characterized by significant 
antibody deposits and complement activation (pattern II) (Lucchinetti et al., 2000). In 
contrast, in acute lesions of patients with established MS, a more homogenous pattern 
was observed (Breij et al., 2008). Complement activation supports the role of 
pathogenic antibodies and antibody-mediated effector functions and is found in areas 
of demyelination (Storch et al., 1998; Lucchinetti et al., 2000). Furthermore, patients 
with pattern II histopathologic lesions respond well to plasma exchange therapy, further 
implicating the role of antibodies in MS (Keegan et al., 2005). In further support of this, 
clonally expanded populations of memory B cells and plasma cells are found in MS 
lesions and in the CSF of MS patients with Serafini and colleagues being the first to 
report the formation of B-cell follicle-like structures in the brains of patients with MS 
(Baranzini et al., 1999; Villar et al., 2002; Serafini et al., 2004).
It has proven challenging to definitively identify the target antigen to which these 
autoantibodies bind. There is evidence that autoantibodies derived from patients with 
MS bind lipids (Brennan et al., 2011), carbohydrates (Lolli et al., 2005; Schwarz et al., 
2006) and DNA (Williamson et al., 2001), however, the majority of research has 
focused on components of the myelin sheath, in particular MBP, MOG, and PLP as 
possible targets of these autoantibodies, with MBP being the most extensively studied. 
MBP is one of the principal components of the myelin sheath and is the second most 
abundant protein in the CNS (Boggs 2006). MOG is present on the outer layer of the 
myelin sheath and is thus more accessible to antibody binding (Brunner et al., 1989). 
Both MBP and MOG can act as autoantigens to trigger EAE (Gold et al., 2006), yet no 
unequivocal evidence of this CNS reactivity has been established to date in MS. In 
active demyelinating MS lesions, antibodies to myelin, especially to MOG, were found 
by immunohistochemical analysis (Genain et al., 1999) and IgGs extracted from
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inflamed CNS also recognised MOG (O’Connor et al., 2005). Elevated antibody titres 
against MBP and/or MOG were also reported in the serum and CSF of MS patients 
(Reindl et al., 1999; Schmidt et al., 2001) and in serum of children with the first episode 
of CNS demyelination (Brilot et al., 2009; Selter et al., 2010). Furthermore, serum 
antibodies to MBP and MOG were observed in sub-groups of patients with MS (Lalive 
et al., 2006; Zhou et al., 2006). Intrathecal IgG from MS patients demonstrate reactivity 
to several myelin epitopes including: MBP, MOG, MAG and PLP (Archelos et al., 2000; 
Cross et al., 2001) suggesting that these may contribute to MS pathogenesis. 
However, myelin-specific antibodies can also be detected in other neurological 
diseases and healthy controls (Kami et al., 1999; Lampasona et al., 2004), suggesting 
that these targets are not specifically predictive of disease.
Breakdown in immunological self-tolerance, leading to the production of autoantibodies 
in MS, might arise from immune recognition of self-proteins that have undergone post- 
translational modification under pathophysiological conditions (Carillo-Vico et al, 2009). 
Such modifications might change the structure of the component proteins of myelin, 
such as MBP and MOG, through the generation of novel epitopes to which the immune 
system is no longer tolerant resuiting in the production of autoantibodies against these 
modified epitopes. Citrullination is one possible PTM which may be responsible for 
these changes in MS (Moscarello et al., 2007; Musse and Harauz 2007). Interest in 
citrullination in MS first developed from studies showing increased citrullination of MBP 
in patients, particularly those with hyperacute Marburg’s syndrome (Wood and 
Moscarello 1989; Moscarello et al., 1994; Wood et al., 1996). Since these earlier 
findings, a number of studies have shown increased citrullination to occur in MS brain 
post-mortem tissue compared to control brain tissue (Nicholas et al., 2004; Mastronardi 
et al., 2006; Mastronardi et al., 2007; Wood et al., 2008; Oguz et al., 2009). A study by 
Musse et al. (2006) showed that citrullination of membrane bound MBP in MS exposes 
an immunodominant epitope, which is highly susceptible to cleavage by myelin- 
associated proteases, which may result in its release and priming of the immune 
system (Cao et al., 1999; Musse et al., 2006). Furthermore, peripheral T cells from 
patients with MS have shown enhanced reactivity to citrullinated MBP compared to 
non-citrullinated MBP and control individuals (Tranquill et al., 2000).
Antibodies to citrullinated proteins have been reported in another autoimmune disease, 
RA, targeting multiple RA-specific proteins, including vimentin, fibronectin and filaggrin 
amongst others (Klareskog et al., 2008). Testing of ACPAs in individuals with RA is 
now one of the prime biomarkers used in the diagnosis of RA, with the ability to predict 
disease onset and is associated with a more severe disease course (Whiting et al.,
2010).
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Previous studies investigating the presence of autoantibodies to citrullinated peptides 
in MS patients are limited. A study by De Seze et al. (2001) using paired CSF and 
serum samples from 60 patients with MS and 30 other neurological disease (OND) 
controls, followed by incubation with both citrullinated and non-citrullinated MBP 
peptides in an enzyme-linked immunosorbent assay (ELISA), did not demonstrate any 
difference in antibody responses to citrullinated MBP peptides between individuals with 
MS and OND controls (De Seze et al., 2001). A more recent study using serum from 85 
patients with MS and a commercially available RA specific ELISA kit coated with cyclic- 
citrulline containing peptides, showed only 3 patients demonstrated serum reactivity to 
these citrulline containing peptides (Bodil Roth et al., 2008). However this low positivity 
amongst patients with MS is most likely attributed to the fact that the antigen used in 
this assay was developed to diagnose RA.
Based on these previous studies and studies in chapter 3 of this thesis showing 
extensive citrullination within the CNS associated with demyelination in MS, a study 
was carried out to further identify proteins that are specifically citrullinated in MS. This 
predominantly involved the use of mass spectrometry for peptide identification, with the 
aim of being able to use these newly identified citrullinated peptides to coat the wells of 
an ELISA plate to develop an assay more specific for ACPA in MS patients.
The conversion of an arginine to citrulline results in a 0.984 Da mass increase and loss 
of one positive charge per modified citrulline (Gyorgy et al., 2006). This latter change 
has a substantial effect on the acidity of the amino acid side chain, changing the 
isoelectric point (p/) from 11.41 for arginine to 5.91 for citrulline (Orgovan and Noszal
2011). Both the mass difference and the shift from a basic to a neutral pH will have 
consequences on the detection of citrullinated proteins and peptides, by mass 
spectrometry (De Ceuleneer et al., 2012).
The most common detection method for citrullinated proteins is western blotting, 
whereby a tissue extract containing citrullinated proteins is separated by SDS-PAGE, 
followed by electrophoretic transfer to a membrane which is then incubated with a 
primary antibody against citrullinated proteins followed by a labelled secondary 
antibody for immunodetection. Although very specific, this method only gives an 
indication of citrullination state, but not of the identity of the citrullinated protein, nor of 
the location of the citrullinated residues within this protein. Two SDS-PAGE analyses of 
the same sample are often executed concurrently. One gel being used for the 
determination of the citrullination status by blotting followed by immunodetection with 
an antibody specific for citrullinated proteins and the other stained and matched with 
the blot, after which proteins of interest are excised and identified using mass 
spectrometry.
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This chapter describes the investigation of novel citrullinated proteins in post-mortem 
MS brain tissue utilising SDS-PAGE and mass spectrometry to follow on from the 
previous chapter (chapter 3) whereby multiple citrullinated protein bands were 
observed following western blotting of proteins extracted from control, MS NAWM and 
MS lesional brain tissue. Mass spectrometry was employed to ascertain the identities 
of these citrullinated proteins, with the aim of being able to use these newly identified 
citrullinated peptides to develop an assay to measure ACPAs in individuals with MS.
4.1.1 Aim of the study
To identify novel citrullinated proteins in MS brain tissue and determine if antibodies 
against these citrullinated proteins are present in MS patient serum and CSF.
4.1.2 Objectives of the study
1. Identify novel citrullinated proteins in MS brain tissue using MALDI-MS.
2. Develop an ELISA method for the detection of ACPAs in MS serum and CSF, 
specifically targeted to citrullinated MBP and/or other CNS proteins.
3. Detect the presence of ACPAs in paired patient serum and CSF samples from 
MS patients, ONDs and non-neurological patient controls using this developed 
ELISA technique and determine whether antibody levels can be used to identify 
patients with MS.
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4.2 Materials and methods
4.2.1 Suppliers used in this chapter
Axis-Shield Pic, Luna Place, The Technology Park, Dundee, DD2 1XA, Scotland; 
eBioscience Ltd, 2nd floor, Titan Court, 3 Bishop Square, Hatfield, AL10 9NA, UK; 
Millipore Ltd, Suite 3 & 5, Building 6, Croxley Green Business Park, Watford, WD18 
8YH, UK; Pepceuticals Ltd, 4 Feldspar Close, Warrens Park, Enderby, Leicestershire, 
LE19 4JS, UK; Peprotech EC Ltd, Peprotech House, 29 Margravine Road, London, 
W6 8LL, UK; Sigma-Aldrich, The Old Brickyard, New Road, Gillingham, Dorset, SP8 
4XT, UK; Waters Corporation, Floats Road, Manchester, M23 9LZ, UK.
4.2.2 Reconstitution of human MBP
Recombinant human MBP (Sigma, UK) (1 mg) was reconstituted in 1000 pL sterile 
H20  to give a final concentration of 1mg/mL. This stock solution of MBP was stored in 
20 pL aliquots at -20°C until required.
4.2.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
MS tissue protein extract (MS058 P1C3) which had showed the most extensive 
citrullination by immunohistochemical and western blot analysis (Chapter 3) (30 pg) 
(see sections 3.2.4.1 and 3.2.4.2) and pure MBP (10 pg) (Sigma, UK) as a positive 
control were fractionated on pre-cast 10% Bis-Tris gels using SDS-PAGE (see section 
3.2.4.4). Following SDS-PAGE, the gel was stained using Instant Blue (Expedion, UK) 
for 1 hr at RT in order to visualise the protein bands. Protein bands of interest were 
then excised from the gel using a sterile blade and placed into Eppendorf tubes and 
stored at -80°C.
4.2.4 In-gel digest and extraction of peptides
Prior to carrying out an in-gel tryptic digest 10 mM dithiothreitol (DTT) solution in 25 
mM NH2C 03 (1.5 mg DTT in 1 mL 25 mM (NH4)2C 03) and 55 mM idoacetamide 
solution was made in 25 mM (NH4)2C 03 (10 mg iodoacetamide in 1 mL 25 mM 
(NH4)2C 03) were prepared. The first step involves the reduction and alkylation of gel 
pieces. Briefly, each gel piece was rehydrated in 40 pL 10 mM DTT, vortexed followed 
by pulse-centrifugation. The sample was then incubated on a heat block at 56°C for 45 
minutes. Following this, the supernatant was then removed and 40 pL 55 mM
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idoacetamide was added to each gel piece, vortexed followed by pulse-centrifugation. 
The sample was then placed in the dark and left to incubate for 30 minutes to allow the 
reaction to proceed. Following this, the supernatant was discarded and the gel piece 
was washed by the addition of 100 pL 25 mM (NH4)2C03, vortexed for 10 minutes 
followed by pulse-centrifugation. The supernatant was then removed and 200 pL 100% 
acetonitrile (ACN) was added to the gel piece, vortexed briefly and then left to stand for 
approximately 10 minutes until the gel pieces started to shrink and turn white. Lastly, 
the supernatant was removed and samples were subjected to Speed Vac for 
approximately 10 minutes until the gel pieces were dry.
Once the gel pieces had been successfully reduced and alkylated the tryptic digest was 
performed. Briefly, 25 pL (10 pg/mL) trypsin solution (Promega trypsin made up in 25 
mM (NH4)2C 03; pH 8.1) was added to each gel piece and samples were allowed to 
rehydrate for 1 hour on ice. Following this the excess trypsin solution was removed and 
the gel piece was covered with ~ 40 pL 25 mM (NH4)2C 03. The gel pieces were then 
incubated on a shaker overnight at 37°C.
The next day, peptides were extracted from the gel pieces. Briefly, gel pieces were 
subjected to pulse-centrifugation, and following this the supernatant was removed and 
transferred to a clean Eppendorf tube. 30 pL 50% ACN 0.1% TFA was added to each 
gel piece, vortexed for 15 minutes and then subjected to pulse-centrifugation. The 
supernatant was then removed and added to the supernatant from the previous step. 
The step with the addition of 50% ACN 0.1% TFA was then repeated. The resulting 
extract was the subjected to Speed Vac centrifuge to reduce the sample to 
approximately 10 pL.
In-gel digests were also performed with Lysine C (Lys C) (Promega, UK), which digests 
proteins at the carboxyl side of lysine residues allowing for the detection of peptides 
with probable arginine modifications. In this instance the same procedure as above 
was followed except the (NH4)2C 03 buffer was replaced with 25 mM Tris-HCI (pH 9.3) 
and the Lys C was incubated with the gel piece for 18 hours at 37°C.
4.2.5 Mass spectrometry
Mass spectrometry is used to measure the molecular mass of a sample within 
approximately 0.01-0.2% of the total mass, which enables detection of minor mass 
changes such as post-translational modifications or amino acid substitutions (Karas et 
al., 1990).
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4.2.5.1 Principles of MALDI mass spectrometry
Matrix assisted laser desorption ionisation (MALDI) is a useful tool for the analysis of 
non-volatile organic compounds of high Mr. This ionisation technique is used for the 
analysis of proteins, peptides, glycoproteins, oligosaccharides and oligonucleotides 
(Yan et al., 2000). A basic mass spectrometer consists of three main components: the 
ionisation source, a mass analyser that measures the mass-to-charge ratio (m/z) of the 
ionised analytes, and a detector that registers the numbers of ions at each m/z value 
(Aebersold and Mann 2003). Experimental samples are mixed with an organic 
compound with a strong absorption at the appropriate laser wavelength and then 
spotted onto a stainless steel target plate and left to air-dry. The matrix and sample are 
mixed with approximately 100-1000-fold molar excess of the matrix. The required 
amount of the sample is low, between 0.5 and 2.0 pL of the analyte/matrix mixture is 
usually sufficient (Schiller et al., 2004). Once the solvent has evaporated and the matrix 
has crystallised, the plate is placed into the mass spectrometer, where ionisation 
begins. The laser beam hits the sample-matrix crystal in pulses, leading to absorption 
of the laser energy by the matrix. UV lasers are most commonly used in MALDI and 
emit light at a fixed wavelength, usually a nitrogen iaser at a wavelength of 337 nm is 
used (El-Aneed et al., 2009) (Figure 4.1a). Energy is then transferred from the matrix 
molecules to the sample within the matrix, and both sample and matrix desorb from the 
condensed state and enter the vapour phase. During this process ion formation occurs 
whereby protons transfer from the matrix to the sample. Following this, under a high 
potential, the ions accelerate down a vacuumed drift scope tube. The ions are then 
passed through a series of extraction and focusing electrodes and lenses in the 
analyser region, where separation according to mass (m) -to-charge (z) ratio (m/z) 
occurs, before the ions are detected.
MALDI is a soft ionisation method that enables the analysis of biomolecules of higher 
molecular weights without major degradation, reducing the risk of fragmentation and 
produces singly-charged ions (Schiller et al., 2004). Mass analysers with high m/z 
capabilities are therefore used in addition to MALDI, such as the time-of-flight (TOF) 
analyser or quadrupoles, which all separate ions based on their m/z ratio, however, 
they differ in their m/z range coverage, accuracy or resolution. The TOF mass analyser 
measures the time for ions to travel between the accelerator electrode and the 
detector, i.e. along the drift tube, and from this determines the m/z value (Figure 4.1b). 
Equally charged low mass ions arrive at the detector in a shorter time than high mass 
ions.
The laser pulses produce discrete groups of ions intermittently, which facilitates 
measurement of the flight time. The resolution of the TOF is improved by the addition
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of a reflectron, which focuses the energy spread of the ions (El-Aneed et al., 2009). 
These reflectrons are repelling devices that cause the ion to change direction and 
accelerate back towards the detector. Ions with higher kinetic energy will penetrate 
deeper into the ion mirror and therefore travel further into the reflectron and have a 
longer flight path. This leads to all ions of a specific m/z ratio arriving at the detector in 
a narrower time span, which improves the TOF spectrum.
These analysers can be used alone or joined together to take advantage of the 
strengths of each to form a hybrid. Tandem (MS-MS) mass spectrometers have more 
than one analyser and are useful in acquiring structural and sequence data, for 
example the quadrupole-time-of-flight version. Ion mobility separation (IMS) is used 
extensively to assess the structure and identity of a large number of molecular analytes 
and can also be incorporated into modern mass spectrometers. Hybrid I MS-MS 
instruments that have taken multiple forms, and recent advances have seen 
improvements in both the IMS and MS stages in modern instrumentation. Among these 
hybrid instruments, the quadrupole (Q)-IM-TOF MS instrument, known as the Synapt 2 
HDMS system, has been recently developed (Waters Corporation, UK). This 
instrument consists of four components: ionisation source for ion generation, a 
modified quadrupole mass analyser for ion selection, tri-wave IMS which uses time- 
varying potential ‘waves’ to drive ions through the drift tube, and a high-performance 
TOF mass analyser for high-resolution mass analysis (Zhong et al., 2011).
MALDI can be used in either positive or negative ion mode, depending on whether the 
sample either gains or loses a proton respectively, i.e. (M+H)+ or (M-H)', where M 
represents the molecular ion. Positive mode is generally used for protein and peptide 
analysis. In positive mode, other species commonly identified are (M+NH4)+ salt 
adducts, such as (M+Na)+. Traces of doubly charged molecular ions at half the m/z 
value, or dimers at twice the m/z value, can sometimes be identified. Since spectra are 
primarily recorded in the positive ion detection mode cationising agents are often 
added to the matrix to increase the ion yield, such as TFA in a concentration of 0.1% 
(Schiller et al., 2004).
There are numerous detectors available to suit the type of analyser used, but detection 
of ions is always based on their charge, their mass or their velocity. The ion current is 
monitored by the detector, which also amplifies it and transmit signals to the data 
system, which records it as a mass spectra.
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Figure 4.1: Schematic diagram demonstrating MALDI-TOF mass spectrometer 
and a TOF mass spectrometer.
a) Prior to MALDI mass spectrometry analysis the sample is mixed with a matrix and 
spotted onto a target plate and left to air dry. Once dry the matrix crystallises and forms 
co-crystals with the sample. The target plate is then inserted into the mass 
spectrometer, where a laser is fired onto the sample. Desorption occurs as the matrix 
absorbs the laser energy, causing rapid heating and subsequent sublimination of 
matrix molecules. Matrix and analyte clusters expand into the vapour phase, and are 
ejected from the target surface. Excited matrix molecules are stabilised by proton 
transfer to the analyte, and cation attachment to the analyte occurs. The matrix 
evaporates away to leave free analyte ions.
b) Singly charged ions generated from the desorption-ionisation process pass through 
a charged grid, and are accelerated into the TOF drift tube, which is under a high 
vacuum. The length of this tube is typically 0.5-3 m long, and since the separation of 
ions is achieved over this distance, determines the possible mass resolution achieved. 
In order to improve resolution, longer flight tubes can be used or an “electrostatic 
mirror” can be incorporated to reflect ions at the end of the flight tube to reach a 
“reflector-detector”, thereby lengthening the field-free path travelled. Equally charged 
low mass ions reach the end of the flight tube in a shorter time than high mass ions, 
and as they are equally charged, separation based on mass is achieved. A detector at 
the end of the tube produces a signal upon impact of each ion, and m/z spectra are 
produced from this signal as a function of time.
[M+H+] = ion formed by interaction of a molecule with a proton; TOF = time-of-flight
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The m/z values are plotted against their intensities, and the resulting spectra show the 
molecular mass of the sample components and their relative abundance. From this 
spectra, peptide mass fingerprinting can be carried out to identify the protein. This set 
of masses, typically obtained by MALDI-TOF, is then compared to the theoretically 
expected tryptic peptide masses for each entry in the database (Cottrell 2011). The 
proteins can be ranked according to the number of peptide matches. When high mass 
accuracy is achieved, at least 5 peptide masses need to be matched to the protein 
(Cottrell 2011).
In MALDI, resulting spectra usually only contain the ionised molecule with very little 
fragmentation data and therefore MS spectra are of little use for structural 
characterisation. In these cases, induced fragmentation is required using collision- 
induced dissociation (CID) and tandem mass spectrometry (Mann et al., 2001). This is 
carried out by first selecting and focussing the precursor ion in the first mass 
spectrometer analyser (e.g. quadrupole) followed by transfer of the precursor ion to the 
CID collision cells where it interacts with a collision gas and fragments. The resulting 
fragments are then separated in the second mass analyser (e.g. TOF) producing the 
typical MS/MS spectrum which can be used for sequencing, structural elucidation and 
analyte identification through fragment fingerprinting (Zhong et al., 2011). Tandem 
mass spectra data contains structural information related to the sequence of the 
peptide, rather than only the mass, therefore databases can also be searched to 
identify peptide sequences which match known sequences (Cottrell 2011).
Multiple collisions impart energy onto the molecule until it fragments, where several 
bonds along the backbone can be broken by these collisions (Figure 4.2). CID 
fragments peptide ions by cleaving at the N-C bonds. The most common ion types are 
the b and y ions, which denote fragmentation at the amide bond with charge retention 
on the N or C terminus, respectively (Mann et al., 2001). These b and y fragment ions 
provide sequence information which can then be searched against a protein database 
(Creese et al., 2011).
Protein identification using peptide CID spectra are more clear-cut than those achieved 
by mass mapping because, in addition to the peptide mass, the peak pattern in the CID 
spectrum also provides information about the peptide sequence (Aebersold and Mann 
2003). The CID spectra are scanned against comprehensive protein sequence 
databases, such as Mascot, using one of a number of different algorithms to find a 
positive identification with a known peptide.
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4.2.5.2 Matrix requirements for MALDI mass spectrometry
The type of matrix selected for use in MALDI mass spectrometry (MALDI-MS) is very 
important and greatly affects the results obtained. Different matrices are selected 
dependent on the sample being analysed. For peptides and protein samples, a-cyano- 
4-hydroxycinnamic acid (a-CHCA) is most commonly used. The matrices consist of 
small organic compounds which absorb the laser energy at the selected wavelength 
and should mix well with the analyte resulting in homogenous co-crystallisation 
(Schiller et al., 2004). In addition, the matrix should also separate the analyte 
molecules from each other to prevent cluster formation and avoiding direct laser hits on 
the analyte that would lead to intense fragmentation (Pan et al., 2007).
MALDI preparations should ideally have a low concentration of analyte molecules and 
an excess of matrix on the target plate, usually matrix and sample are mixed with 
~100-1000-fold excess of the matrix, which helps to prevent fragmentation of the 
analyte (Schiller et al., 2004). Most importantly, a matrix should be selected that has 
good absorption properties with the laser used, and that mixes well with the analyte to 
give homogenous co-crystallisation.
4.2.5.3 Use of Zip Tips® in sample preparation for analysis by mass spectrometry
Mass spectrometry is often complicated by the presence of salts and contaminants in 
the sample, which can obscure the protein of interest, particularly when it is present at 
low concentrations. To concentrate and purify samples for optimal results with MALDI- 
quadrupole/TOF (MALDI-QTOF) analysis, Zip Tips® (Millipore, UK) were used prior to 
spotting samples onto the target plate. Zip Tips® are 10 pL pipette tips that contain 
chromatography resin.
Various resins are available for different applications, and for concentrating small 
proteins, Zip Tips® with 0.6 pL of a C18 resin were used, composed of 15 pm silica 
with 20 nm pores.
Citrullinated protein digested samples were analysed by MALDI-MS both with, and 
without, the use of Zip Tips® in the sample preparation stage. Preliminary experiments 
were thus performed where samples were compared after being mixed with matrix and 
spotted onto the target plate, or first passed through a Zip Tip® according to the 
following protocol.
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Figure 4.2: Nomenclature for the product ions generated in the fragmentation of 
peptide molecules. Collision-induced dissociation (CID) causes a single cleavage to 
occur randomly at the various amide bonds in the peptide molecules. This process 
generates a series of fragments that differ by a single amino acid residue. Peptide 
fragments are named according to whether the fragments contains the N- or C- 
terminus, the peptide bond that is cleaved, and the position along the peptide chain. 
The b-ion type contains the N-terminus whereas the y-ion type contains the C- 
terminus. The subscript number is the residue number relative to the terminus that the 
fragment contains. Additional ion types correspond to cleavage at different positions in 
the backbone dotted lines).
(adapted from
http://www.lamondlab.com/MSResource/LCMS/MassSpectrometry/peptideFragmentati
on.php).
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The Zip Tip® was wetted twice with 10 pL ACN, which was then expelled before two 
equilibrium steps involving slow uptake and expulsion of 10 pL equilibration/wash 
solution (0.1% TFA in dH20). The digest sample was then cycled slowly through the 
Zip Tip® between 8 and 10 times in an Eppendorf tube and then expelled. Three x 10 
pL of wash solution (0.1% TFA in dH20 ) were then drawn up and ejected, followed by 
2 pL of elution solution (0.1% v/v TFA, 50% v/v ACN, 50% v/v methanol, 12.5 mg/ml_ 
a-CFICA) which was aspirated and cycled 3 to 4 times into a clean Eppendorf tube 
before being spotted directly onto a target plate.
4.2.2.4 MALDI-MS/MS of peptides
Preliminary data supported the use of Zip Tips® in the preparation of samples prior to 
mass spectrometry; therefore all subsequent experiments were performed following 
sample preparation with Zip Tips® (see section 4.2.2.3).
Peptide mass fingerprints of pure MBP samples were initially acquired by MALDI-MS 
using a Q-Star Pulsar / Quadrupole time-of-flight mass spectrometer (Applied 
Biosystems, UK). Initially peptide mass fingerprints of unknown samples were also 
acquired using the above instrument, however, due to the higher resolution achieved 
and ability to perform IMS-MS/MS subsequent experimental samples were analysed 
using HDMS SYNAPT ™ G2 system (Waters Corporation, UK).
MALDI IMS/MS and MALDI IMS-MS/MS were performed using a HDMS SYNAPT™ G2 
system (Waters Corporation, UK). Laura Cole (Sheffield Hallam University) provided 
support for acquisition of mass spectra and data interpretation. The instrument was 
used in positive ionisation mode. In order to achieve good quality MS/MS spectra, 
spectra were acquired by manually moving the laser position and adjusting the collision 
energy to achieve good signal to noise for product ions across the full m/z range of the 
spectrum. Collision energies were adjusted from 70 to 100 eV during acquisition and 
acquisition times were generally 5-10 seconds per spectrum. The resulting peaks 
obtained from the MS/MS spectra were uploaded in a text file format to perform a 
Mascot (Matrix Science, UK) search which used the UniProt database in order to 
generate a sequence match. Searches were performed with either Trypsin or Lys C 
specificity and two missed cleavages were allowed. Mass deviations for precursor ions 
and for fragment ions were set at 10 ppm and 0.75 Da, respectively.
4.2.6 Enzyme-linked immunosorbant assay (ELISA)
ELISA is used for both the detection and quantification of a specific antigen or antibody 
in a range of biological samples. In this method, an enzyme, which reacts with a
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colourless substrate to produce a coloured product, is covalently linked to a specific 
antibody that recognises a target antigen or antibody (Berg et al., 2002). If the antigen 
or antibody is present, the antibody-enzyme complex will bind to it, and the enzyme 
component of the antibody-enzyme complex will catalyse the reaction generating the 
coloured product. The presence of the coloured product indicates the presence of the 
antigen or antibody. There are several types of ELISAs, but an indirect ELISA and a 
sandwich ELISA are most commonly used. An indirect ELISA is used to detect the 
presence of an antibody whereas a sandwich ELISA is generally used for the detection 
of an antigen. This chapter uses an indirect ELISA (Figure 4.3). In the indirect ELISA 
specific proteins (antigens) are absorbed to the bottom of a well of a 96-well plate, 
serum or CSF containing antibodies of interest are then added to the coated well and 
allowed to bind to the antigen. Enzyme-linked antibodies that recognise human 
immunoglobulins are then added and bind to the target antibody. At each stage of the 
assay washes are performed to remove unbound antigen and antibodies. Lastly, a 
substrate is applied, resulting in a colour change which can be measured and is directly 
proportional to the amount of antibody present (Berg et al., 2002).
4.2.6.1 CSF and serum samples and ethical approval
In total paired CSF and serum samples were collected from 197 patients attending the 
Neurology Department at the Royal Hallamshire Hospital (RHH), Sheffield (Table 4.1). 
Ethical approval for this study was obtained from the Leeds West Research Ethics 
Committee (See Appendix 2). Informed consent was obtained from each patient 
participant by Consultant Neurologist, Dr Basil Sharrack. There were 36 patients with 
definite MS, 23 patients with inflammatory CNS, 69 patients with CNS disorders, 14 
patients with idiopathic intracranial hypertension (IIH), 33 patients with 
headache/migraine, and 20 control individuals.
4.2.6.2 Preparation and storage of CSF and serum samples
Following collection of paired CSF and serum samples from the RHH, CSF and blood 
samples were centrifuged for ten minutes at 3000 rpm (SorvaLL RT 6000D) at 4°C. 
CSF was then aliquoted into 1 mL Eppendorf tubes and stored at -80°C. Serum was 
removed from the top layer of the serum separator tube (SST) gold-topped tube and 
aliquoted into 500 pL Eppendorf tube for storage at -80°C.
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4.2.6.3 Detection of ACPAs using a commercial ACPA ELISA used for detection 
of these antibodies in RA
Patient CSF and serum samples were tested for the presence of RA-specific anti-cyclic 
citrullinated peptide (CCP) antibodies using a commercially available ELISA kit 
according to the manufacturers’ instructions (Axis-Shield, UK). Briefly, 100 pL serum 
samples and controls (diluted 1:100 in sample diluent), along with calibrators, were 
loaded in duplicate into a 96-well ELISA plate and left to incubate for 1 hour at RT. 
Subsequently, the contents were aspirated and wells washed four times with wash 
buffer, through quick inversion and blotting on a paper towel. 100 pL of conjugated 
secondary antibody was then added to each well and left to incubate for 30 minutes at 
RT, this was then aspirated and the plate washed four times, as described above. 
Following this, 100 pL of substrate was added to each well, and left to incubate for 30 
minutes avoiding direct sunlight. 100 pL stop solution was added to each well and left 
for 10 minutes at RT, and then the absorbance of wells was measured at 450 nm using 
a Wallac® plate reader. The OD reading of each patient sample was then plotted on a 
graph, grouped into disease type.
4.2.6.4 Antigens
As novel citrullinated peptides were not identified through mass spectrometry, three 
MBP peptide sequences containing citrulline residues were designed based on 
previous publications (Tranquill et al., 2000; De Seze et al., 2001) and the resulting 
peptides synthesised (Pepceuticals, UK) (Table 4.2).
4.2.6.5 Optimisation of ELISA
Initially eight known MS patient sera and CSF were used for optimisation, as this 
disease group was most likely to have the highest level of ACPAs. 1, 5 and 10 pg/well 
of peptides 1 and 2 were used to coat the 96-well plates. CSF samples were used both 
neat and diluted 1:5, whereas serum was diluted 1:50 and 1:200 before analysis by 
ELISA.
4.2.6.6 ELISA
ELISA was performed using 96-well microtitere plates (eBioscience, UK) coated with
500 pg/mL MBP-peptide solution in PBS overnight at 4°C (5 pg/well). Following this
plates were washed five times with 0.1% PBS-Tween (PBS-T) and blocked with 5%
BSA (Sigma, UK) in PBS for 2 hours at RT. Following this, plates were washed five
times with 0.1% PBS-T, followed by incubation with 100 pL of CSF (diluted 1:5) or
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seum (diluted 1 in 50) in 0.5% BSA in 0.1% PBS-T per well for 1 hour at RT. Plates 
were then washed five times with PBS-T, and incubated for a further one hour at RT 
with alkaline phosphatase-conjugated goat anti-human IgG (Fc specific) secondary 
antibody (Sigma, UK). Reaction products were then visualised with p- 
nitrophenylphosphate substrate (Sigma, UK) and the optical denisty was determined at 
405 nm after 90 minutes. All data were corrected by subtraction of the mean 
background values i.e. absorbance of wells coated with citrullinated MBP peptides and 
no serum/CSF. All samples were run in duplicate and an average OD value taken to 
allow for intra-assay variability.
4.2.6.7 Statistical analysis
Data obtained from the ELISA was analysed for any statistical significance between 
absorbance of the three peptides and between disease groups using a General Linear 
Model (GLM) followed by univariate analysis. To determine any correlation between 
absorbance of wells linear regression analysis was carried out. Statistical significance 
was set at p<0.05.
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Table 4.2: Citrullinated MBP peptides used as the antigenic substrate in ELISA 
assays.
Peptide 1 (MBP18.38) ASTMDHACitHGFLPRHRDTGIL
Peptide 2 (MBP115.131) SWGAEGQCitPGFGYGGCitA
Peptide 3 (MBP151.170)
I
SKIFKLGGCitDSRSGSPMARCit
Key: MBP; myelin basic protein
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4.3 Results
4.3.1 Identification of citrullinated peptides
Initially an in-gel tryptic digest was performed using pure MBP followed by analysis on 
the QStar /' Pulsar MALDI-TOF-MS as a positive control to ensure the technique was 
performed correctly. MS spectra obtained showed multiple peptide peaks which 
correctly corresponded to a number of theoretical digest peaks for MBP (Figure 4.4). 
Subsequently, in-gel tryptic digest was performed using SDS-PAGE bands excised at 
-18.5 and -50 kDa from MS058 P1D3 (Figure 4.5a-b) followed by analysis on the 
QStar /' Pulsar MALDI-TOF-MS. MS spectra obtained showed a number of peptide 
peaks which corresponded to a number of theoretical digest peaks for human GFAP 
(Figure 4.6a). However, MS spectra from an in-gel tryptic digest of a -  18.5 kDa band 
did not produce any peptide peaks which corresponded to theoretical digest peaks for 
MBP (Figure 4.6b). Trypsin cleaves polypeptides at both the lysine and arginine 
residues, and is therefore unable to cleave arginine residues that have been post- 
translationally modified to citrulline; therefore subsequent in-gel digests were 
performed using the endoproteinase Lys C which cleaves the carboxylic bond of lysine 
residues in proteins (Wada and Kadoya 2003) and analysis was performed using the 
Synapt G2 MALDI-IMS-MS. Initially an (NH4)2C 0 3 buffer was used during the in-gel 
digest and subsequent extraction of peptides; however, this produced very poor MS 
spectra (Figure 4.7a). Subsequently, changing the buffer to Tris-HCI produced high 
quality MS spectra with a number of peaks (Figure 4.7b). MALDI-MS without prior 
sample preparation using a Zip-Tip® resulted in a high background noise with 
dominant MALDI matrix adduct signals and smaller peptide signals observed at m/z of 
1491 and 1897 (Figure 4.8a). Sample preparation with a Zip-Tip® prior to sample 
spotting resulted in a low background noise with a significant reduction in the MALDI 
matrix adduct signals and a significant increase in peptide intensity at m/z 1491 and 
1897 (Figure 4.8b).
A number of MBP and GFAP peptides were positively identified from in-gel digests of 
bands corresponding to -18.5 and -15 kDa and -48 and -50 kDa, respectively (Table 
4.3). An example of MS spectra showing a peak corresponding to GFAP is shown in 
Figure 4.9a with subsequent MS/MS spectra showing positive identification of GFAP 
(Figure 4.9b). An example of MS spectra showing a peak corresponding to MBP is 
shown in Figure 4.10a with subsequent MS/MS spectra showing positive identification 
of MBP (Figure 4.10b). Citrullinated peptides were not identified.
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Figure 4.4: MALDI mass spectrum obtained following in-gel digestion of 
recombinant human MBP. MBP tryptic peptides at m/z 643, 698, 726, 760, 819, 
1051, 1339, 1460, 1538 and 1828 are highlighted based on theoretical human MBP 
tryptic digest peaks from Mascot.
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a) b)
Figure 4.5: Western blotting of MS brain tissue showing citrullinated proteins 
identified with F95 mAb and corresponding Instant Blue® SDS-PAGE gel. (a)
western blot showing the presence of citrullinated protein bands using protein extracted 
from MS058 P1D3 and (b) corresponding Instant Blue® SDS-PAGE gel. Red arrows 
indicate bands of interest that were excised for in-gel digestion and subsequent mass 
spectrometry for protein identification.
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4.3.2 Detection of RA-specific ACPAs
No significant differences in patient sera immunoreactivity were observed between the 
disease groups, with the mean absorbance readings of -0.10 for all groups (Figure 
4.11a). The inflammatory CNS disease group and the MS group showed slightly higher 
CSF immunoreactivity to citrullinated proteins compared to the other disease groups; 
however there was no statistical significance (Figure 4.11b).
4.3.3 Optimisation of MBP ELISA
Initial optimisation using eight known MS patient serum samples and citrullinated MBP 
(cit-MBP) peptide 1 showed that diluting the serum 1 in 50 produced higher 
absorbance readings than a 1 in 200 dilution, with a greater spread of data points 
(Figure 4.12a-b). There was very little difference in the absorbance values obtained 
when coating the ELISA plate with 1, 5 or 10 pg peptide 1 (Figure 4.12a). Much higher 
absorbance values were obtained when using the secondary antibody diluted 1 in 1000 
compared to 1 in 5000 (Figure 4.11a). Similar results for these variables were obtained 
when using peptide 2 to coat the ELISA plates (Figure 4.13a-b).
The corresponding CSF samples from the 8 MS patients were also used for 
optimisation and cit-MBP peptide 1. Using neat CSF produced higher absorbance 
values than using CSF diluted 1 in 5 (Figure 4.12c-d). Lower absorbance values were 
obtained when coating the ELISA plate with 1 pg of peptide 1, whereas similar 
absorbance readings were observed when using either 5 or 10 pg peptide 1 (Figure 
4.12c-d). Higher absorbance values were obtained when using the secondary antibody 
at a 1 in 1,000 dilution compared to 1 in 5,000 (Figure 4.12c-d) as expected. Identical 
results were obtained when using cit-MBP peptide 2 to coat the ELISA plates (Figure 
4.13c-d).
Based on these results it was decided that serum would be diluted 1 in 50 and CSF 
would be diluted 1 in 5 for all subsequent analyses by ELISA. It was decided that 5 pg 
of peptide would be used to coat the ELISA plates and the secondary antibody would 
be used at a dilution of 1 in 1000.
218
Figure 4.11: Analysis of immune response by ELISA to RA-specific citrullinated 
peptides in patients with MS, other neurological disorders and controls, (a) sera 
and (b) CSF. Data is presented as a scatter plot with each symbol representing an 
individual patient {n -197). The solid line indicates the mean absorbance value. Data 
was analysed for any statistical significance between absorbance values for each 
peptide and between disease groups using a General Linear Model followed by 
univariate analysis using SPSS. Statistical significance was set at p<0.05.
Key: CNS; central nervous system, IIH; idiopathic intracranial hypertension, Nl; non­
inflammatory.
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Figure 4.12: Optimisation of citrullinated MBP peptide ELISA, (a) serum 1 in 50 (b)
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The solid line indicates the mean absorbance value.
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4.3.4 Detection of MS-specific ACPAs
Serum immunoreactivity towards cit-MBP peptide 1 was slightly higher in patients with 
CNS disorders and controls compared to other disease groups, however these results 
were not statistically significant (Figure 4.14a). This higher serum immunoreactivity in 
CNS disorders and controls was also observed against peptide 2 and 3, however 
statistical significance was not reached (Figure 4.14b-c).
CSF immunoreactivity towards cit-MBP peptide 1 was slightly higher in patients with IIH 
compared to other disease groups and controls, however, this difference was not 
statistically significant (Figure 4.15a). Interestingly, CSF immunoreactivity towards both 
cit-MBP peptide 2 and 3 was higher in patients with MS compared to other disease 
groups and controls, however this difference was not statistically significant (Figure 
4.15b-c).
Using linear regression analysis, a strong relationship was shown to exist between 
serum immunoreactivity for peptide 1 and 2 (R2 = 0.9120) (Figure 4.16a). This strong 
relationship was also observed between serum immunoreactivity for peptide 1 and 3 
(R2 = 0.8268) (Figure 4.16b). Lastly, a strong relationship between serum 
immunoreactivity of peptide 2 and 3 was also observed (R2 = 0.8453) (Figure 4.16c). 
This showed that where high absorbance readings were observed against one peptide 
it was highly likely that a high absorbance reading would also be observed against a 
different peptide.
A weak relationship was observed in CSF absorbance values between peptide 1 and 2 
(R2=0.1415) (Figure 4.17a). A weak relationship was also observed in CSF absorbance 
values between peptide 1 and 3 (R2 = 0.2721) (Figure 4.17b). Lastly, a weak 
relationship was also shown to exist between CSF absorbance values between peptide 
2 and 3 (R2=0.3139) (Figure 4.17c).
No statistically significant relationship was observed between high immunoreactivity to 
peptide 1 and the presence or absence of OCBs (Figure 4.18a). A statistically 
significant relationship was shown to exist between high immunoreactivity to peptide 2 
and the presence of OCBs (p=0.002) compared to readings obtained from individuals 
who tested negative for OCBs (Figure 4.18b). This relationship was also shown to exist 
between high immunoreactivity to peptide 3 and the presence of OCBs (p=0.004) 
compared to readings obtained from individuals who tested negative for OCBs (Figure 
4.18c).
No relationship was observed between the albumin/IgG ratio and serum 
immunoreactivity towards peptides 1, 2 and 3 (R2 = 0.01518, 0.01682 and 0.008834,
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respectively) (Figure 4.19a-c). A weak correlation was found between the albumin/IgG 
ratio and CSF reactivity to peptide 1, 2 and 3 (R2 = 0.08996, R2 = 0.1698 and R2 = 
0.3004, respectively) (Figure 4.20a-c). This showed that the albumin/IgG ratio did not 
affect the level of ACPAs detected.
A weak relationship was shown to exist between the serum IgG concentration and 
serum immunoreactivity to peptides 1, 2 and 3 (R2 = 0.1190, R2 = 0.1279 and R2 = 
0.1475, respectively) (Figure 4.21 a-c). Similarly, a weak relationship was also exhibited 
between the CSF IgG concentration and corresponding CSF immunoreacitivity to 
peptides 1, 2 and 3 (R2 = 0.1631, R2 = 0.1722 and R2 = 0.4959, respectively) (Figure 
4.22a-c), but was strongest for peptide 3.
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Figure 4.14: Analysis of immune response by ELISA to different citrullinated 
MBP peptides in the sera of patients with MS, other neurological disorders and 
controls, (a) peptide 1 (b) peptide 2 and (c) peptide 3. Data is presented as a scatter 
plot with each symbol representing an individual patient {n= 197). The solid line 
indicates the mean absorbance value. Data was analysed for any statistical 
significance between absorbance of peptides and between disease groups using a 
General Linear Model followed by univariate analysis. Statistical significance was set at 
p< 0.05.
Key: CNS; central nervous system, IIH; idiopathic intracranial hypertension, Nl; non­
inflammatory.
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Figure 4.15: Analysis of immune response by ELISA to different citrullinated 
MBP peptides in the CSF of patients with MS, other neurological disorders and 
controls, (a) peptide 1 (b) peptide 2 and (c) peptide 3. Data is presented as a scatter 
plot with each symbol representing an individual patient (n=197). The solid line 
indicates the mean absorbance value. Data was analysed for any statistical 
significance between absorbance of peptides and between disease groups using a 
General Linear Model followed by univariate analysis. Statistical significance was set at 
p< 0.05.
Key: CNS; central nervous system, IIH; idiopathic intracranial hypertension, Nl; non­
inflammatory.
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Figure 4.16: Correlation between patient sera antibodies against different cit- 
MBP peptides by ELISA, (a) peptide 1 versus peptide 2, (b) peptide 3 versus peptide 
1 and (c) peptide 3 versus peptide 2 (n=197). Correlation coefficients (R2) were 
determined using linear regression analysis.
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Figure 4.17: Correlation between patient CSF antibodies against different cit- 
MBP peptides by ELISA, (a) peptide 1 versus peptide 2, (b) peptide 3 versus peptide 
1 and (c) peptide 3 versus peptide 2 (n=197). Correlation coefficients (R2) were 
determined using linear regression analysis.
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Figure 4.18: CSF Absorbance values by ELISA from patients with and without 
oligoclonal bands (OCBs). (a) peptide 1, (b) peptide 2, (c) peptide 3. Data is 
presented as the spread of absorbance values with each bar representing 95% 
confidence interval for the mean of each group (n=138; 34 positive for OCBs and 118 
negative for OCBs). The central circle represents the mean. Data was analysed for any 
statistical significance between absorbance of peptides and between disease groups 
using a General Linear Model followed by univariate analysis. Statistical significance 
was set at *p<0.05.
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Figure 4.19: Correlation between patient albumin/IgG ratio and patient serum 
antibodies to cit-MBP peptides, (a) peptide 1, (b) peptide 2 and (c) peptide 3 
(n=137). Correlation coefficients (R2) were determined using linear regression analysis.
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Figure 4.20: Correlation between patient albumin/IgG ratio and patient CSF 
antibodies to cit-MBP peptides, (a) peptide 1, (b) peptide 2 and (c) peptide 3 
(n=137). Correlation coefficients (R2) were determined using linear regression analysis.
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Figure 4.21: Correlation between patient serum IgG concentration and patient
serum antibodies to cit-MBP peptides, (a) peptide 1, (b) peptide 2 and (c) peptide 3
(n=158). Correlation coefficients (R2) were determined using linear regression analysis.
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Figure 4.22: Correlation between patient CSF IgG concentration and patient CSF 
antibodies to cit-MBP peptides, (a) peptide 1, (b) peptide 2 and (c) peptide 3 
(n=152). Correlation coefficients (R2) were determined using linear regression analysis.
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4.4 Discussion
4.4.1 Citrullinated peptide detection by mass spectrometry
Mass spectrometry was able to confirm the presence of GFAP and MBP from excised 
bands; however, no citrullinated peptides were identified. The positive identification of 
GFAP from bands excised at both -48 and -50 kDa confirmed previous results of the 
immunohistochemistry and western blotting where citrullinated GFAP was readily 
detectable in MS tissue (Chapter 3). The positive identification of MBP from bands 
excised at both -15 and -18.5 kDa confirmed that MBP is also citrullinated.
The detection of citrullinated peptides through MS/MS is difficult due to the 1 Da shift 
following citrullination, which often falls within the isotope peak range of the 
uncitrullinated peptide, if both are present in the same sample, which is a problem most 
likely to occur in in vivo tissue samples (De Ceuleneer et a i, 2012). In this case, both 
versions of the peptides will therefore be selected for MS/MS, since the m/z window 
used for data-dependent analysis is usually wide enough to encompass isotope peaks 
to enhance sensitivity. Fragment peaks from both peptides will consequently be 
present in the MS/MS spectrum and may hamper correct interpretation (De Ceuleneer 
et a i, 2012). Furthermore, citrullination is a PTM known to be of low abundance and 
difficult to detect (Hermansson et al., 2010), therefore when in a mixed sample 
containing unmodified proteins, the peptide peaks containing citrulline may be much 
smaller and become masked by the large unmodified peptide peaks, again making 
detection of citrullinated peptides difficult.
A further difficulty in relying upon this 1 Da mass shift to detect citrullinated peptides is 
that some peptides may contain asparagine or glutamine, which upon deamidation 
yield the same mass shift as citrullination, and also have a similar retention time shift 
compared to the unmodified peptide (Hermansson et a i, 2010). Although MS/MS can 
distinguish between deamidation and deimination (citrullination), MS/MS data on 
citrullinated peptides from in vivo samples is frequently missing or of poor quality 
therefore resulting in the incorrect selection of deamidated peptides for subsequent 
peptide identification (Hermansson et ai, 2010).
Mass spectrometry has become the method of choice for the analysis of post- 
translationally modified proteins and peptides. Peptides carrying a given PTM are, 
however, usually present in small amounts and in heterogenous mixtures, making their 
characterisation challenging. Therefore, methods which allow a more targeted analysis 
of PTM polypeptides have been developed (Stensland et al., 2009). A specific
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modification can pinpoint the presence of citrullinated peptides much more clearly than 
the method relying on the 1 Da mass shift (De Ceuleneer et al., 2011).
Methods are now available which can specifically modify citrulline residues to enable 
their detection. An example of this is the modification of the ureido group of a citrulline 
residue by 2,3-butanedione and antipyrine, which results in a specific +238 Da mass 
shift that is easily detected by a mass spectrometer. In a recent study a synthetic 
peptide sequence (human vimentin 65-77) containing a citrulline residue was modified 
in this manner and analysed by QTOF instrumentation. Fragmentation of a doubly 
charged peptide observed at 790.918 produced a modification-derived fragment ion at 
m/z 201.104 as the dominant signal. However, sequence-specific fragments containing 
modified citrulline were of very low intensity. As the fragment at m/z 201.1 is derived 
from chemically modified citrulline residues, it may be used as a particular signature ion 
for the detection of peptides carrying derivatised citrulline residues. However, the 
favoured generation of this fragment resulted in a lack of b- and y-ions and therefore 
compromises peptide identification, as there was not sufficient information to identify 
the sequence of the selected precursor ion and citrullination site (Stensland et al.,
2009). In addition, this modification requires large amounts of peptides, where the 
amount of citrullinated peptides will only be a fraction of the total protein content of the 
sample (De Ceuleneer et al., 2012). Thus future work could apply to the use of 2,3- 
butanedione with CNS cell extracts to increase the sensitivity of the mass spectrometry 
detection of citrullinated CNS proteins.
An alternative approach would be to select only citrullinated proteins prior to mass 
spectrometry analysis, through the selective immobilisation of specifically modified 
citrullinated peptides with 4-hydroxyphenylglyoxal immobilised on beads (Tutturen et 
al., 2010). With this technique, citrullinated peptides could selectively be enriched from 
protein digests by cross-linking them to beads with guanidine and afterwards cleaving 
the modified peptide. This results in a less complex mixture of citrullinated peptides that 
can then be spotted onto a MALDI plate.
A previous study has shown that with very low peptide concentration samples, reducing 
the matrix concentration further improves peptide ionisation and peptide fragmentation 
(Zhu and Papayannopoulos 2003). In this study, three additional peptides from a BSA 
trypsin digest were observed with 2 mg/mL a-CHCA compared with 5 mg/mL a-CHCA, 
with the presence of more abundant and numerous MS/MS fragment ions from these 
peptides, resulting in more complete peptide sequences allowing for higher protein 
scores to be obtained (Zhu and Papayannopoulos 2003). In this study 5 mg/mL a- 
CHCA was used, reducing the matrix concentration to 2 mg/mL may have improved the 
mass spectra obtained and subsequent protein identifications.
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It may have also been useful to remove abundant proteins from the MS tissue extract 
prior to SDS-PAGE and in-gel digestion using a multiple affinity removal spin cartridge 
for the depletion of high-abundant proteins (Hermansson et al., 2010). This would have 
left an enriched pool of low-abundant proteins, which would have prevented abundant 
proteins from interfering with identifications of less abundant proteins in the sample.
Hermansson and colleagues (2010), using synovial tissue extracts and subsequent in­
gel digestion of bands which matched the in vitro citrullinated fibrinogen a- and (3- 
chains in size, were excised and in-gel digested with endoproteinase Lys C. The 
resulting peptide mixtures were subjected to HPLC-MS/MS and analysed for presence 
of citrullinated peptides. This approach identified the a- and (3-chains of fibrinogen in 
the sample but no citrullinated peptides were detected by global MS/MS analysis, 
which indicated low levels of citrullination and the necessity to apply a targeted 
approach.
The method of peptide fragmentation is also important in the identification of 
citrullinated peptides, as many PTMs are not stable. A recent study showed that 
citrullinated BSA peptides were unstable following CID, with only two small signals 
assigned to fragments which had maintained the citrulline modification (Stensland et 
al., 2009). In the same study electron-transfer dissociation (ETD)-based fragmentation 
maintained the modification and resulted in spectra with nearly complete sequence 
coverage compared to CID-based fragmentation and the identification of three 
additional citrullination sites (Stensland et al., 2009). Therefore, it may have been 
useful to compare different fragmentation techniques.
Analysis of citrulline-containing peptides is also possible without chemical 
derivatisation. With modern LC/MS/MS instrumentation citrullinated peptides can be 
separated from their non-deiminated counterparts and the high resolution and mass 
accuracy allow their identification by CID (Stensland et al., 2009). The slight change in 
hydrophobicity caused by the loss of a protonated arginine side chain will cause a 
higher retention on reverse phase-LC (RP-LC) columns for citrullinated peptides. 
However, this approach requires extensive optimisation for every peptide of interest 
and is therefore less practical for use in a shotgun proteome analysis (Hermansson et 
al., 2010). It may have been useful to have carried out RP-LC prior to mass 
spectrometry to separate the non-citrullinated and citrullinated peptides. However, this 
equipment was not available.
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4.4.2 ACPAs were not significantly different in MS
In this study there were no significant differences in the level of ACPAs in patients with 
MS compared to those with other ONDs and non-neurological controls using a 
commercial ELISA designed for RA. On the basis of ACPA in RA it was anticipated that 
antibodies towards citrullinated MBP may be raised at disease onset, as 
immunohistochemistry results on MS CNS tissue suggests citrullination (see chapter 3) 
precedes demyelination, it was predicted that antibodies towards citrulline would occur 
early in the disease course and contribute to the demyelination which is a classical 
hallmark of MS. ACPAs were slightly higher against citrullinated MBP peptides 2 and 3 
in CSF from patients with MS compared to other neurological disease and non- 
neurological controls, but this was not significant. Interestingly, higher CSF ACPA 
levels towards both citrullinated MBP peptides 2 and 3 were significantly associated 
with patients that tested positive for OCBs, whereas those with lower ACPA levels were 
significantly associated with patients that tested negative for OCBs. This provided a 
good indication that absorbance values were not due to non-specific binding of IgG in 
the CSF. Furthermore, these results suggest that the antibody response towards 
citrullinated proteins is restricted to the CSF, i.e. intrathecal antibody production, and is 
not a peripheral immune response and indicates that patients with these OCBs contain 
antibodies against citrulline residues. In addition, these findings also support the B cell 
follicle hypothesis (Serafini et al., 2004).
MBP has been described as a potential target for autoimmune reactivity in MS (Reindl 
et al., 1999). However, previous studies have also failed to detect significantly high 
levels of ACPAs towards MBP in serum and CSF of MS patients compared to ONDs 
and controls (De Seze et al., 2001). In fact De Seze and colleagues (2001) showed 
that the physiological substitution of only one arginine residue with citrulline at the 
MBP-122 position of this peptide dramatically reduced the immune response in MS 
patients, whereas this response did not alter the immune recognition in sera and CSF 
of patients with ONDs (De Seze et al., 2001). In comparison, this group did not detect 
any significant modification of immune reactivity to the citrullinated MBP151.170 epitope in 
either CSF or sera of MS patients. Whereas, a previous study showed a higher 
peripheral T-cell response to the citrullinated MBP15-m70 epitope in MS compared to 
control subjects (Tranquill et al., 2000). However, in this latter study, comparative 
evaluation between unmodified and citrullinated MBP epitopes was not performed. The 
current study and previous studies have only focussed on physiologically citrullinated 
MBP peptides, and not on the entire human MBP-C8.
In addition, immunohistochemical and western blot studies using an antibody specific
to all deca-citrullinated peptides have shown the predominance of citrullinated GFAP
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as opposed to MBP in MS brain tissue, therefore the predominant immune response to 
citrullinated proteins may be directed towards GFAP positive astrocytes rather than 
MBP. However, due to being unable to identify citrullinated GFAP peptides through 
mass spectrometry in this study, and therefore determine which specific arginine amino 
acids are citrullinated in GFAP, specific citrullinated GFAP peptides could not be used 
to coat the wells of an ELISA plate for this study and no other studies have reported 
this information to date.
Previous ELISA studies have included controls and compared binding to BSA and the 
specific peptide to check for non-specific binding of patient antibodies by coating wells 
with BSA (De Seze et al., 2001). This control procedure was not carried out in this 
study, but a blocking step was employed prior to incubation with patient serum and 
CSF which should have prevented any non-specific binding of antbodies. In addition, 
there were weak correlations observed between ACPA levels in CSF and all three 
citrullinated MBP peptides, i.e. a high ACPA response of a patient to peptide 1 did not 
predict a high ACPA response to peptides 2 and 3, suggesting that the antibody 
binding within the wells was not due to non-specific binding. However, there were 
srong correlations between ACPA levels in serum for all three citrullinated MBP 
peptides, i.e. where there was a high ACPA response to peptide 1 this was also 
observed towards peptides 2 and 3. This could indicate non-specific binding of patient 
serum antibodies to the citrullinated peptides, but could also indicate a genuine 
antibody response to all citrullinated peptides.
Although antibody reactivities would be attractive for use as biomarkers to predict 
relapses or progression in MS, no antibody that is specific to MS has yet been 
identified. This may be in part due to shortcomings in the assays used to determine 
antibody responses to CNS proteins. Especially to membrane proteins which are highly 
folded, and are the conformational epitope targets of autoantibodies, which are not 
preserved in conventional assays such as ELISA or western blot. This problem has 
been recently overcome by cell-based assays, in which MOG is expressed by a 
transfected cell line. Serum antibodies to native MOG were observed in a subgroup of 
patients using this assay (Lalive et al., 2006; Zhou et al., 2006). Interestingly, high 
antibody titres to native MOG were recently reported in two independent studies in 
paediatric CIS, ADEM, and MS (O'Connor et al., 2007; McLaughlin et al., 2009). The 
use of whole myelin particles also revealed a more frequent positive reactivity in MS 
and CIS patients (Vogt et al., 2009).
Previous studies have shown sample antigenicity is affected by changes in the 
composition of the buffers used to immobilise proteins to the ELISA plate wells (Miura 
et al., 2012). Furthermore, to develop a more sensitive and reliable ELISA-based
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diagnostic tests for RA, synthetic cyclic citrullinated filaggrin peptides were used in the 
anti-CCP assay (Schellekens et al., 2001). This cyclisation forces the peptide to adopt 
a (3-hairpin conformation, as cysteine-bridged cyclic peptides have been shown to 
mimic the (3-turn structure of the antigenic epitope, and therefore antibodies bind these 
with enhanced affinity (Dorow et al., 1985). Furthermore, in these cyclic peptides, the 
citrulline moiety is optimally exposed for antibody binding (Vossenaar and van Venrooij 
2004). In this current study only linear citrullinated peptides were used to coat the 
ELISA wells, therefore, the use of CCPs may be necessary in order for sufficient 
binding of antibodies to occur. Another possible reason for the low level reactivity to 
citrullinated peptides in the CSF of patients with MS may be that these autoantibodies 
are largely bound to their tissue targets, rather than freely soluble within the CSF 
(Cross and Waubant 2011).
Furthermore, MS is very heterogenous with respect to histopathological changes 
(Lucchinetti et al., 2000), CSF phenotype (Cepok et al., 2001), disease course 
(Noseworthy et al., 2000), and response to therapy. Accordingly, different mechanisms 
may play a role in demyelination. Not all patients might have a prominent antibody 
response, or specific autoantibodies may characterise distinct clinical entities (Weber et 
al., 2011).
4.4.3 Conclusion
The identification of citrullinated proteins by mass spectrometry is inherently difficult, as 
shown by this study and previous studies, due to low levels of citrullinated peptides in 
tissue extracts and the small mass shift caused by the conversion of arginine to 
citrulline within the protein. The results of the ELISA assay employing citrullinated MBP 
peptides showed increased reactivity of MS patient CSF Igs towards certain 
citrullinated MBP peptides which has provided promising preliminary results. However, 
further controls and optimisation of the assay is needed to further define these antibody 
specificities, and possibly the recruitment of larger patient groups. Future research to 
investigate specific arginine residues that are citrullinated in GFAP may provide a 
better target to which antibodies towards citrulline residues may bind, as results of 
western blotting and immunohistochemistry on MS post-mortem brain tissue have 
indicated that citrullination occurs to a much greater extent in GFAP as opposed to 
MBP, as described in chapter 3.
Chapter 5
General Discussion
5.1 General Discussion
The main overall aim of this thesis was to investigate the role of PADs and citrullination 
in the pathogensis of MS. This involved a four-pronged approach. The first part of this 
study involved an in vitro investigation into the expression of PADs in cells of the CNS 
and treatment of these cells with pro-inflammatory cytokines to determine if cytokines 
are involved in the modulation of PADs. The second part of the study involved a 
detailed investigation into the expression of PADs and citrullinated protein in post­
mortem MS and control brain tissue in order to determine the cell types which have 
citrullinated proteins and determine any differences in the levels of citrullination 
between MS and control individuals. The third part involved using mass spectrometry 
to identify any novel citrullinated proteins from MS brain tissue extracts, which could be 
used to develop an in-house ELISA assay for the detection of ACPAs in individuals 
with MS. The final part involved the determination of ACPAs in the serum and CSF of 
individuals with MS, other neurological diseases and controls, using ELISA, in order to 
determine if higher levels are associated with MS.
Previous studies have shown an increase in PAD2 and PAD4 expression along with an 
increase in citrullination in MS brain tissue compared to control brain tissue (Moscarello 
et al., 1994; Wood et al., 1996; Wood et al., 2008). Due to this direct association 
between the expression of PADs and the increase in citrullination, a number of studies 
have attempted to understand what factors lead to this increase in the PAD enzymes. 
Studies have identified that PADs are calcium-dependent enzymes and therefore high 
levels of PAD are required for their subsequent activation (Vossenaar et al., 2004). 
Other studies have identified additional environmental conditions which can lead to 
PAD activation, including hypoxia, kainic acid and pressure (Asaga et al., 2002; 
Sambandam et al., 2004; Bhattacharya et al., 2006a; Bhattacharya et al., 2006b). 
However, studies investigating the involvement of pro-inflammatory cytokines, which 
are significantly increased in MS brains (for review see (Imitola et al., 2005), in the 
modulation of PADs are limited. A previous study has shown citrullination to be rapidly 
induced in neutrophils following exposure to the pro-inflammatory cytokine TNF-a 
(Neeli et al., 2008). Furthermore, TNF-a has been shown to be necessary for 
translocation of PAD4 to the nucleus (Mastronardi et al., 2006).
The findings reported in this thesis suggest that pro-inflammatory cytokines are either 
not involved in the modulation of PAD2 or implicate an anti-inflammatory role for PAD2, 
as significant down-regulation in PAD2 mRNA expression was observed following 
cytokine treatment with IL-1 (3, TNF-a and IFN-y in astrocytes and microglia. Down- 
regulation of PAD2 mRNA in brain endothelial cells was only observed following
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treatment with TNF-a. Overall, dual treatment of these cytokines also resulted in 
significant down-regulation in PAD2 mRNA in astrocytes, microglia and brain 
endothelial cells. This indicates that pro-inflammatory cytokines are not involved in the 
up-regulation of PAD2 and that additional mechanisms may be involved in the 
modulation of PAD2. Additional mechanisms have been identified which are important 
in this transcriptional regulation of PAD2 at the mRNA level. Previously, the PAD2 
promoter in MS brains has been shown to be hypomethylated compared to control 
brains, leading to increased transcription of PAD2 (Mastronardi et al., 2007). 
Furthermore, PAD2 protein was also shown to be upregulated in MS NAWM compared 
to control white matter (Mastronardi et al., 2007). Calcium has also been shown to be 
involved in the recruitment of transcription factors to the PAD2 gene, resulting in the 
transcription of PAD2 (Dong et al., 2005). It is difficult to reproduce in vitro the complex 
inflammatory milieu within the CNS during inflammation and demyelination, however, 
based on the data obtained in this thesis pro-inflammatory cytokines downregulate 
PAD2 mRNA expression.
A limitation of this current study is that only PAD2 mRNA expression was investigated. 
mRNA levels do not always reflect protein levels (Bhattachyra et al., 2006). Previous 
studies investigating PAD2 expression have shown that the enzyme can be present at 
the protein level and absent at the mRNA level (Vossenaar et al., 2004). mRNA is 
much less stable than protein, therefore, protein expression may have given a better 
indication of whether cytokines are involved in the modulation of PAD2, as proteins 
have a much longer half-life than mRNA (Gygi et al., 1999). Furthermore, PAD2 activity 
was not investigated, which would have provided information on the actual activity of 
the enzymes, and hence ability to citrullinate CNS proteins.
This study investigated single cell types grown in media, and did not determine the 
effects of co-cultures on the expression of PAD2 mRNA. It is important to consider the 
reciprocal communication between different cell types, such as astrocytes and 
neurons, in the in vivo situation (Carmignoto 2000). Expression of PADs may require 
communication between these different cell types in order for modulation of PAD2 to 
occur. In normal physiology, astrocytes have been shown to play a decisive role as the 
linker between neurons and blood vessels (Zonta et al., 2003; Fellin and Carmignoto 
2004; Fellin 2009) and to act to supply oxygen and energy via internal stores and 
vasodilation to support neuronal activity (Zonta et al., 2003; Brown and Ransom 2007). 
These mechanisms are involved in increases in intracellular Ca2+ in astrocytes, and 
these events trigger Ca2+ waves to neighbouring astrocytes (Cornell-Bell et al., 1990; 
Zonta et al., 2003; Fiacco and McCarthy 2006). Therefore Ca2+ signalling as a result of
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interactions of astrocytes with neurons may be necessary in order for PAD2 to become 
activated in vitro.
Previous studies have shown the expression of citrullinated proteins to be increased in 
MS brain tissue compared to control brains, and that this is associated with increased 
expression of PAD2 and PAD4 enzymes in the brains of these individuals (Mastronardi 
et al., 2006; Wood et al., 2008). The results from this thesis confirmed previous 
findings, that citrullination is increased in MS brain tissue compared to control brain 
tissue. However, this study also identified that citrullination is highest in the lesion 
edges where myelin is either thining or where active demyelination is occurring rather 
than associated with areas of complete myelin loss. The findings of this study indicate 
that citrullination of MBP precedes demyelination in MS, which agrees with the 
proposed hypothesis that citrullination of MBP precedes myelin loss leading to a 
conformational change in the structure of myelin resulting in direct demyelination and 
also exposure of new epitopes not recognized by the immune system as self. This 
contributes to earlier studies which have shown that up to 45-90% of MBP in patients 
with MS is citrullinated compared to only 18% in control individuals (Moscarello et al., 
1994; Wood et al., 1996). A number of studies have shown that deiminated MBP is 
unable to compact lipid bilayers, causing membrane destabilisation, thereby, possibly 
promoting demyelination (Brady et al., 1981; Wood and Moscarello 1989; Boggs et al., 
1999; Beniac et al., 2000). In addition, deiminated MBP is more susceptible to 
proteolytic digestion by myelin-associated proteases (Cao et al., 1999; Pritzker et al., 
2000; D’Souza and Moscarello 2006; Musse et al., 2006). This greater surface 
exposure and greater enzymatic cleavage of the citrullinated protein would lead to 
increased release of the immunodominant epitope, which could prime the innate 
immune cells of the CNS and sensitize peripheral blood T cells (Musse et al., 2006; 
Musse and Harauz 2007). These results reported in this thesis support previous 
studies as at sites of ongoing demyelination there is an increase in citrullinated 
proteins.
Previous studies have focused on citrullination and its association with MBP 
(Moscarello et al., 1994; Wood et al., 1996; Mastronardi and Moscarello 2005; Wood et 
al., 2008); however, in this study citrullination was shown to be predominantly 
associated with GFAP, the structural component of astrocytes. This agrees with a 
pervious study carried out by Nicholas et al. (2004) which also showed the co­
localisation of citrulline with GFAP in the NAWM of MS brain tissue. However, Nicholas 
et al. (2004) showed increased citrullination in the NAWM, whereas in this study the 
highest levels of citrullination were observed in areas of myelin thining and ongoing 
demyelination. The reasons for this difference between this latter study and this study
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are unclear, except that in the study by Nicholas et al. (2004) only three MS blocks 
were used as opposed to this study where 12 blocks were used. In addition, Nicholas 
et al. did not characterise the tissue sections using H&E, ORO, HLA-DR and MOG or 
any other markers prior to staining for citrullinated proteins. Due to the tissue sections 
in this latter study not undergoing classification, it seems possible that the NAWM may 
have actually contained lesions.
Similarly, post-mortem immunohistochemical studies investigating citrullination in sCJD 
have also shown increased citrullinated proteins in sCJD infected brains compared to 
control brains, with these citrullinated proteins mostly co-localised with GFAP-postive 
astrocytes (Jang et al., 2010). Reactive gliosis is accompanied by activation and 
upregulation of various proteins with potent biological effects, including L-type Ca2+ 
channels, various receptors, PAD2 and its well known substrates including GFAP 
(Aronica et al., 2001; Jang et al., 2008). Although citrullinated forms of astrocyte- 
specific GFAP have been reported in various neurodegenerative conditions, a 
functional role for citrullinated GFAP in the CNS has not been elucidated (Nicholas et 
al., 2004; Ishigami et al., 2005; Jang et al., 2008). It remains unknown whether the 
accumulation level of citrullination is different amongst different neurodegenerative 
conditions and whether specific citrullinated proteins are present in these 
neurodegenerative conditions.
GFAP is the main intermediate filament protein in mature astrocytes and is involved in 
a number of structural and functional processes, including motility, proliferation, vesicle 
trafficking, autophagy and synaptic interactions with neurons (Middeldorp and Hoi 
2011). GFAP is also thought to play an important role in astrocyte motility, with motility 
of GFAP-/- astrocytes shown to be greatly reduced compared to GFAP-expressing 
astrocytes (Lepekhin et al., 2001). Vesicle trafficking has also been shown to be 
reduced in astrocytes from mice with double knock-out of GFAP and vimentin (Potokar 
et al., 2007; Potokar et al., 2008). Neuronal activity is closely linked to the release and 
uptake of the neurotransmitter glutamate, which requires the interaction between 
astrocytes and neurons. Glutamate transporters have been identified on neuronal and 
astrocytic membranes and are important for removal of extracellular glutamate (Pines 
et al., 1992; Storck et al., 1992; Rothstein et al., 1994). GFAP plays a key role in 
modulating astrocytic and neuronal glutamate transporter trafficking and function and in 
the control of glutamine production. In cortical and hippocampal synaptosomal 
preparations from adult GFAP-/- mice a reduced glutamate uptake was found together 
with decreased glutamate transport activity (Hughes et al., 2004). GFAP is subjected to 
multiple post-translational modifications that have important consequences for its 
structure and functions. Although the exact effect of citrullination of GFAP in astrocytes
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is currently unknown, it may have detrimental effects on a number of these 
physiological processes described above, such as reducing astrocyte motility and 
vesicle trafficking, preventing the phosphorylation of GFAP during cell proliferation 
(Inagaki et al., 1994), or affect the ability of astrocytes to effectively remove glutamate 
from the extracellular environment leading to neuronal glutamate excitotoxicity, 
contributing to pathological processes in MS (Bak et al., 2006).
Previous studies have shown the increased expression of PAD2 and PAD4 at both the 
mRNA and protein level in MS lesions compared to controls; with studies showing its 
co-localisation with astrocytes and microglia (Vincent et al., 1992; Asaga et al., 2001; 
Ishigami et al., 2002). In this study no difference in the expression of PAD2 at the 
protein level was observed between MS lesional tissue, MS NAWM and control brain 
tissue. Furthermore, PAD2 expression was shown to co-localise with some but not all 
microglia and was not co-localised with astrocytes. PAD4 staining was very difficult to 
identify above background level. These findings were unexpected as based on 
previous studies it was anticipated that PAD2 would be upregulated in MS lesions and 
would be associated with microglia and astrocytes. However, there were difficulties 
with the anti-human PAD2 antibody used even following stringent optimisation, as 
staining was generally weak even when the highest concentration of antibody was 
applied to the tissue section. A second primary antibody against PAD2 was also tested 
with similar results. Furthermore, the isotype control also showed very high levels of 
staining. Although the staining was less intense than for the PAD2 antibody, the results 
of the PAD2 staining should still be treated with caution. Similarly, a second antibody 
against human PAD4 was also tested, but specific staining above background levels 
was not observed, and corresponding isotype control showed similar non-specific 
staining. Obtaining anti-human PAD2 and PAD4 primary antibodies was problematic as 
the majority of previously published work showing high immunostaining for these 
enzymes used antibodies that had been produced in-house by the research groups 
themselves and were not available commercially. Furthermore, both PAD2 and PAD4 
mRNA was shown to be present in control, MS NAWM and MS lesional brain tissue; 
although the expression of PAD2 was relatively low and PAD4 was 100-fold lower than 
the expression of PAD2 mRNA.
Through the use of western blotting of brain homogenates from an MS brain block 
known to contain high levels of citrullinated proteins, multiple proteins in the brain were 
shown to be citrullinated. Mass spectrometry identified four of the proteins as GFAP 
and MBP isoforms, however, the remaining three proteins were not identified. 
Furthermore, specific citrullinated residues were not identified by mass spcectrometry. 
Previous studies have been able to identify citrullinated proteins through the use of
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mass spectrometry. However these studies have applied different approaches in order 
to identify these citrullinated proteins.
Based on previous studies showing the effects of citrullination on the structure of MBP 
(Pritzker et al., 2000), along with the high levels of citrullination observed in this study, 
and the possibility of citrullination introducing new epitopes that are not recognised as 
being self by the immune system, it was anticipated that antibodies may be produced 
directed specifically against citrullinated proteins. In addition, citrullinated peptides have 
been shown to have increased binding to HLA-DR (Hill et at., 2003; James et at.,
2010). Furthermore, in RA, ACPAs have been shown to present specifically in RA and 
are now routinely used in the diagnosis of this disease. Testing for the presence of 
antibodies towards citrullinated MBP peptides in paired CSF and serum from 
individuals with MS, ONDs and controls, did not show any significant differences in 
serum or CSF reactivity between these groups. Previous studies have also failed to 
identify any significant reactivity towards citrullinated proteins in the serum and CSF of 
individuals with MS (De Seze et al., 2001). A previous study by Tranquil et al. (2000) 
showed a higher peripheral T-cell response to citrullinated MBP in patients with MS 
compared to control, although a comparison in reactivity towards unmodified MBP was 
not carried out in this study (Tranquill et al., 2000). This lack of association of the 
presence of ACPAs and diagnosis of MS may be due to a number of factors. In this 
thesis citrullinated proteins were shown to be predominantly associated with GFAP, 
rather than MBP, however due to the inability to identify which amino acids are 
citrullinated in GFAP peptides could not be synthesised containing citrulline residues 
for coating the ELISA plates. Therefore, a greater reactivity of MS patient CSF and 
serum towards citrullinated proteins may have been observed if citrullinated GFAP 
peptides were used. In addition, the RA-specific ACPA test utilises CCPs to coat the 
ELISA plates, as this has been shown to optimally expose the peptide for antibody 
binding (Dorow et al., 1985; Vossenaar et al., 2004). It is also possible that any 
autoantibodies present in patient CSF and serum may be bound to their tissue targets, 
rather than freely soluble, which would account for the low reactivity observed (Cross 
and Waubant 2011).
5.1.1 Future work
Although conflicting results exist, accumulating evidence strongly supports a role for 
PADs and subsequent citrullination of CNS proteins in the pathogenesis of MS, and 
certainly warrants further investigation. It is important that future research focusses on 
determining the mechanisms that trigger the activation of PADs and subsequent 
citrullination.
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Since the addition of pro-inflammatory cytokines to CNS cells used in this thesis did not 
result in upregulation of PADs, it is worth investigating additional factors which may be 
involved in the regulation of these enzymes. However, due to the known differential 
expression of mRNA and protein, it may be worth assessing the expression of PAD2 
and PAD4 protein following cytokine treatment rather than just mRNA as measured in 
this study. It would also be useful to determine PAD2 and PAD4 activity as the mRNA 
levels do not necessarily reflect the activity of the enzymes. Although the calcium 
concentration of the cell culture media was the concentration known to activate PADs, 
incubation with calcium ionophores may also be necessary to modulate the mRNA and 
subsequent activation of PADs. Due to the close relationship of astrocytes with 
neurons co-culture of these cells may provide more information on the modulation of 
PADs (Zonta et al., 2003; Fellin and Carmignoto 2004; Fellin 2009).
There are no publications investigating the effects of citrullination on the structure and 
function of GFAP, therefore it would be useful to investigate these effects.
In terms of the variable results obtained with western blotting of citrullinated proteins 
from MS, NAWM and control brain tissues, immunoprecipitation using the F95 antibody 
to specifically obtain citrullinated proteins would provide better quantitative data. It may 
also be useful to assess PAD2 and PAD4 enzyme activity in these tissue sections. 
Testing of further PAD2 primary antibodies is needed in order to make concrete 
conclusions.
Immunoprecipitation of citrullinated proteins from MS brain tissue using an F95 primary 
antibody to capture citrullinated proteins may also be useful prior to mass spectrometry 
and make identification of citrullinated proteins easier. Performing in-gel digestion using 
both LysC and Trypsin may assist in identifying citrullinated proteins from the 
unmodified proteins as different cleavage products will be generated. Performing liquid 
chromatography prior to mass spectrometry may further enhance separation of 
citrullinated peptides from non-citrullinated peptides before performing MS/MS.
In terms of the patient study, greater serum and CSF antibody reactivities may be 
observed if the ELISA plates are coated with cyclic citrullinated MBP and GFAP, as this 
has been shown to enhance antibody binding in RA-patients, therefore this is also 
worth investigating in MS patients.
5.1.2 Conclusions
This thesis has investigated in detail the expression of PADs and citrullination in MS. 
Evidence presented here has shown that citrullination is increased in MS lesions 
compared to control and NAWM, and is associated with GFAP-positive astrocytes and
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myelin breakdown. In vitro studies have shown this increase in citrullination is not due 
to the modulation of PADs by pro-inflammatory cytokines. Lastly, although there is 
serum and CSF reactivity observed towards citrullinated MBP peptides in patients with 
MS, this reactivity is not significantly different from serum and CSF from ONDs and 
controls. Due to the inability to detect significant serum and CSF reactivity towards 
citrullinated MBP in patients with MS, definitive conclusions cannot be made regarding 
the role of citrullination of proteins in MS. However, the evidence based on 
immunohistochemistry and western blotting indicates citrullination is involved in MS 
pathogenesis (Figure 5.1). The most interesting finding in this thesis is the dominant 
colocalisation of citrullinated proteins within astocytes in MS lesions, which may result 
in significant changes in both the astrocyte structure and function, which could have 
important implications in MS (Figure 5.1). The results of this thesis indicate that further 
investigations into the role of citrullination in MS are required.
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REC reference number 08/MRE09/31
Name of applicant PROFESSOR RICHARD REYNOLDS 
(DESIGNATED INDIVIDUAL MR G ROPER)
Date of approval 08 MAY 2008
Ethical approval is given to the Research Tissue Bank ( the Bank ) by the Research Ethics Committee 
(“ the Committee'’) subject to the following conditions
1. Further communications with the Committee
1 1 Further communications with the Committee are the personal responsibility of the applicant
2. Duration of approval
2 1 Approval is given for a period of 5 years, which may be renewed on consideration of a new
application by the Committee, taking account of developments in legislation, policy and 
guidance in the interim New applications should include relevant changes of policy or practice 
made by the Bank since the onginal approval together with any proposed new developments
3. Licensing
3 1 A copy of the Licence from the Human Tissue Authority (HTA) should be provided when
available (if not already submitted)
3 2 The Committee should be notified if the Authonty renews the licence, varies the licensing
conditions or revokes the Licence, or of any change of Designated Individual If the Licence is 
revoked, ethical approval would be terminated
4. Generic ethical approval for projects receiving tissue
SOPs version 3 1 oared 10 January 2007
SL-AC1 Approval conditions (C TIM Pi
4 1 Samples of human tissue or other biological material may be supplied and used in research 
projects to be conducted within the establishment responsible for the Bank and/or by 
researchers and research institutions external to the Bank within the UK and in other countries 
in accordance with the following conditions
4 11 The research project should be within the fields of medical or biomedical research 
described in the approved application form
4 1 2 The Bank should be satisfied that the research has been subject to scientific critique
is appropriately designed in relation to its objectives and (with the exception of student 
research below doctoral level) is likely to add something useful to existing knowledge
4 1 3 Where tissue samples have been donated with informed consent for use in future
research ( broad consent), the Bank should be satisfied that the use of the samples 
complies with the terms of the donor consent
4 14 All samples and any associated clinical information must be non-identifiable to the 
researcher at the point of release (i e anonymised or linked anonymised)
4 1 5 Samples will not be released to any project requiring further data or tissue from
donors or involving any other research procedures Any contact with donors must be 
confined to ethically approved arrangements for the feedback of clinically significant 
information
4 16 A supply agreement must be in place with the researcher to ensure storage use and 
disposal of the samples in accordance with the HTA Codes of Practice, the terms of 
the ethical approval and any other conditions required by the Bank
4 2 A research project in the UK using tissue provided by a Bank in accordance with these
conditions will be considered to have ethical approval from the Committee under the terms of 
this approval In England. Wales and Northern Ireland this means that the researcher will not 
require a licence from the Human Tissue Authority for storage of the tissue for use in relation 
to this project.
4 3 The Bank may require any researcher to seek specific ethical approval for their project. Such
applications should normally be made to the Committee and booked via the COREC Central 
Allocation System
4 4 A Notice of Amendment form should be submitted to seek the Committee s agreement to
change the conditions of generic approval
5. Records
5 1 The Bank should maintain a record of all research projects to which tissue has been supplied
The record should contain at least the full title of the project a summary of its purpose the 
name of the Chief Investigator, the sponsor, the location of the research, the date on which the 
project was approved by the Bank, details of the tissue released and any relevant reference 
numbers
5 2 The Committee may request access to these records at any time
6. Annual reports
6.1 An annual report should be provided to the Committee listing all projects for which tissue has 
been released in the previous year The list should give the full title of each project, the name 
of the Chief Investigator, the sponsor, the location of the research and the date of approval by 
the Bank The report is due on the anniversary of the date on which ethical approval for the 
Bank was given.
SOPs version 3 0 cateo June 2005
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6 2 The Committee may request additional reports on the management of the Bank at any time
7. Substantial amendments
7 1 Substantial amendments should be notified to the Committee and ethical approval sought
before implementing the amendment A substantial amendment generally means any 
significant change to the arrangements for the management of the Bank as descnbed in the 
application to the Committee and supporting documentation
7 2 The CGREC Notice of Amendment form should be used to seek approval The form is
available at http .;www.corec .orq.uk/applicants/apply/amendments htmgother
7 3 The following changes should always be notified as substantial amendments
7.3.1 Any significant change to the policy for use of the tissue in research, including changes to the
types of research to be undertaken or supported by the Bank
7 3 2 Any significant change to the types of biological matenal to be collected and stored or the 
circumstances of collection
7 3 3 Any significant change to informed consent arrangements including new/modified information 
sheets and consent forms
7 3 4 A change to the conditions of generic approval
7 3 5 Any other significant change to the governance of the RTB
8. Serious adverse events
8 1 The Committee shouid be notified as soon as possible of any serious adverse event or 
reaction, any senous breach of security or confidentiality or any other incident that 
could undermine public confidence in the ethical management of the tissue The criteria for 
notifying the Committee will be the same as those for notifying the Human Tissue Authority in 
the case of research tissue banks in England Wales and Northern Ireland
9. Other information to be notified
9 1 The Committee should be notified of any change in the contact details for the applicant or where 
the applicant hands over responsibility for communication with the Committee to another person 
at the establishment
10. Closure of the Bank
10.1 Any plans to close the Bank should be notified to the Committee as early as possible and at 
least two months before closure The Committee should be informed what arrangements are to 
be made for disposal of the tissue or transfer to another research tissue bank
10 2 Where tissue is transferred to another research tissue bank the ethical approval for the Bank is 
not transferable Where the second bank is ethically approved it should notify the responsible 
Research Ethics Committee The terms of its own ethical approval would apply to any tissue it 
receives
11. Breaches of approval conditions
SOPs verson 3 0 dated June 2005
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11.1 The Committee should be notified as soon as possible of any breach of these approval 
conditions
11.2 Where serious breaches occur, the Committee may review its ethical approval and may, 
exceptionally, suspend or terminate the approval
SOPs version 3.0 dated June 2005
SL-AC1 Approval conditions (CTIMP)
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Appendix 2
Leeds (West) Research Ethics Committee
Room 22 
Floor CD, Block 40 
King Edward Home 
Leeds General Infirmary 
Leeds 
LS1 3EX
Telephone: 0113 3923181 
Facsimile: 0113 3926799
14 January 2010
Dr. Basil Sharrack 
Consultant Neurologist 
Department of Neurology 
Royal Hallamshire Hospital 
Glossop Road, Sheffield 
S10 2JF
Dear Dr. Sharrack
Study Title: Antibodies as indicators of specific neurological
conditions.
REC reference number: 10/H1307/1
Protocol number: 1
The Research Ethics Committee reviewed the above application at the meeting held on 
08 January 2010. The Committee would like to thank Ms Bradford and Professor 
Woodroofe for attending to discuss the study. The recruitment procedure was
discussed; Ms Bradford confirmed that the clinicians would approach the potential 
participants and take consent.
Ms Bradford explained that the clinicians would decide whether a lumbar puncture is 
required and would be in a position within 3 months to know if a positive multiple 
sclerosis diagnosis is made. Ms Bradford confirmed that severity of symptoms would 
be assessed by EDSS; members commented that no mention is made in the 
application to routine clinical data being collected.
The Committee were concerned that the application indicated that 30 mis of CSF would 
be taken; Professor Woodroofe confirmed that only a 5mls sample would be required 
and a larger amount of blood.
Discussion took place on the storage of the samples at the end of the study; Professor 
Woodroofe confirmed that collection will be during Ms Bradford’s second year of study, 
the samples would be analysed during her third year and the samples would be stored 
for a further year after which a decision would be made on whether to conduct a further 
ethics project.
Documents reviewed
The documents reviewed at the meeting were:
Document Version
Date
Covering Letter
1 23 November 
2009
REC application
2.5 27 July 2009
Protocol
1 20 October 2009
Investigator CV
1 23 November 
2009
Participant Information Sheet: Information Sheet for 
Patients
1 07 August 2009
Participant Consent Form: Patient Consent Form
1 01 October 2009
Letter from Statistician
1 19 November 
2009
Award Letter
1 11 August 2008
CV - Claire Bradford
1 23 November 
2009
CV - Nicola Woodroofe
1 23 November 
2009
Provisional opinion
The Committee would be content to give a favourable ethical opinion of the research, 
subject to receiving a complete response to the request for further information set out 
below.
The Committee delegated authority to confirm its final opinion on the application to a 
meeting of the sub-committee of the REC.
Further information or clarification required
1 The Committee considers that potential participants should not be excluded if 
they do not speak English, and that the translators who have been employed for 
clinical reasons could assist.
2 The participant information sheet should be simplified and should state that the
study is for an educational qualification.
3 The consent form should follow NRES guidelines and should have the
mandatory section on regulatory authorities.
4 Information should be provided on the routine clinical data to be recorded.
5 Please confirm that data transferred electronically will be encrypted.
When submitting your response to the Committee, please send revised documentation 
where appropriate underlining or otherwise highlighting the changes you have made 
and giving revised version numbers and dates.
If the committee has asked for clarification or changes to any answers given in the 
application form, please do not submit a revised copy of the application form; these can 
be addressed in a covering letter to the REC.
The Committee will confirm the final ethical opinion within a maximum of 60 days from 
the date of initial receipt of the application, excluding the time taken by you to respond
fully to the above points. A response should be submitted by no later than 14 May 
2010 .
Membership of the Committee
The members of the Committee who were present at the meeting are listed on the 
attached sheet.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK.
10/H1307/1  Please quote this number on all correspondence
Yours sincerely
Dr Rhona Bratt 
Chair
Email: Elaine.hazell@leedsth.nhs.uk
Enclosures: List of names and professions of members who were present at
the meeting and those who submitted written comments.
Copy to: Dr Ramila Patel
Leeds (West) Research Ethics Committee 
Attendance at Committee meeting on 08 January 2010
Committee Members:
Name Profession Present
Notes
Miss Brygitta Atraszkiewicz
Information Analyst Yes
Professor Howard Bird
Consultant Rheumatologist Yes
Dr Rhona Bratt
Retired Multimedia Project 
Manager
Yes
Mr Stephen Bush
Consultant in Emergency 
Medicine
Yes
Dr Sheila E. Fisher
NCRI Associate Director 
for PPI
Yes
Dr Stella Kwan
Senior Lecturer in Dental 
Public Health
No
Mr Peter Margerison
Retired Solicitor No
Miss Eve Miles
Medical student Yes
Dr Wendy Neil
Consultant Psychiatrist No
Dr Vera Neumann
Consultant in Rehabilitation 
Medicine
Yes
Dr Jane Orton
Consultant Oncologist Yes
Dr Michael Rivlin
Medical Ethics Lecturer 
Lay Member,
No
Dr Ken Shenderey
General Practitioner No
Revd. Chris Swift
Hospital Chaplain Yes
Also in attendance:
Name
Position (or reason for attending)
Mrs Elaine Hazell
REC Co-ordinator
Ms Claire Kelly
Assistant Co-ordinator
Written comments received from:
Name Position
Mr Peter Margerison
Retired Solicitor
